var title_f19_26_19872="Invasive aspergillus PA";
var content_f19_26_19872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Invasive aspergillosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows multiple confluent nodules and masses due to invasive aspergillosis in a patient with systemic lupus erythematosus who was receiving glucocorticoids.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19872=[""].join("\n");
var outline_f19_26_19872=null;
var title_f19_26_19873="What's new in rheumatology";
var content_f19_26_19873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   What's new in rheumatology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/26/19873/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19873/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/26/19873/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DRUG THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Herpes zoster and tumor necrosis factor-alpha inhibitors",
"    </span>",
"   </p>",
"   <p>",
"    There have been conflicting data regarding whether tumor necrosis factor (TNF)-alpha inhibitors confer a greater risk of herpes zoster compared with other therapies in patients with underlying autoimmune disease. The largest study to address this issue was a multicenter cohort study, which compared the incidence of herpes zoster in patients with rheumatoid arthritis or another autoimmune disease who initiated a TNF-alpha inhibitor or a nonbiologic disease-modifying antirheumatic drug (DMARD) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19873/abstract/1\">",
"     1",
"    </a>",
"    ].&nbsp;Risk for herpes zoster was not increased in patients who initiated a TNF-alpha inhibitor compared with patients initiating nonbiologic DMARDs. The study also showed that baseline use of glucocorticoids at a dose of &ge;10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day prednisone equivalents was associated with an increased risk of herpes zoster, as seen in previous studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link&amp;anchor=H12#H12\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\", section on 'Herpes zoster'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\", section on 'Autoimmune disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NEUROMUSCULAR DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Statins and myalgias",
"    </span>",
"   </p>",
"   <p>",
"    Despite common clinical experience, higher rates of myalgia with statins, compared to placebo, have not typically been found in randomized trials designed to evaluate treatment for cardiovascular prevention. However, a six-month randomized trial in 420 healthy adults designed specifically to examine the effects of statin therapy on skeletal muscle function has found a higher incidence of myalgia in patients treated with atorvastatin 80 mg daily than with placebo (9.3 versus 4.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19873/abstract/2\">",
"     2",
"    </a>",
"    ]. Although there have been concerns about the effects of statin therapy on exercise tolerance, no statistically-significant differences were seen in muscle strength, muscle endurance, or aerobic performance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link&amp;anchor=H4#H4\">",
"     \"Statin myopathy\", section on 'Myalgias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OSTEOPOROSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bisphosphonates in solid organ transplantation",
"    </span>",
"   </p>",
"   <p>",
"    Bisphosphonates are effective for prevention of bone loss after solid organ or stem cell transplant. There are few data to support the use of one bisphosphonate over another. In one trial, 84 adults undergoing liver or heart transplant were randomly assigned to zoledronic acid (single 5 mg infusion) or alendronate (70 mg weekly) initiated within 30 days of transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19873/abstract/3\">",
"     3",
"    </a>",
"    ]. Both groups were also compared with a reference group of concurrently transplanted patients who had T-scores &ge;-1.5 and who declined participation in the randomized trial. After 12 months, femoral neck and total hip bone mineral density did not change significantly from baseline in the zoledronic acid and alendronate groups. Lumbar spine bone mineral density increased from baseline (2.0 percent) in the zoledronic acid group and did not change in the alendronate group. In the reference group, bone mineral density declined at all sites. Thus, either oral or intravenous bisphosphonates can be administered. We favor intravenous zoledronic acid for patients at high risk for fracture (eg, osteoporosis at baseline, prior vertebral fragility fracture, T-scores below -1.5 prior to beginning glucocorticoids) and for those who find the weekly dosing schedule of alendronate too burdensome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=see_link&amp;anchor=H11#H11\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\", section on 'Bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Calcitonin for osteoporosis",
"    </span>",
"   </p>",
"   <p>",
"    The European Medicines Agency reviewed data provided by the companies who manufacture calcitonin-containing medications, post-marketing safety data, and randomized trials and reported that a higher proportion of patients treated with calcitonin-containing medications for long periods of time developed cancer (various types) than patients taking placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19873/abstract/4\">",
"     4",
"    </a>",
"    ]. The increases in cancer rates were small and ranged from 0.7 to 2.4 percent for oral and nasal calcitonin formulations, respectively. Because calcitonin is a weak osteoporosis drug, and there are more effective drugs to prevent bone loss and fracture, the European Medicines Agency concluded that the benefits of calcitonin do not outweigh the risks for the treatment of osteoporosis. We typically do not use calcitonin to treat osteoporosis, unless pain from an acute osteoporotic fracture is a problem. In this setting, calcitonin could be used in the short-term (until the pain has abated), and then the patient should be switched to an osteoporosis therapy that more effectively prevents subsequent fracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=see_link&amp;anchor=H6#H6\">",
"     \"Calcitonin in the prevention and treatment of osteoporosis\", section on 'Concerns about the use of calcitonin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PEDIATRIC RHEUMATOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Biologic agents for systemic onset juvenile idiopathic arthritis",
"    </span>",
"   </p>",
"   <p>",
"    Glucocorticoids provide rapid onset of action and almost uniform efficacy for severely ill children with systemic onset juvenile idiopathic arthritis (JIA). Thus, historically, most pediatric rheumatologists have used glucocorticoids in these patients, with methotrexate used as a steroid-sparing agent for longer-term control. However, three recent randomized trials have demonstrated that anticytokine biologic agents, such as monoclonal antibodies to interleukin-1 (IL-1) or IL-6, are effective in reducing clinical symptoms in patients with systemic onset JIA refractory to conventional therapy (nonsteroidal antiinflammatory drugs, glucocorticoids,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    methotrexate) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19873/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. More limited data suggest they are also beneficial when used early in the care of children with severe systemic onset JIA (ie, instead of glucocorticoids) once the diagnosis is confirmed. In addition, most biologic agents (eg, anakinra, canakinumab, tocilizumab) have more favorable side effect profiles than cytotoxic agents (eg, methotrexate) or long-term use of glucocorticoids. Thus, the choice for first-line therapy for refractory disease, and in some cases for initial therapy for severe disease, has shifted to the biologic agents.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5274?source=see_link&amp;anchor=H15847723#H15847723\">",
"     \"Systemic onset juvenile idiopathic arthritis: Treatment\", section on 'Therapy for refractory disease/Initial therapy for severe disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SYSTEMIC LUPUS ERYTHEMATOSUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lenalidomide for refractory cutaneous lupus",
"    </span>",
"   </p>",
"   <p>",
"    Thalidomide is an established therapy for refractory cutaneous lupus. Lenalidomide is a derivative of thalidomide that has more potent anti-tumor necrosis factor activity and a lower risk for&nbsp;certain side effects. In an open-label study in which 15 women with refractory cutaneous lupus were treated with lenalidomide, 12 patients achieved complete responses, including 4 who previously failed thalidomide therapy&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19873/abstract/7\">",
"     7",
"    </a>",
"    ]. Two patients achieved only partial improvement (at least 50 percent improvement in CLASI score), and one patient was withdrawn from the study due to poor gastrointestinal tolerance of the drug. Relapses were common after the tapering or cessation of therapy.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31498?source=see_link&amp;anchor=H10482425#H10482425\">",
"     \"Management of refractory discoid lupus and subacute cutaneous lupus\", section on 'Lenalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil versus cyclophosphamide for lupus nephritis",
"    </span>",
"   </p>",
"   <p>",
"    Mycophenolate mofetil (MMF) is an alternative to cyclophosphamide as induction therapy for proliferative lupus nephritis. In a meta-analysis that included 45 trials involving 2846 patients, there were no significant differences between cyclophosphamide-based and MMF-based induction therapy with respect to mortality, incidence of end-stage renal disease, and relapse during induction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19873/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, MMF produced a numerically higher rate of complete remissions (19.5 versus 13.8 percent), although this was not statistically significant. Major infections were also similar with both drugs, but MMF therapy resulted in less ovarian failure and alopecia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     VASCULITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chapel Hill Consensus Conference on nomenclature of vasculitides",
"    </span>",
"   </p>",
"   <p>",
"    Revisions in the commonly used terms for the various vasculitides have been proposed by the 2012 International Chapel Hill Consensus Conference (CHCC) on nomenclature of vasculitides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19873/abstract/10\">",
"     10",
"    </a>",
"    ]. The&nbsp;2012 CHCC suggests&nbsp;\"eosinophilic granulomatosis with polyangiitis (Churg-Strauss),\" abbreviated EGPA, in place of Churg-Strauss syndrome, and formal adoption of \"antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)\" for the group&nbsp;of disorders&nbsp;that includes&nbsp;microscopic polyangiitis, granulomatosis with polyangiitis (Wegener&rsquo;s), and EGPA. Some of the other changes suggested by the 2012 CHCC included \"immunoglobulin A (IgA) vasculitis (Henoch-Sch&ouml;nlein)\" in lieu of Henoch-Sch&ouml;nlein purpura, further definition of hypocomplementemic urticarial vasculitis (HUV) as \"HUV (anti-C1q vasculitis),\" and \"cryoglobulinemic vasculitis\" in place of essential cryoglobulinemic vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHER RHEUMATOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Adalimumab for cutaneous sarcoidosis",
"    </span>",
"   </p>",
"   <p>",
"    Case reports and case series have documented benefit of adalimumab for cutaneous sarcoidosis.&nbsp;A new randomized trial compared adalimumab with placebo in 15 patients with cutaneous sarcoidosis&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19873/abstract/11\">",
"     11",
"    </a>",
"    ]. The trial found a statistically-nonsignificant difference in&nbsp;the physician global assessment score (5 of 10 patients in the adalimumab group versus 1 of 5 patients in the placebo group achieved at least a two grade improvement). However, the area of target lesions in the adalimumab group decreased by an average of 32 percent compared to an average 54 percent increase in the area of target lesions in the placebo group; this difference was statistically significant.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16522?source=see_link&amp;anchor=H7842116#H7842116\">",
"     \"Management of cutaneous sarcoidosis\", section on 'Adalimumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Classification criteria for Sjogren's syndrome",
"    </span>",
"   </p>",
"   <p>",
"    New classification criteria for Sj&ouml;gren&rsquo;s syndrome (SS) have been developed by the Sj&ouml;gren&rsquo;s International Collaborative Clinical Alliance investigators and were adopted as a provisional criteria set by the American College of Rheumatology (ACR) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19873/abstract/12\">",
"     12",
"    </a>",
"    ]. These provisional ACR classification criteria require at least two of three objective findings (abnormalities in serologic findings, ocular staining, or lymphocytic sialadenitis), but they differ from the well-established American-European Consensus Group criteria in not including criteria based upon symptoms of glandular manifestations (ie, ocular and oral dryness) and do not distinguish between primary and secondary forms of SS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H26379282#H26379282\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'ACR classification criteria for SS'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19873/abstract/1\">",
"      Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19873/abstract/2\">",
"      Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013; 127:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19873/abstract/3\">",
"      Shane E, Cohen A, Stein EM, et al. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab 2012; 97:4481.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency recommends limiting long-term use of calcitonin medicines file://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2012/07/human_pha_detail_000065.jsp&amp;mid=WC0b01ac058001d126 (Accessed on October 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19873/abstract/5\">",
"      Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19873/abstract/6\">",
"      De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19873/abstract/7\">",
"      Cort&eacute;s-Hern&aacute;ndez J, Avila G, Vilardell-Tarr&eacute;s M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 2012; 14:R265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19873/abstract/8\">",
"      Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013; 61:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19873/abstract/9\">",
"      Henderson L, Masson P, Craig JC, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2012; 12:CD002922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19873/abstract/10\">",
"      Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19873/abstract/11\">",
"      Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19873/abstract/12\">",
"      Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sj&ouml;gren's syndrome: a data-driven, expert consensus approach in the Sj&ouml;gren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64:475.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8356 Version 2375.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.232-6BE48C4D1D-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19873=[""].join("\n");
var outline_f19_26_19873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Herpes zoster and tumor necrosis factor-alpha inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NEUROMUSCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Statins and myalgias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OSTEOPOROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bisphosphonates in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Calcitonin for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PEDIATRIC RHEUMATOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Biologic agents for systemic onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SYSTEMIC LUPUS ERYTHEMATOSUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lenalidomide for refractory cutaneous lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mycophenolate mofetil versus cyclophosphamide for lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      VASCULITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chapel Hill Consensus Conference on nomenclature of vasculitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHER RHEUMATOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Adalimumab for cutaneous sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Classification criteria for Sjogren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=related_link\">",
"      Calcitonin in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16522?source=related_link\">",
"      Management of cutaneous sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31498?source=related_link\">",
"      Management of refractory discoid lupus and subacute cutaneous lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=related_link\">",
"      Osteoporosis after solid organ or stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5274?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_26_19874="Nodular lymphocyte predominant HL";
var content_f19_26_19874=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular lymphocyte predominant Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAO4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCjqSXd28hut94hAj2mMb02nIKnPIGTzVCO207fNIbZZLaJzmQnO7uPLPZu5+lbejTh9OHzM8qylWj5DbDx8rdjU+t6Tcx6JYRQW9vsid9+w8YOfvd811qVtD77msrGLdAPYTPJtJuZA0Sw/KFXABZwOvTms+3e4FlqM0V0lvdF1DRljmXb3HGMHPH0qfT554jdfZzao0EQjNtK2N4JPOT/AEqfVmi1G+ia3kt2hFuA6xjDIR/Dxx681XkyWr7le0sLm8lJuEVmkBLyPJywHzEj/Z4qM2waS6lt3PkxAeWyNyuOWwfx60r2AvLJXs4pBHGixGYyEMB1YKB2J71E6pdWrJbbQ6gq9tCCTkdsj1FMBqwW00/2XhGbL5cArj+EDP3s85p1zvtmtgQQjMrsUO9eDyAfTNF3skiEUlt5bQgLDLKf3gB7hew4PWo/7RaOzEFrAUs3wryNG2I23469+PTvVagTXcaX32dUgEMLphxKNu/LHLY/AVU1Am/1Vrm82AMuX2NlcjgYHQ1Z1CF7uWBnvGdEcrC8oxvGBgY+ucZo8mK40aSSRFjnhmLHaPk2t0HHABOKEwKUkMUU8SNO8zxcAIPuhj19DkflUMcaOZZTCkkKAhET5gB6e5PepbNHf7OGlXB3D5QCoI5Iz71aitI7W0Hl8bTmSJTwAe7Y+7+HpTvYq9h+nELFEq6eoF2pAwfmSIHdtHoCQDir0MEhkM0UykW5JSD7uUKgn8Ac5HesZluvtjNAVCxd8kg88HIq9eSPILss/lRy7T5hjPBAGf8A9Xek0S+5bmAgt7+OK7kC3LiUSu/yhB0QY6jJNVbCaWNpTb2iXPmuqiTqWfG7gnoDj9afPJGzCCRx9kI8uDcAGTI4I28YPPTpWa0txaubeZZRAG8k7RzuC4ycc4HXPpQlcVtDQ+zNLf8A2EQi4umJ3QE7Y1OM4dvQZxkZqa3/AOKeRzDMst5HGqCfHyJIcgqvsMjjviprayvJ9A+yXUSlEkVMh9shUHdjI5xzuPsa0Lu1jjt9PsybZdz75riEFowV6vtPTr2781LfRj5uhV1TSbh57S3ukmacWpMUitta4lHJlOegAyMVUudVtdL0O2gSByYZ/tE5C4Ny5AAD/wCyCOorUuwlza+beXL/AGOAFoJ5X+eYK2Nq5457kde9cusV/Z2Qnlkbyb0t5IkBbYgOcHPAC9fxojruUtUT2VxMhuIZILZp0IZnKbiFIOFUd8U/TdLl1K5WGefbDg7DNx82MlRjO3Jz9KsSlRplo3lRG5ntzNI6yfdB6dORnr+Fa3g3yjatczWwa58oxLEScgk/fJPGT1ye1Nuyuim2rtHO63ZxQTC2hvfM2IrMbg7g/PKqe68fWssXd5Kks1qJGiZnMyJ8oCZ5Ge47V1vizT4oLV5JxFCSY3ZlOCACdwH5jpXOPYSIqMDtYygBNzDeVGe/bPAz1zVRd0TzaF231VLaS58y0jjZY41ELOwDKQMDOODjvVWG3e7Mq3M1s5s4zGhmJPlKTkDp27Gkmv5p7iK5u/KCTKxlZsEAZK7do/i4wM8VKi+UZGYwOzp5RjQ9/XB+8AMc0bEGjPEt0ttbRBZY7ZTNLc3LcSM3DbR1wCcAVVuY3tI0t7vyLi02MqRp8qBuq5xzSaYkkFyfNcyI0gXEi4cqBhm9AB05qnfQxveybXk8tixO4EFQOwHckUktbAjTjuBCYrxpJFeTeRbpGWkUEDnPZuOPaqUFzFG3mfNIpXClovMcL29sHrmjz7q3vWtlcRTDfE8m8rkEDnd0PpxVvQ9Rli2JJMsOyMoFAVVIBwDuPXjjHpRsNGz4Ykm0++mmhU3KBkUqPuxk52qynkk/WtrxRqeGu4LkFJDxJGg3mJj94nGMgc1xltLNDqEDDdNdOSIkib5+RwzHopGPWrEfnSySTPM8tzK4inO48r3HPX3NZOOt2K2t2ZuoTqrMkV2H2urKsabucAH9APpVi/tyb2ODz2En3DEsf3eMqGI/Hmp7iWRpt4jlL27LErTjaHIOdox1O0jFVPIk+07ZPMEeTKgWMA49HHpVjLEkzm1SG5uxEIo/nRmwXP4e3SrWmRw/ZxPEFjwQ+yNuoXpz61WkTz59ykIjApJIsQVFOPlG32H51I6y21nahFh/c8faYwd7D1J6UMH2NXTbGy2QR3k0ctlchnmknk+eF+wB/u+h+tZWpy/6Lcx26eVJu8smFco8YPv0qFgzW1pNBulIfYlxwu3HVWGcVM/2tmuEWIyReRi8YnAA6/KB0P8AOkkK1ncZbS2jxo05LSDbN5+cgAcdPTioba4McDK9nC1tNh3YtynoFH8Qxn8aA8VqwLRRy5gIjjDbSPYEe2PzqnNuEpSOULaiPdIg+7H2wR75qrXHYm1GOK2unh01hJavEHZpDhy390enGATTobyCC8SWTLJxJ5ROfNx/CT3A/rVoRJcW0ipGkS20Y3Kx3YQDIznpn2qnarGZSrmNd2WfeSGB4wOByfcUdAWxY1C6trrUILlN1rGiiR1Uen/oQziqdzdy3c6Pbom24y6IykEkE4YDPTPardw/2ciW4YZQZfg8s/ZfQ4J5qlIlqkmPKdkRgAAxLtnp+Oe/Smhsmh89rkLI8Ufk8tJv5JHdeOc5/SpIUQkxTFop7iUNDPsPCbeWfn8KRpilrZyWsrG8ncqYxHh1HY57r6/hVVVAe6t2MlvPbqqtOV5RD/rBj3ORn0osJnQCP+0zMtpNLLfyx7HjJyGVeN+B0BArTihsbjT73ULiTybGNTbqGXZlSRwR6kin+H9PNjAL6wuPJaRM/aSBu8sdgR3I/TGaL60nj0CZdkaQspkEMjhmibI3OCuc84596yb1siDPgtpo0g/4l9yILQtNGJRkr8pO36N29AadqF1cTaBc6jNJHM77iNqbRGzADy0Xv06+uanm8QTtokb3c87M8XlOkcY5I6cjquK4+5NzqFuJCVZYcbURdrM2eMY/DNUk29TWC7iWqz3LR29qjSbgkZC/cXJ6E/rjtg16CsFr4fsr1WUrK2REDwARwznrgHk/SsXQ72CO8h0y8uXCEMXmjHEZxzv9RnAwMjmsu81RzqtxPEwu7a0CBUSLb5gIAAcH+E9ADQ05Owpu7JTbyhNQuJUuZZHiHnQFc7Yv4W3HgAnPasnxNBdWd2kGqTTySxkOwXGMEYOCOwBxn3q9d3Em9jPPP9nuF82aBvlDEfdh46AenTmqik388zwiKNkiKJDMNrsoIDq/b0OfarjpqQtzPurSOOLZbf8AHuWXY6HeVUjksvcj17Vd0+U2l5BOo/cxRkMWjyq9mPvnIz+FVo4xFbRZESsrldz/AMZP3QpHbpipreTzYnSdgZXOJGulxtA6Yx3qmVuWLm2WzKSczeUpVxHlmVDwMntnr+lBt187yNNWW5d1VpYpPvbM4GPaluFCQGSK9aS3djFviHEpHdu+3098VDHHNazRp5a+ZEreW/mcuCOSvekHmWtHjt2a6tp0adhuucP8qIw4Kkcknp0NVLO5WEloIovtDZIjeQFYkz93OOue1H2u4sJozbTZuWUFJmTMgXuc+vb2pqQwXMi+aBZjDMI5W+8Cchtw6nHWmkO3c3LHTY4rbzbmVhZ53iRWAMueo/lxVuURT6lO1oskVtFEpikZSQXAx27cmq2j2myzihiuFiS4uCWVjwMYxg/3hzkVr6mWige1lulumM7Eoq56n26Vi3qJmZKbyS2kuNQVFtYpeCxwZZNoAP8AwEY5FVB/aJleR2PnXDDgMGwg9cf55rUvLhrmzjguG+xRxbSqOmfunqfY9M1jtJbx27sm5XYFA6HlCCMrj06c0IRLPLcqIYYREkVxMXXeysYyOzA9ePxFXJo5Clq6EvZyMC8asNxOSDhew46GsW6jBtDJG0AdG2+XtLEk9T14Hb61fgcWkaRwNL9rdlUxOM8npg9qdgJ7ZUSwdZFQwx7l2bgO4+Yj1rLuNSEscN06pAWO3ALYcKcYxnkjGOetOt7e3uXJuC0ch4Dj5N4U8gjnPJGKL4rc+UZIo0kEpQOi7WCjjeB9apbjKtpN5SrItshblfNIJAbquB6nOPwrQtoo4rmKZ7byrWZAskUrbjnHX65xxVK0jMcsiWkzvFEC6A/x565PatKZyU869ik/doGYIdoCN93A9u9DEyukkccV0sE+2IZWSYr5hXvgjqfx+lTQ7UmtRqBiigCDe3U7hkjntnPP4VBcxqt3aGNVihWMEDO3c+eC554I9qWKWWa0lM8OySaRTKh42AkjaDz6A/jSGi1qen25iDXV0ReTqskcsLbkVOo3D0PQfWs+8ke3uRM8pjmulCNIqBAAOAqgjg05AkX2tpZV2oygyRjO3sVJ7+nA4GalvDBqEz3Flbrs4VVK7dgUDLjJ5B6ds+1NeYbC3czRBDHHMtyj5n3IQEbsFJ6j2HrTbITrY6urToElQJKzjLKhYNnPu2Fz71Q0rzbi4V0thczQIWczSlCcnAPQ4x+Pauo0yW2sLdNOt/tN1cNKSS0YbyR3U884+9+FEtBNEumw3g0WOPSZJGt0g3SLcxFVVwTkKfpim6xbXrwobSGLMbskhST5ihwcqOy8d6z2vLuC3exa6It4ZTcWrIfkkUH5hju3XjtWtY2V/a3lpd3gilXPmNdGTAcYIO5cfLjcAOvWoempL0MjRQ11rQEjh7eyBuG8p8EActx0IHI+lV9szX11frG1pYSo90scZBKw9CyKfzrRins7fRby6s50+1i5Nr5SjawO7A3e3r6is/ULiW3hsViuFlW3QyYgTHLEgpk9sjJH0qluaJ3YkNxeW1+bN4RG8MTR7mjH95SeD14HPvit6aFZtRsL27W1SzuFxGrNgtg43vj+72B44FczpnnfbYZ5b1GGf3zyLzhjyB69Bmux1bSkkml8/wAq4gmt2jtYY3wJG25yPp0xSloyZHAag9y+ozSCZGtDMwE75CJ6D1zwajsLx1aOS6gM8aSFfKU58wDnaxPzAYHr0qdLOK6kSxuYpJrtkysiycCRf4cY+6Rx7Y70T3swsksfISCMSGQRK4J3EHvjnIzzWodLE00lq8hGzCs4nJiUso7hEXtgYGalvRF9nlluUlaY4YKyHMgHdT3x3qrcLbWNlHDER9oDBt6tu8tW42n155+lRTXDLeCLJZY/3RZvn37eQMdgd3X2pWFfoEfkGESxxyC4clFEbZjkwe+Pu9OlPYNNbqJJLVLkoTGQSGXJI49qgtJBD5hMUcbu4dWlbIZsg/N/LFTyLGbyMRxxIys0jySnBhz1APcHtTY/MjvJYRPe/wBnQyyRIoxgltwxhmx1AyaXw2ZbmJIoyRNAhQmVAwUZ+6AeQe/NJf2csOmyTiSKCVsFQpwXkJ5wPTp+dObULy0EcdihjuiGNz8wbLZ6E47dKOmgN6aHVaTDFPeQWcDeYDmaOEONqP3P49/oK0JrgQR+dHbICh2zBWxKVzgkAdRiuetpJo7pRZBZo3bbEqqEZGPWMHufYVrv9qlSG6t7NiJ0Id9hEiY6IO2SOTWDQ2iWS5F1H51m6MqMJYy4xhQehzzzjAo1awMGm3Es9s620nlqSEG4nneQR0/h5osJ7VpbeS5mt0VQVMHlk5PpnPPv75xVzxEJ2sZb9RMsVvGA3loxVw3bbnntyKnZ2JZzEbWxhkR9sWBuVkQblOMfNn+XTNJIw8hog0fmsoLSxkg7R1BU8DNRpJJdiJRZrEVQI4c43KBnzM+xFVZrWU35jgZZFY+W0rOCCCOCfbORmtbFWSL8UB1ITObjy2hj86MPx8oI+Q47nr+FVvtPmSMZUlkWUCXYWDBwG52/1FT28iRSSw29s/mSAOiKwYg/3mz/AJ5qJsQQSLNFGJJDuMhyArBfmUY7YznFCEV0iEQ2oR5hjLwoiAkkk4X0/P0qUGW6dbnUlSSB12SuSoYHqAw7YxjPvVdbdU0lnuRLDArsSAdpAwMZPXB9q3bbSTPZ3N0S0bLGpYMBsAPTI74GcU20gcraozikrM0rqjwsAkRI2lR/CoPfnue1CG2js3z5hmmOIzvIVCO+Bx65pba2URRySfLDJLut4SG/eEDHmYzwBjGPai3tpIbUkyFwkoXMqYVWJ4P068d6Q0XLiQaddtEiWs6tEEiwuFGfvAY7e/eqzLLb6hcrqsdtdJ9mLwvCd3mDb0BHYD5cdeKbqaGK1e7gkVvs8jwFhwVJPQL/ABD2HQVRaN44I9PgtkQkbwgY5ZsZwD2U/wA6EgNVrqC61dPssLWqPAIo8k/vCBy+DwS3A59K0dN05Z7WSW4DW8iJiIK374OflUZXrgnHp61j+VdLpFpkC3hf99HcbS/m7jgkHt0wPqa6S6VtJ0vT5bJQZ3Zo5VckeS3XYT2HGM0pdkLyRQ0zTZEnLG0ikbTX2SZKlGX7zZLcK4JJyK29Q1NNQ0ixtWkaWeVSZBGufkHRgewJI6elc/pt9PqNvcWt1NGLaGJ52lQjBIJwrD+LPT14rGur0XMZaFmksrVBAswBQFT0Hy4Ofp6UuVt6hy3Zf1i3jsUitZxBHdfIXbO4AkAluOM9jWVayRXTvbSXXllpG+8MRrjvz/DT3jBu1gtWadfK2+VtMgHHVu+O5PaodQsoRaGaH/SJ4lJdUU4Xpke4xWiKVrGtoqQ3dyrBzbrEwnAXBXGCSmT2OOvWruqNcM0gtblRAT5sdvB1VmXdtVhxgZ57VlXVoJFBadGEahhG58tWQDGTjtkjrVbytTvbRLfSPMk+zKfMC4QxknnHsOmT1FTa7uFr7kNn50moSi7dll8xDI3lAYxnnb0479uRVe6tknvXjVHkiA82Jo+rjqFwe3vW2Rd6fFO1zC0k1xETFcbC6+WeG3Y6jjrV/RNulwxT28YvJrniO7VMiNAQOF9s9KrmtqS9NTmZYJYIXvJ2QB1JWOMjzUA6ncPSobKJ5b1Yo9yXUmHLt8u7IPAB+g61pXtpHbJKjTPIomeSKVAMO+SSGHXBHbp2rMt5F+z3C3tvN9pVvMV0J5J4w2eRjtjjmrTuhFe8uFu4w8xcqAqeW3RT6k+mO1TQJLMLpomh+zwKI9vyqXB6BS2N3OeakazWO+aCOJSIYsXEZb5nb1yeM9z+NMksGNyLZ033rjfGxUkqu0EbewHvRdDXkQXNr9hu7m0uZBDdEhGi2bhnHA3D+la+hXX2UT2l5BBeE7HkV5vLIYLgEke3atCz8PzLpwunuY4VKAtbswLA8jO49hnrUUmmQ6dDaW832eZFjJa5gG4yOT3JyD9anmTDTqbniK3zMslhNDeQzuyFIx5YjVcY2+/J5pj2ls0onvbh5GcD96j42gDCnHqDjP41TQgW8UTobZFzKoZgXJ7j2+hqHCIYo2AvIGk80SRY6nuPRc8HtWSRooj7Jo4guZopWCt/qovvKWIO0E8E85PYVv3T3XlLHaXR+zttijjlfG1vb6elY1vNFFqoaV3eyVXxBAiszOBnqeAoz06cetXrm4uLiCFWzc26qBwg+ZvT69j+FJrUmSGiK9gSae7igOQY/Mj569Cfr6VhC0jubgW9sylmYmYjP7sgA8/0xXY22oW8UMjNaGxtrIrJ5EgB80HB8tm9D7Vz8scl7rcF5aQm1M0hmit7c7zD6ggdsc8+tEWQtyoLNra6a6gBurgMQWhXJlGOi+3p9DUTxziWP7aJhIiZiUDJDEZXPr2rpdSME1p/aGns8F5Z4MGzcIwr8Y47+vYZqrDZ6kkQjfdE0jlsiIlFZf4g+OOR0z+lNSBS6mfLK813LNeqPNQI005IPPQL2GeKks2hvdTurq5ufMt1XcY0G0KB/ED6AZ7VIujpdSvHdFV0qVf9Hmuhht4+9n+Hk9M+lN0TTVtUmglntZFXIt3k+QONp4ZRySff607qwaEGmyWbXbzvFJPbmUQhgPl2v0HtwRmpbn7PClxG3ltLFNmzYdVX/aHcDtVVrGS4spZoijWixh3tmkMZeQHGAepxjIojsWlnuDNI6bLXcsjqcbfbHX609B6FeyAl+xqWG9pfJYuhO+TB3Bf7vGcnt71032CHTrlb4tDHctGYIbcHeirkjn1z3PFcxbT/AGZHhu5JpEkeKLehHyqf7q+tdW+j6Hc6g9ul9PvKcvJ1DL2z64wPUUpOwNdzPuQqPDfTapHcJDL5EEaoQkP91SvQL170x7SXS9aDoIpL4BXUSkshXbzx3OM4NN1aWG2e7tocLGsm5bQuPlJGMerMf0qPwMbg69FAVJaMukhlbdg4PyjdwMDr6ijpcpLS6M7Ujak3EdrZ7raQtJ50mRIox8yY9M5OPetezSe/sLSwtopFtIkdyWO0SMo6txyORXV/Zo0na8jtorhHG1pmACMQcFivYYwPfHFYuu36XHkx2pmMl2FNzL5gCMVBAEag8Dk8jr3pKd9Cb30RyltaTfYmYOlskOJXWIZAlYZAHdh7UQakiPIPtZklc5jEA2ZYjkHI4x1I56irdrp09iu43CQtnMTFgnIbg+w28jNQalPaLO/lqTdTEBxsLADu4PXJ9fatNy9DqvDtuW010uUC3ksRkErMCwY/eUe3SqkMy2U7vbxRwkbVuZBJjA4yAPTHX3rlbnUpIraGKEmWMNuW5j+RsnrhR09/SnvqBS1gBMc5mmIBCYET7cfO3f1NTyMTRva1LqurRrNbsy2MqmOKHcAFjPAEY9yDU9/cW1jCsVtbSRW9vGGCM+GDFTvPuue1c/pd7Fe3SRH5zBuSHLfK7cZGOw9DW9q8+mX09xf34NoiENHbkAR71+UH3yCeBSatZE26HITaUZp3lF4ws1xOFc4bcVzkfzx6VKxhs7edDdSqrFSPsw3jYOjAnBDZJ7VaupbRoLh7Usl1cybGglXeQNuNxJ6ccitHwqbGR/8AWB75IXxDPgIDwCCw6AdR3NaOTtqDWhnaLpMl3Il5bWEklvb3Chnkl/1hxhi+R3z2rQv0gvEvRNO5igd48RjIKkevXAOVH0rfurC8s5YraweExj94sLks+SM7wTwVJ6jtXKXCbIpHM2yW3ZpdzhVQEnDIQOSeOAfWoT5ncFrqblvaEaBp72WLm4lQJcwxf6wRE/MCPQYX6Vp2WjtqL3SiSW2eGZkDRyjhc9G44JPOBn61g6VNNZRvfXFxHYyagMPKHXEqdkIBypPf6Cp4zHKBY6V51zPGBNM3mGOP5hwOcEsM4Papsyde5G8Utzq7wzXMAfzR+7VM9e3qeK3NXghOnTpp0ZeSMhpJI0wiJnBBx0GOa52WUWl5bXcYETSkmG7HzNIT13L29jU93BdadCslpcM8TJmQq2FkwRjHoe3vSa2NmRLMbKbbLNbQxzxsEltV8xZABnCnt15PrmlNykUYt4nkWS1fZlz9xHGcsw4PT0qZFRLAus0Uk0bl3TO7YzDKjPbk9Km0Hw6+pKxuDDbyW8xVUdMNIvdvbHGPxptpasWj3EsvD8F5ZwXE+sRQWzSHymkYkkqO4PGPc1o6LPEl5frciNHFt/o0vKpK4Jw28dR9Kzp7eCHVTpUlyLiWQjeWUqSAemfQfrXT3uv2x0uXRo2+0SpF5VqkXDSSDkAHsBUNszldlKxSHWbA2UF1HDJbsjrb9ec8qAOT9KteKp3bxDbQst0lsy+Xbxp9xyVwy4HQ9cViXJN1dwXdqz6VqCkk2xcYYgcu3YAnHFW9KlvLrVYtLl1C1jaZTPO4TIjbZjaG7n6fpRbqJq2oyT95am3isZGEAVHs7jJ2nJ5B9azI9Iht4Y5L7z7eO9VxE4/eKWB7n17e1bWqWKaJMk1tJNNeRxbYxLz5smTy3vj+VP8A7KlhtpbubUEX920CSK4ICEEkBew4FClYL9Tn9UFwum2s5tBbxwHbBLG3mEnpvYe38q27bTdW1q3mkjskNrJCiQuJNvkpznA9Cec1h2Fm8Yje3Ma27Rq2UQjAHOcd8/1rotD1EMg07TckK/mOFcq0mf4VX+6O/wBacnbYck7aGHqln9lXT4b1kVvPYA7Au0n+Jm+vTGMVZtLfR7S0+z3Vw8UIkcSPvBnkc8AKO/PetmLS5tU8R3IKjy2jC3MzP8kb9QF9QPwrkvEKuvidpJWM9xB+5CImBIuMBxjsPX2pxfNoPfQ2Psdld3VtaXu2GXygAssfzgnO0hu3TknPWtKPS7T+z5iJ444Y+JoScyGQjlgRyD1HPWsHToNUvNRmazBiljXzHuN2NsQ/hUdj6mql7BFGpNyJVM8rbGAKgknksD1Unv2oavpcdn0NfxJqEWqWMENjdvbzwFTHEU24CjqT0+pOR7UzTTbhTBo9kb2M7IftQcNtyD5mTjgZ24I61zaQo11Pah8QbAHLcFW/uqe6Gu20i4tdP+y2mnOzWaEiSXbseSU8N83Qj0/GiS5VZA9FZHO6z4eTT4Wur1VeVsqYUl3mQA8ZHYAVDLZRTXCQJEVKQ7meN9/lt1GMcs2CMCtbXtIf5kN99n0+2LM0AjEpwT95WJBJPX2rZ0f7JomiRXZs4HjyCtxEfMdgegJ/h+lHNoRzW1OUvdIibzNRh32jN/qbaRP3kzAH5lPQZ9Mc0eD9It76J3nkeJgS8aFdpDkYPynvuzz0q94k14arqSJbSNFbWq+U0jj5WYkA4x936jNVYbSaw0/yLMxk3dzi2kL72gYdWYnGFNO75dQ5tDn9Ttnt5omtIy90kuzznG1yuTyMcDHPOK3VstV1bQ4FhtYbnzNkuWIHkkAgkg9Sc9sVkDTm23umzTeZcwx/uZw2SozlgvY9e5FT6XqFzHJFYX199mWFi+ITh4mznr3z1q3e2haV9CDU9J1W1u4ra+jUStbOIthANweTj8B264GKtaFPHZ6vZ3Utoz2dtGHI2/f6jdn+8OeDnFaHiS7t9RtbaCyeO8ukO8xrnzHLHG4seAD3GaztMEtk9+VS2i8tkiczEMAcEtx/UUJ3jqO2mp0lxdrcavLb6ZiNZIEcXOckD+HHpx1FczHO2oX0tvfeXDIjMryCP+7yXx3JGAKbeXiSWHmWc7LBdsIsTAksuM/K3ZcgcVk3F49zEwW4kFysixn5fYDBP04FEYDjE6BrCQWV5FK0K3aIGaTIYQqTzx2c8Zq9oN1axy/Z7JIpnVXLFlL7fm6cEE/WuWt2dHZy0RzltswK7sjjI7ng9fapV1G4tYbea0uHUOm2RXbYSwxzjtxx79afK3oS43NqFY47sxTJFcxx/vZTI7KCR1Hy9+eBU832fUNOjNu8QtbdSYwzcKepLep9PeqviKxu7O4jntYC7iMPG5XBYkfeI9PQ1Tu1urLw9Bb3YHnXGxlYLjaAOh/D9eKjezNUuqLTSwH7FCYWgSfmdnAVmbPB+nTmuts44W8PNLLclp0BWNlGC4HfPp9K8+0qKa6vkiAeVmnVcSAqcYHy85+Xvn3rutE1e1ksjpl4I2hhBWMxjLJGDzj1wcVFRES8hJrq0uUe6km2zW1p5nlsgDSs3AHPIAJHvWBpiLJeI0gS2llyPmdVUyMBwp6g4xzXf22hWl+FnuIUmjjGFYHBm4yp9u3Fc54jsLbSr9LQwtcw3SApIw+aEknHP1zUxktkQpJ6Iwr9JAztBCJdsu+RpDkyL0LD17fpXTeGLNS90X3Tpaw+YZJgIyoJ4Ckd8dfU1z3n3JdrQ25I2pHbrEctOO30wAa7Syv/ALPAkV7sjsXhZEOMFyDghvUD+dOT0CafQh8QwQ6daprF6jXcKt5kYVifL4HJXv8A0rl7zVFTT/tq2URVpd6oy/e7Mu48ZBIODwcV0F7ePBDFIsqyM5ZRbuNwdcD5h6LXn2pyGaaVS00cU0nmBDys8RPBPoQcZxinTjfccIto65NL1K809Z4pdiwqxiQSbN6Fecg9sk4I4rMJkQQXNnJBJKFVjKjYmgAJD7h0A6fe610WkCWbw3Eb3yPPDGOFy+0kKeOO69hXOSQzzXF5ax+bcX7OZLuVgIxEcDCEd1IpxerQloXrzWZbKK7We9h3MrGWKIbSpPQnP8Q9OlZ012WaGWyuXa/jgOXUbGwFz06H1461Wk09DvuHdzcqg8qBxuLgdTnuO+faq6SJBdjfMLqeOLeJZflj3jkAY9sAj2qlFGiijovCV3Jbh55keS1MR24kAJ2n5s9zkkcd8c9Ksajfxy37X98pu4ziAWoGRDnoozxkjrjis60EaXUOotbmS3ww8m0yXaQ43qV9PunPar1tbahe62yxstvDENlvIyjHmEZOB/FjpUu17ktJamX5lxqVy5ms5LEfeKeWGxEOA49AMf4VfgukkY2F/JNNaTExfuY+YnUZAA659D9a2GtBoepRQwzljPFsk3NkPJ1IKnoMnI5xWV4mgtbfTZCjyC7mby5PL53OOdoI9PUe/WldPQi4WM0C3sM18plVFyFdSCrYwDk8cjse9Wbxll09bDT/ANxaXQMflRKctJnPzZ/i57cGsO21eKSxW4j843TjZKsw3AbRjeB2z9z8c1hJe7r6P7LJIs8WZY1AI2L3QH19/TFXyNiep0tlY2uos1ld7dOSGDaxd2AAPII2/eyQDnoMVVgtS9u9paxyzTybUCH5hKw4DAdACe/41Tt0kui9tbMjmaISSyOSkaBQcpk5ORWr4bksZZpZbZrn+0Y2RA7NtAj2A5x9eaHdBsriaJYbZbn7QjxXBtHjmRxn5s9QDxge1VdbtdM+waIlrbyhkTbdyPGFM0o4+XPJwemeMZNeh3EMWlwwXkMKSxzgvKzyA5T+Jh654wPasK1v47jW/NggaNZE2TNcABlbODtXsahTbdxJ31Rx+n2l1ZLfkWswWLDyxttyozyR2Y45CisnVjbXEkr6fbsIliDqBuwp7szf5/Sur8YXNnZXkFtNcrcoFdJNqlpITkkkYI5245OcVnxy21xYRy+aWOxo7pyAkZUkbSB3H9c1qn1NlJszLfVGXTQsBivYpsxeVKuTEcHLrjnLDI9s1RjE9rdxw3UBVo0zsJ+YjGQcjgkD/Ctu70+Q+KNMhmljtfPTMjx4CKo5ViR7dRV+yWyn1G7uJFZ5g+22toUJbYvViD2PLAe9PmSE5K5yeslP7XuHiWWXzRvXcx3E/TvjsPrV610yG6CF5kjuY41RoXkEnYZcA9Mnt2rodQ0K43i61RUimuLkNAsaZkHB6c9BWT/YMM100ccspjjXC3CJkP8A3gffNPmTQ1LmVrmnM13daJBdvcmaBNqxoufMjHOFP65+tR6laXE8cMscC20Sld6bh8uDy3OOM+lb09vDPcyW2ny7ZI1G2MkLgn7yt78DrWv5KWVnbzXVoLmSPBf7SygBAflA9ecZrDnsDl2PN/MeSdBcToqjzHkZn5RV6EY5OasAywWVwVZ4hMAqoc+bn39PU/hV7VYbfUNVkiaxW2e4kGJ4ck5JzsHtWbqeqSvHPBaTSyyRylfPeNd+zjk8cdOtXuUtGbujeIrrTbOO0kY3NrJGPMljcBoyOh5OQxHJNXLi/uNWaJdXiZ7Vd/2a7iTLMAAR5o/Hhq5uVy4jnhhge1RiPLOF84HjG7uVz19q6Ox26dYtb3cckQZvNEqvkBP7gzUNJahJRWtjNa3YJEQ0iXcC5jkjI81QT/FzgHjgg+taXiS322Vqbq6nMrAGaAx7CIyM7yB+eR1HvWfJKbm7hBkgghuXLiRcNnH8O0ckHjH0rR1mza4tkjhurmO/TYJjOwZyq4OAOuOOg7U+qM7tNHOESRSQxu58hSIY2jyVRevLdRnPAq0bKS4cF2g+zvuhSLyzvdSDls9hnGBUsWswlrMtbNEGLNcRFcqqLwM+hJzyatC2lea1lkt5Y5SRmGNmCOvQYb2yAfcim20Nt+hXsdKmvEj05oyu6ISK55EUa/KxA6ZOCeuatQPZ2lnqUTCbZMwaUSodzMvAKnt9RVy5v7PTrN4I3mSO2lxKwUgrJj7jbvvDHcd6bql8uqfaJF32a28QjZJGCs5PYZ4A+vrU3b3FqzI1q1t7ixO5rgJGQ6FiTI5xjHHbv+FZtzJcW9nYx3CWzRXBJDnjaAOmB+f1qzDJJZXEs9uyXDZMSFJC2FHylTk8HnnvTLeGFlmtnaFCi/6twf3Tddqk8kd8960WholoWdJuYLNba9udQeOIIBEIkKyOc8hm7A8flWpq97czvJa26GVp2e4ibftEmAdw9lB7nviuWjaW7uYwuwWcjeS8bEsp989iOPzNXDDfm7WeSCYz7GQygFoZFAIC8dAfSk4q9yJI39O1GXVNGdpnt2mkQ2Sb4h5kb4yWwfvDBAz7Vzer3NvdzWUcjlZLWTaYFj3KeP4QOgHvjrVTz3RXTZIl1t8yFYvmY9iATnHTHrxUkDXUZWW3b7PdtuyCBudT65/i/wAKpRs7keZAsTmSeUSTuq4FyUYgyKDwMnHG7HStDUHu5UfV7gx+TOBCZI/kUnGMAeuAuc9apq1zIsXn3KSCzUblY4J+cMcgdR61pXtxLd394QYgvlKzKvEAz2VDzupvcWpWW9kt1s7iN2muFlMpRVIUMOAfcc9O1a8eqRXE9wVMTSXChbp2Ta0ZZuw6FQTy3pVGaO5ElnZyTeW8MjFG2DLYILoOxPAqzLukkum1C1MT3TNhDjBVuACe2FI46E1LsA9YraaSVpblDaQyCO3VXyfO7bc4GDVC5khtbIWNpNAtxCrSSXIj3PIzMP3bDuO4+lMjslEFy9zj90rwrblR9442kD+Ejrk+tTahaq84ithtZmQBjgNKRwGwOcHPahbgjPaOQXyQ/ZpLaUr5IdWw7luTz2yDj9KvWdnD4ev4odQM80FuC8Ux4WQj+Fk9Pm/HFTLcXcertdXhiihtnED8FmhP8LDPXLcZo1O/k1K9kkNxHJb2zbk2ICSMfKD+OetF29OheyNbwqgvba4lsPKuriAeWfMTyx6qRnpjHJ71qW0U6ahfazeT2MQKrCbkIAx4+Zto7dvfFcf9slntLIMESWQB9xYqkrZ3GPjvx0P0rV1FVsNDfUISs012zLLbytxHx8qj0APPNQ46kSTuWdQvJYNRRbUrNGtq0kUucNhujkH7vcEDrkVQ0mWW3sopIZLRbFQY2S7XZiYnJ6Zyev4VSmN6q6dOzWrzPukbcc/Z04zvHvxgHpTUMFtK0msXbXMLceUkWfn67hgdAOOeatKwdDQnAhgntkuZEk8oyEhM7y3Tc3YiprC3N34cMcFy8tvbSYvEc/OQD2J7Zxmq1vrUglbT5WhH2glXdidqYxg8cDqRzU4W8nuhYtHHAsquF+XaIlU45P8AFmoehrciv72WbT1do50kQSbWwAqx4wMDvmqP2d90cwVvOaPDMseA/oMZ61rWFtZz2l9EjzmKHhMNudnI29Dx1HAqOTT5rNFa+zJqhIZUYY2MRxgD2H0oTWwr9itpEkkOmXEWpeVcskEkzKBgROxwc+pwSAKbczXF3aW8SRiER248oYxj3J7frVWzZ59JlQrdOWlLTRoTlyG+XPphsDPpWhYmKE8XKXF0JkdrQttQj0AHG4HueabGnrcqCDGoRyW1vHp9gcBZgflRl9c+tdReagLsSNJFFOeALqMbXfjBLHtj9ayRDb2tnNHcpO5upfLnlaUO6r1TaM4wefyptz5k+l/Y9PkG9QWVUHPycgkjkdPpSeopa6j7VBFKGNwsUxcFFhHzlTwWYH6VctpprDUNYE8a3lscyxW5bcyMf9Wy+/Wq9vcPDBfDyElmkCuJQMZ4GYtx6D0PrnNQ5bTLR5YbeOaSciRJVUmNP4fmPqCfwpbhy3LVw0ELRvBIgvYdpMtw4YQs3LMx7nJIrPubuWSVftiSfZ7nCoQg3uxJ5PPtVY29kbmCztlN7eM5e5it2LDYR8zAHjIOeetVNat2sz9njgc2W9mtXlhPnSk43R5xn0x+NUkiuVI0Ly0nuI54vNEQt3VJBGBFlD0VevIHBPrVG5nvIZHEsMJt2/dRBf3hj7e3zEVZ0V4b7UJIEss3VuGTaJQFLgHLdcEAZ5FU725C20xjnjjlDqgMUhHuSD6Ac5POcgVS3sCtsXd+mz28dvLLLuYtIUgH+t6ct6Y9KjkD2c3lvPNtwJVPmYWbnHyn1Gf89aoXbm1j0+zMEVsNmNxYl2Y9GOen404ETw+RIyPMg8mORUwm8MAw9NwGRkU7ESViJvNsJ9zwPbmYb4pnXlQGJBX3JyKivmFsRgpPI5bcGBQ7v4hjnGB3qa+MjJ9pu/Pm8omKLzXyY4wOevOM5x2FUoZAgMNzII4cbnmWIMyseobPXsM+9UgT7luGz3RAT/unEeYmdtilD90Hr2xTpSbSwjljtg968hLBxtVQAAGA53DrzTrCNJImLJDtZlj8ocBjkHr6fSrai2eaO5CLGr7y8SfKQOgAPpkHPelckg1mCa9ut6TW/mbVYzq5/h+8B7npUbCa+E3lyyW1vGizI7HGxQ3OM9SOvtTLqRPKt7pl2NISyxA/u2RRgpxzuyQcH0qrPZS7Elv4Gt3ABJHzBsnIJPrjtQgsb08xlglk+0KkM8KGfeNx3AnaT7mr9lZnT5NIu7Rovtd5E7OH+6zLxsGT8p5yPpVLQoRY6qh1FrdikSgxZ3CLJO1wRwfetDWNJOoXn22S5gsOkJG8YcfwsMcDPXNQ30BblDRLH+0BrHmzMrOPlZpP3chzyBxye31FVry9it0thJayuzIYvk4R3/hU+o61nafYXyNdzzXKzQwNgvk5XDZBT8eSK0LrUbb7TpptU3OzGVVLcS9iC38PsRVW1LklfQZC1vDaQQSSEXcMhDHONxJzjPOB79ulbFjFNd2d8dSkRrVFC5KfdbPDdeQBjBq/JoFsbRo7Ly45YWaS5jmfeHUjJCt2Ga5K31FdJZoLRJAZQXkL4YIPYdCMfjU/FsZ/FsQ3tw1pFOkbv8zb7iRBlgp4wfbpzT9EsbK0sYxqc8BMmZIo5XPyoeQeP196pMk1zMlrFN5ctyC84z8rxj7oPqevFdx4TtZHu5ntre0tiIkXdcDzA3AycdVJPNXJ8qKlpEyb7ydTm3aYsUBlKxiErzcEE81e153hgthco5vk3qv7zduUn7uByPrWHZP58YnuJArQxfuYwcBpB1z7c1ZtLh7fUIvMkQyuGL3Ezb8ZB4C+n41m0NrULq9eVdzxGOCBSREg5lfGOWHORium0m8gmCSJdS3WrxbVMRAJk9QD2xXN21zc3FnPay29mixMHFxIuGLA8fmMcVZv4xDpdsyO8eoGQMzHCoCuc7D1289+tJq+gNXLesX0llqEpht4og0Tidowxcgg4ABOOvOcVh2YjZbY6XaiMFhK0pyzFx0GOp559Oa6PTp7VY28qxvLhpU2Eu215JM9VJ6L2rHSEadM09zYhYiGCIp3yY7gmmuxUeyOj0XSbWXRZT9n/fPJkb5Oi9cj8u/Sss3SoyTQn7PcK5ZlJCRug4VQepz1681ly6guqNb2aR+UVHlMdu2MFep3ZzkdOnetKa3ks9PW8jtVaOaPYkYYl2YcDHHA7ilZrcHpuK8VzrkMMzyQWcS7vN+zNuV1/uDORk1lXBuNMujBYuZ7W8bzFhaQlAgOFB9Sc5yPStvT5Lm6tooVQKsALuoTaY4xy3mH2z2zmudhig3QPMBKQJGighXi2fP3Ac8g+vanHsHMRWYuLKSG7tZgjySM8ska4YlXIwB1xxgDvWnYPJKBftfTPJbvI0u+YGVX42gKeFB57dqS6/0uNp42u4gI0R2AGQ/UhfbNVrHVnW5t3js4vsx2eSZvlMqgkZZecknODntVbgp3G6vsmit3sDJGJGZJdkW0xcE7B9RnP51VudCCaJaXM0jJctK0SQFdwxjIbj72AQa1PESLJPLHBbxJaCQSBcZaJyQGZsdep49KjutTb7PY2ilfsUMrJlkx5754XvwMg9uDTTdlYpSOeicLbedclDJIm0q7FmJU8jnkDpjPvXZ6dLDJplxHPa262ktujLCZMGFnx8/1JOc1ydpYT2WovFZbjbyOVZwu7yyOgbPTqa7WDSXktLSbNxCWdbeBioAlTGSPYZHFE2iKuhzH2O6FoJZrkCNd0T7mA+UfwqT97Pf0FZ81vusLqItNLGm3zABgBP58cc1u6xZQKyWsVtGl4ZczKGJLEHg4+mM1QaBHjRJA2WiHmRhtquQfXtj0ppkpmbDGw+QTOPKUKgYfLtPAx9a1rFHjQL5yBo2CKpG4t6N7YOajhjk8j5AI4d2JWT5R83JYdeT29K1rayMjW37o7Sd0Ym+9Iq9jjr69utEmFyhpjW7fLK8X2hFLRwMwABPUsenTOKrqktwJbR0lkE5HklZMYG7HU+/y461ZWHFwohChJI/Lnkj4RCf7+eh4wKaiCeSGwt0tjciRnN2ZCrIgGAH49eRQJmgk2mC3u1hinR3fyMoN6qCAMEeoIP50/S7Mzxkwxx39xJGuQciOMjkLzweATx6VSRXE4ZlQXDyDyldsefngjHY8Zx7+9byWMVlaPJK++EqCUJ/jHDOuOhAJqHoK5mW86oInmtXWea4y8kYwkY+6evHQZAqCa30yOG7ETreWMB8gQ8eYqMc8Y/iBz0qa+vLMafPFbzT3cchJtrZfkXPTJPVuOe1Y15b2UVkCt1dEswVpFT5Ub+9+pGaaRa1NfT7a5ubK8/spDK6v5SmVzteJDke+7gZz1rOu7w6om6NRFc3TkLDsCeSFHzcfmRVrw9eyWKXEdrJFqFpkxiKT5CSAVV1PpVPVherJcX0hgn89Ujkt1+URtnaEB9eM/jTW4W1JU0/fJDCAIpYYRLNKDkgZ4f8A/VXQ2i3VzAF0+Dz5kJ3xjIcj++SPfisvT7uG00uCwuFlmu7tmaYY4jQ4+QY69M49q6vw9JpVsGDzN5kYMaMDtPl5yufXjBqJtomT6HHC3iWy0/VJGe3V5jCY1XcFVe/oSc011uLbzZJdP2sp+0gMwUuG6EjrxntxUNtBdHdaeQHnRgphdj5aMeScA+mK0DfXFvJcR2UMey9AjeS5fO0jjywT0X3qmU7ixQSXkizCzMs0sRlUysqh8cYznjp1PNWNI0i51u+ZWhKvnzpZJBlPbaPQY47GorS6e3tGgCROySq0zO2SB0Kr6jjiuh8MzrZ6289sslrY3cWDEX3+Rj+Jj0X6VEm1ewN2Whg6rbXtqrJcXTSs5MbBUJ8nH3fpkc8VZnjisfC8cSXg+3FkYSKSQI8nhvcnNT6xr1nLqC+fc/uJzuZ4kyLkKcJgfka5+9me6vVSCEcZPPTB4O4fhQk2lcpLuR3NhaRzWzrcpExDebBHkygH7uSeDu9u2a14L+5ilsrOadbeCzhYsMsQCRhdpPVhwAa6OLRrbSdLlvPOjlvp1xAPK+ZUPRec81y9tqqWVxbz3u+aSGYqPOQbQG42nj1P4UX5iHK67l/Vbh4tTh0xs/Y1hWe2jkYBpAxPzOT1BIPHtVXT4LeeKd4544vNlPlzBSVjj2n5lC92OPYVkXkNze3N3fNOizxxFcSsCQCx2qo/OpoWbTIUjjRYw4BjYZBUtwVI6FcEnjpVculkTZ2Kxt7hrKBLOQRqzn5mf93IwOPl/r6VJCsk0tslyp843QjkKtjbEo/hHcZJ4q5A1pBojR+XH8k7GR1yzIgX7wTsCf0qG8Ekk8cwdCsbEtLFzgEDOT9MU7lg8/nyPFZJ9luFdttwzbGYhuC3sBx75qvcG6jtZRPLFHvuQIkQbnd8AnkdMnp6VX2RSXJ3vPMIwE2lceaMcEfQ4NaV1Hcw2/lxRRI67S7K4JU9nz9eOPSnsCdhun3l014IpFxDPFiV3BO9weCG7devTiu31e6dIvsoZbqQxxrBHGCZFYYDPjpt6n+dc3YT2yaWZrxX+1DZCY4+mRnt75BqCxF1L4hl+0PcB4woW53BSm7lh78Z+X8Kzkru/Yb95FuDT7i6sb02F4r36gymTAyQvTn2OaxtkEhWaG2SJXURT5H3n7tz69639ds7bT1EmmSNKHG/KPsLAkjOPTIOa5w2sssTv5qxFE8+MO+dzk/d/nTi+pkiwHTy5oZbGOGKIbModx9QT7A065u7hBBEszxeSCI9qdVYcjI9ffpVeF5ZJC0pdQAyhQQQxx2x1GeP1pNNENnNO2otMXRMhd42se3+FVYfQj1JpI2ZsSvGUcySoSAY8gZIPuRzUVsJbf8A0eCJM3Pz+YyghlX1B+makuFfzLsQzCKKfJ2g5LRHso7/AMqbOkkX2mOJGEPkpjdy4wBz+PoKpAyWaPNpFKkouLrzsmVl27kOBkAemD+GK1tQvbnY9mISDFbpL+7XJySMsV9D/LrWHosz2lzBdNINqsYpA5G8Ajqo/vVchneHUZIobiM316BDBM+VcKx5VgeoA9MVLQLTQel9EZoCYRLNK2ySTyQPLjIxsHbGeeOxq9rGk3JEcUyBRJIPLMmQCi+46kZ/HPtTXs4NOtL/AGXjSXEEgVURcRLsALSZOc9/lroDrFtfWkUj2sczhXA8yXAZsL0HbPbHpUttO6C/Y5LWtPSwa1UxYmKsBsc8qTyPoeoA6YrM12ySeyKtDIHhUMJ3Y/NzjDD0HXJrpJ71Pt4kgidhbhI2RyD8zEHAOOwyOPxqPUwjxXEzmAtZNiTyiWX5/u55wQOuPWmpPQ0i3dHNWD3djcwXME7SgPHMxRNhVgDnOccciu/8Oaj5ut3F2/2LfcwB2BiCrHyPlzjk+4rirbZLdJnyZI0lYzhJf3pIGMgehLD2qe21SXTQ32y2mh5MabcFuOCMex6+9VJcwpRuVpHT/RYLcpNcIhlMsLHLn3Jxg+oq/PYmI41Is7TRbhGpyTu4wSOvBqtp6TTFytruiKFljyBzxgntgc1JZXC2yo9vK1xKm5QNhURtggEn6dh3pPyHqzTfSWvfLisoHhIh2TvIN3T7pCHHGMDOeoq/plzawwXEUplLGQ5aRcmRhjI+vpVjw7fOtnFPJFLJKSkZlnJLSHPUL12561DrTwNqcagyuzIZ3njTCqF42hex56ms223ZjS6Mw9TljnvHnu7a38mNT9mbpn/YJ9ccjFbECvJosSxyRW8llKsiiROqtz1756VjLDNcyrC0O23uJUjsklGNg3D593Y445rq73SZG0d1hLGDLxtEvzOrAcbWPoeePWm2lYJNJoZeah9qeeLUEvVke3REjgPTn5vwPB/CuY1jdaySu8s0scgKwKzZVCeCcjk8e1af9si28QLqbR3H2KKPaQingYxs+btz1NVWjuY72JfKRIjJ50SRgMVQDcVY+m38zRFWMirJpqWdtp83n28q3UxV2VyTESBjIx0qvOjPaXkKn5MgEAfNuByGbH0qdYJEuJIBHmCRmlaQDoD2HbNWbWBzcv8Abdtp5x+dYOACPuj1x3P0qrjKe9S6TtcHzwoUyFeckdvpViC8SW3ijeFA0pMpRyRvZuCcf8BH51PBZSNc20Cywife0jMCduCT37DHNULOG7lnuyqLcGPLOYzgegA9vbvRoyrJk9/HZSadp9hDZBZEkkUuCSqs38Oe23+lN0eL95HZi4EaTSqks+Mq2DhgfTjnPerlri1B050WO6miO4mQsEOMnI9TjHFY3+lRSOIngVlRVXBxtjJ6Adz160LXQh9je+W7uUsVtIXYyqCmMBmGcOT2J9ar6on9h6smoSWwaWOcgxeYRCe+cY+8O9QC5Elq4iDO4XEU2/C/KRks3pzwKhv7+e7vm+ZZraIB4w4JYM3HK/Qnk0ktSobm9dapDfSx/aTDbxcSsGY/eY/KoIB78/jWFfRM2pTvGYpAk2/aPvKnYenrVOQtb6sYb1BAVUIdrhdm7ox7AeuOa0La3jDuLy4lhMUMjGOJPlypUKAx+8Tk00uXYUo21FugJ/8ATIg4RcKWbkbsfn75x/jVG6hhjs2e5twh5Tc43bT1HPbrn8avOfttjJK8XlysoEflsqbQo53A+oBIzT7iC4mmeM+TEkqD7Mu3zFLgchsZXJGKaYkzNn1FGhhnhVQj/M2V/wBWuMHH+yDiszU5Z0McccKyzuFRApwPL+9n/gR/nXQC8sLqyjW3csB/q2dNrMAQGB9j71ejOm/aHv5LJpJ54WiZZGUCNUPBTbwTgDine3Qd0tbHOeG0e7trxXXyjEvmxpMcMm08EZ75Jq5K0gvQsxE0pdQ++LlwQSMkdCPQVZ1C3bMf7iIRToSTuJEY/utu43dD6c1Rh1CYw2zW8M0Zjy8jE8iRuMgd8Ake2aN9Rbmpplze3djf2+lW6sLvEW0phg27bnJ5AxUFy9tbakUin8q7T5Z42wqKcYOz29ah0qdrGVbyfzXu5JjCNsj4iUjBmPrgevpVvVLZNMFzLeS2s7lNjMIA+Q3QuSMZHY0uoLexo6Fpz31zAyXNpLaeWRujXgEDA3Hu3YmptXs4bC3ltYYP30se/KPxIR2ye3/6qxdKmbTvD11b2aSs07AdCN7IPvqR0BAOR05qHVDf3OjrLdSRL8rP5q/M7YHCjsE9Samz5ty0n1MzWorZZg9heRrYoEZ4V4w3O4A/xYOKl0tLm8vbhZ7OC5UgMXlYcsOMjnqRyfeoI1EUvkPGqJNGEhQxhlwOT+fcj0FMtbSK5mJvll+yqg8kQkIcHB5zx07VqUo+60aNjKYbuXTUdQ02xXGC3Pp14rqjpf2dNRS3uYnt1gVXXbjewIJk/DFYdrYR2nk3EsbsSpjjkLBi+f4jjvV67uS0NpZGGO0lgVhK44OxvT14rKWr0E9divLqSxy2dnfu5Z0CQy2/3trk4B9CT3qVYJItLSKFX/0kZkmd8eWTnjP4VTxEIDbRCTcEJSSRuSo6HPqKvXl5HILPyI8iFQ088hy27Bxx/P8ACj0BeQ/QLTbcfI6Sz2kQuAs5JWTH3gf1xUmq3V099A63cltdzZnECjEYY8b/AG4Aq5YXVu1qYrs7LrAZokBO8MMAZ6YGateI9OlOixXpeMGRQOAAygcKvHXkGovrqJ2b1ObnD3OjrDLYl3Vv30MZI388Pn0puo3V8yyI6rOSI1yTsO049PTpmrNlfxi0QRRwJDbQGBY4Y+bjJGEL+vUke1UbOfynkFu22SQiFlZOWOMZHrjpWiE1qW441eeM72EbqUjUH72PU+1VbXcLYxPNugl27ZfvFmB9exFNimDtF9siRxEHI3SH90TxnH4dRU/lhYVkt0ImibiIg7Oe4fqP8ikBPcwxQSzSxSStGTiTjJPfB9s/pVa1RjbmOzRWtnU7DGdu9s9PdvSmPPd+ZdQuyvlA7kSbVIIw3HfjpjPNVnEbSQrEF80uFhyDtjB7DHXp1+tOw/ItSWscl20tyR5T/KV3/vAx5A9+lVRLZRW7IbGZ7yEMC8Z+ZWZiAp+vHParDBFvrWGLdEiybnKkkR8469wKZq08L3e2FfLEUm2Nh8gmTOWLDuTk00Q9Sos1pbWEt7NGYY7cmMxFvndsjLbfTkVLbXN4ivNZywgyYmliaLBOOQc5qDUrn5UtSfMLZlOP+WgOML6BhzW3pUZm0eayliRpPMDQu33yOpQ+o7UPRFJ21OX1W/1CaeO+vYknF2ys6EfI0ik7QpHcDBI966S2jzoNmL+dpZFZoihG1nIHQey8c96qz2V1c6deQ+VJatKCdhJZVbodh7DAApJrG50u28qa2litpZGMCtLvJJxhiP4R15ounoXJ80bIm0yyHnOLm6iDvFtMpXILBd2wjPBxxVl7aW3tYXcS3luXKqUOzjAOVHqM4B9qrJBHDps/lxjfFKpeRsMGJXG0c8kk5ycVahlmtbJJ2ZHtpCYV3ncQxAwAOzA55pMw8yCws7WS4txexiO22pGqwc7YTnaD6ndj5vrVrTrYpFNb+Wi3IWWNmxkFA5xt/wBrv71kymNLVIzLvmLFFjUYBH49hxTLNpoZCySMJ4m3PICCDj7oAPBHQZoaY5Ikn2NJBJPI62KyfJtHRjwWA/i6D8jVJlXbFbPLNMkRMluUXaX4JPHXn3NXZz5j8zGI4eQySHoxx86/7Xas+SSa4kDaeZ0tmXy32KD5meSRk+o7cYzVocUR20sdwJDZ3E5ndW2ExlscZ2kex+XPtWpaXTSWVslzF9pyplkaZcGYLwqN7DJOfpWTZwn7WsrRSMTkFMjgg4BP1xxWzpdwLW0kuYIFXy5GRWkfIij43x49M4NEhl+2t2urWW3tXulEsnmNKMHzIyMNkfwkgn60y6vbCSaTS9Olu47AY8wqoLxwgANkkexx+uadp+tzaIz23nRwteKojB/eHOMEg+uePrVObR2VZYw4snl2BFjHmJcfNlnYHGCM4x6is+upSjrYzZNTub+4Mup7bQWsO2MIAVfH3dvoT3PtWZpy2y26vqE0sW8kgxnfuOeeOw/nTZLa41G8uFsoRc3xmVQQcNxnJHZQfX2qexh8jUpbd5h9rVMsx+4BkfKMVskloWlZWO01i2hh0+0ubS1eytIAIhIzktK3c464NP022fXLp21Zt06urRbEI5Axn24PQ1JrE0l3pZGpXrrJAgkjRVGxSvX69uferXhtvOtkuJ0LRXDHcivlpMnIwB0ArnvpczexlaikOj6hcmH/AEqeJg0at90E8cnocelVZJI7qR5zH9n89GV2DBs9OR7Zx1q14h0qw0+bzbi2mlnkfiPzMAKDkfr1rN1Oe2TTXRI/InDsWAO4P0wAfX19KpamkUmX1cR21v8A2rMftCkIRFlQmB1z79x6mtaL7X4m1WGxg8zT7azZSzMmTNkcYHauMs52IQqIpyUaZljy/lgPjBPc5rv9MnuI0juDJ5txtSNY05Gc5+du/BHIxilJWJknEyPsjWegJFbIqsksskyuR8uCASqjvz1qISWiRpqMii3hs4ArQFw0rcfLIoP4ZHWugOnXEl1POpjN2gwvlSf6sH2I4rjJUjudbvf7QMrTQjy5Jn5Mx6D5R0AHX6Uo6kv3h0DLLsmXyWcvtIYhQY+uSOo68ir2qzm6uAIw8xlITEXyR7gD8wx/D+tYNtcl1EQgSWYncpPGEU8g1PPK7XI3QLFNJHk7XwWXpn2xmrtqIWe2LSSNcLGI/JyGJy0bDgYXrjI6+tPkQC1t44nAUDe8h+Ukd8HqKpTPFZLbMJmkEjMywMMySADbnP8AdyM4q1GLoxuJFt23rhd7bTgckt6YyMUxsnkhmFpOgV3ZCs75ODFGzA5b1A6fjTL0x3FuWtIg1qZi0LStmWPA+Y+hHXHtikkkTz3kF0LifCgIQfnUjr74OOKJPOghmgd5C+zLJtCGTP8AC3Xb6fShEvuRiOC007ZOhWU3Cur/AOx0O306jiuilsYdPuYo57ovNbuQ38JdSPl255A6c9qzdCXT4hbut8iiXNvIk0ZdoNvII/M1rT3trqOnSJOks1xOxRLlsZGxvmVvQMAeKmTYr6liPVZRFblFjFtbbkOMfOSc7T9M5zVW91HyobX7Laxi6lUebJdONuP7oJ4/CsyykiSaKwuBDbxXBci4OfkIHB/p+FX7WezuY5ra5dTYxQqC7clM98difxqbWKWisY2s232b7XKnk3MO8OxjYkRtt3A8cHnjA70Wlw39nyPGyRNNEHkRgF3gZ+6G7+wrS1nSHtLJ0sY3MLxqBaM3JUsMOW7Z+9WKIFcqLdZoZLePewkX5olBO4Z6Fe+e+atNNE9CG2uIRErTwsXiDq5boisR2PJx3A4pLvMsMKKYfIgUlZSpj3KTnAU9eP8A61FhOfNeCa48mKQFi6ru3DrgD64/HFRWKnUGEMqSXEExbzGlbG4Lzgn+HAHPvVjJVmgvBA3nQQyoWENvJ90EgfMW6AcdDVe+uTIbaSxlVD8y+WqnMYXgnHbIJ4q9YaQj5kgvIp0eUlLe3TMkmB79Pb1wazCTC0Fy0ZKSvgyI33W/vY7nGQR70KwRRcs7uDzYswxl7VDK7lzmUnornoABjGKvK9v/AGbHaWUKvc+YwmLtwwbnAzw1ZsEc8gJkRYbWVjAsh4Erk5Af2KkKG7VrNpC6Fp041R7eW6gbzYxHLyRj7ucfe560nYtIo6fc2thNbXEsEssq7oomKjEag/uy3+10/nV201q7tYLlXhJilk+SNl3yKW4ZUPUsTk+nNZ2k3aXlsxZpA0Z8pAfnQ453E8dx1qveT3E95EVBiuHBYxlMFQOCy89eM5oau7MrlJrqX7PaXqwMlqoZVnZMZkjPYnqSTjgdMHPWltWtLeZktYEMTqHzKwMynptOOg9BVLU9OSe+iWK3dmY5uLdTt8lvTPcnr+FPtXt7q+eG5mktzEnDsNvm88t9c9qpId+502uXEFxNNDMi/daRwkYdUUY4JPb2puly38Onw32mwbopQsZMRKFCOMj09qwdP1OKeW3t7i5LQ28Y/g2jbnLNJ65OK69fEjusZlTyZNxYiJC3TjHHy8jPasmmtAasc7qmL8hbpWMqyhppHk+YbT93Hf3NUJ2u1uGNmfs8ygvFFATIig9WyOBnjNbWrltWvraWGa3EWxi9wyBAgBJAbsD296l0fUbmwSe50+0SbcTHLDGuEbH8an+7znHtTTsi4rTYwtMnaK5jSSQC5iLBxMqkM7A5ySemfyrovC3iO70l9k8UD2wILBT82Mnpnt2/Cufv2a5Wdrvy7iLaJV2xbeccgn69KgsXg80SC3kDiL5fMycRn9Dg5qnFSWopxTWp3Z1y1vHuoVSKWVsbEjOHfae7Dv8A4Vmz/YtQubiC3nEKltrSIrhySclTxg49Se1Zz+UloHhETMsochB5bA4PDkevtgVat7i5fU7fyz5b3QJIkYJHJt5KkdicYqFG2xi0U7PT7y11TyUuFjY7mE2zJKjucdqozSRbJEabE4YBnDnZx3/H0re0c51z/QZZU8tTJL5oyoBJGFJ7D3qDX9EsLe4lsovMa/tlDCKPGHDcqDnrj86aetmBmyAxOk8EjSNAp8sKuA27rnHOM+nGafILWYi4uxKYWUZV24YD+Dd/dzVeBbq8vYorUJE6xlcDIZSOv5nNFxDctIkTW220QbXjJJDepUdM1Q9zSntkdYp4b+FbpEweCVG3jg/XHXnFFq0aXdtHNCLpbrbIqOnLkN8w+hIPSoru6L+HZIfs0kvk3BmmO0LlT9wcDOcHmtW+1CKFdHIkZ5I4+Z9q4tweijA5Pep1IbF0mxVp7qWz3tf2JeUrKMY9lT09+taFpBGulRzSW/2a4lmEqHO1dpGTgfz75qbTLyCa5WbTTcGRX824aRVEuVBwDke5x2PNUr3VYrsWupXcytCs+6NFXOGxjGOxz1qHdsVm9h+upbbbyz1GKF9qGWNANuEI43kc5zkgD1qn4UtWnlhbUIQluy70VMKHI/hPv0+tN8QTrd6rHLEzzJsDOQvDkk5bd0wBgY9qfPex6hYWjFVjuYlzHb7ihVs9fce9PXlsVFWRJ4g1G91mWSMwD7LYSYlXH3/7oz6Y5rNuL+2TTX0yzsZMXEisST93+9k9OmKWe7vrWRY57cpaMJBNNGx53ZJUDvj35qtpURP2prmXyLSCNdkzMDuGTxj/ACaaVkPlSRTvHS8v2Fk7zAxbN68EAEcHNX4bEu7XMHkwRkpGqM2MsANzMfUtmpo7mCG+uftMcEm8lInRSreWv8WBxuPHFVIiZWmYl0tGfJKqHDdup79vY1VwaNawsbbT/COqtc+VHc3cm2OAnlSP4yevc81zt0kUFq8UsMcS27EJsJIkfcBuyPbPFX9Tu1GmT2saJdXDN5LBsiQgcqwPbGTmqFrPZwtFHeXAEXkmNnAJ8tsfK+PU+h6URvuEYvcdEEie7CO9xIFEkSh8q47qAemOuKZfarJeS7pkAtwrKgYg7gQOT2zwR61nPcxWcQKzN5cYwsZ25c9d+RyVz6VfvraGC3glDpHp97ITCWjIQEAbjzywOe1XYuyQ/SlKafO7MltbKuVwPnjJPII6MO/GeRRLdvHK8NvtWCNP9IldATKSM8P/AA8EcdqTU7/y2BsooUP2X/WMd3khh1Ve5PQ+mam0HS1gWAXGJbdox5sa7mQ56qxz6c5Hrip82S5dWVoJ2mtTeGFZJyR5YgYllPd2H8Qx60+XTYiHto3jLb/OaZZA3DD5UHsB1960ZLe1F7Hd2M0iGNCLjGEjhT+FGHUk+lR2sNrp9l58kUWHlYeVKpAGfmB45zjjFF+w4vU5y+ubSHUrUIu0yDyJ5HHyg98e3StWw06efUktpppkhtyCzRceU2M/r2rIVY3a3VIp3Yt5wfP3wOigdCcnmuu0m/a2huJp7vfeZfzMLnzOeevG7PH0zTlpsauTQ+Wytr3VLSFluLiGfDxWsQ2KQDgu59cgmr76i2nefbBibq1BMkRHUHAGfQD0qrNqSXGrRTRGWCW3g3J5bf6xyOUB7cYH1qnqdtL9jGyYwvPgu1yd4X0+bn5jnpWdr7md29GYuo22Li7Es8s10pCgY/dE7htKj0xRpD3ogms42na9kDGMkhVUdDk+nB4qbVNOuNCs2S6Qs88Y3zoMAHrtA7dOtXLBIAlosjZtnXaA74ck9PyPbpWl9C5S0KcVrEqFbK6kkWVyZkhO4yAckc47gVeUrPpkEVnA0UyN5waQ7SGJ5K9eTUuh6daW+qTWVyBCVJfzJFPCjrt49xz711V7o0Gpx2Z09Z44IXEjIz7TIc/KeT9BUSmk9TJs5Wa2urLVbWNonWzmBKq5zvLDqfQZBqksEkGtoTdSyuj5XZxJLlSdwb0GOmK39RjK3DrKzRrsO5ZGG1WJPK+hGM/jWROl0sz3EDR4kQI8ksgURKOM/Q9Bj1oTFe5PY6VbSwJfm82zHd5t0x2MCSSFVecnNXNO0uO5EyT6o7mTE6W55Bx1Mh7H0FUbEwyxl4EW38scvKd6Fvu8Z5z3GKk8NFLG4uN7BEZmLRSISQeNpP15wKHfUcl1Nfw7ZB9T8l7T/RpnDTpHysgH3X56AioUt4h4g1CDyXTTklB3KcrtJ559e3titKG4uJr2C5ti4tUZXcq+3ap4we5GSDio3vIJNT1BRC81tLEUTylz+8Uk52+h75qLsi7uXdO0zF9a7Bi6SLyrt4ZNwmxnbz9DzUFxPp1jazo8USpE7fuhH8jMcnceeDnnFZmjaoscDx2UMr3PMIhwQsf+0T3brxT9ZiuXktl8tJ4JlEs8r8MjLwGCjqc/pStrqCRmm9huktIbO3lMskZjnnQbd2CSDg9ucH2FZ11eE3VtLM04lt8W4k3DefQLx1PqfSnzXEEmoQy3D3Eciv8AJuHMeeCxHvjIFEjuVe9u4rV40vFjHmsVNw2D19APfpWqRsloX77fbXSrcxTbLc/KwbCRhhyc/wB85x+NU9J05NQjFqkNw3mzGRSvBAXnLDPT/wCvxRNqFxFNdwaddwywSsJbguFdPl4AXPBI6fWrGnvGmmPNPNsiR/MIRcGV+wX09MClqkSr2HeII4INVhtNPnEVsSomLnjcRyN38I/OqxNyLm7tCzNaIRhU+ZX+XgDp36msnc7faHvCIY5ohJ5rhmMeWGxQe+OQc8c1HNfJ5jPNPPIRJ5eyHBTOMZHt24qlEfLpY2L24sxb20KKy6azEl1ONzAcqzdee30qla6a165uvMWRvKV4rMoGkZR1CDPb3NQ/u8M7TPMLaMeTBEMoWJPzYP3QPU4zVyO/az5uoxDcSSqggWFRlQCuCR90tkEt14o1WwXaWhStNHS8Wy8474ppzMRKcjaDgqSO+BVpNn2A21sgdrRguJzu4ycqB/DnjjnpUszXAF1L5EUMeBHCsWArHPYjpg8579e9Z63DW8ciRxuz/eXy1DMPU7vUeh9ae4N3NbRoD5Ike78sAEOdoLbSeSR2GMjHvV11tIIYk0tpI7aJjJLIUwSv8HOeB6nsOxrO0q9Em5rxoiWm2BkRVZMDJJI6g4498Ukt0tzPcRwwSRxO2ZYnbDSDorYHHXsOtS1qRZtlUG4TULmeKFvM6tM5yrBe59OvXmtHS0utQnkvLx41gCIge2j3x7iAwGCRzjk1UvYdUMUFtfEBbeHaYUIUsT/A2OPTjpVnQradUSCBrExLHuxcNgKc9NvTPv3pvYGrrQoaRMmnxph4maN9kauwIwf4VP4n8quahoUcgjntpnvLRHDzEKUGSdvXuMnBx3qrqtpDthijikMDkSRoSPLiAAzj6561ueGJLOC7vLqaYySQp8hcboFU8sA3bGCM0S2uipvsCoxhlIRbOVD8wjG75V4GScgdOKgt9Wt7DRFRZHe+a4VvnUFEAzlmzn1qDTb1INDvtQEkEmp3VyxgmdyVhjwOACOePXFc1HcCSE+chZY2yAE27x/ez/dBpKN9xJ3N7UI795YXuFmneRiwDtuRgQdpXHUUy4u3luvKuosmEZjURYcADkVQn1S4jkgbe0k6xFUYMVw2Mg4xj6Cqwt7jcPtsyzSMpnJZs9e5PvjGParS7hY3V1ycu0doga5PDNcclU/vD/CtXT9QvbmNJLKQXItoGZopuNnzn5jjk+tc1eTDVbd0hiCzRxL5aKdqgjq3sT6Uy1fyRII1/eSIUkhJw0WPvfXPPHepcVYlo7PS9Zh1eQvefZbfyyNoYghk/i4/Xnrms+3dbnFqtpbSQbXeKXk4ViM7xnt6dq5y1kZrZntdrRyL5MgAw0Y9B71ou22WwMs01ngMXcH5myRkY9e1JxtsCEv9OuNQuLfSrWaONQGdYyeWC5wwHXOBishNQntgE1ITbopSJGbj972GfoOa3IbhLk6hLHbH7RCCIZG4OBwAB0Pr161PbyQmxmtblESOJS0oIwcHG057kHdTTtuarQi82RPsiWTv9sux+8SY7Ay5++PQHtXT6zdHT4rRdJmKCON2lZUw4O3GM9+a5W4t4JbiPyi4tIVXLj72R7d2PT8abe/ard2axlCBkEkix8kMG+6/vjtUtXsS0mTvr1xBM1hDdQKHkErqBw7Y67uv4g0zTbyVLeTUpYZktcmKK5ik3AAgg5Bz9KkkU31vpqSSoJJyVmiZcF8dBuqHUtSWCwa2ELG3WVYiqNhmJGenoDTt0KSS0SMr+1ZGW3sZ5ElaGbfsRckn13dT8uPl6+lP1m6k1a1S22lLUNvjKDEbt3OTzntjPeqlzLatcvGT9nIXD7hyM/wj1Jpx2m6tU3N5ZBjijLf6odmX2PNXYqyvc6LQ2t7KKytZraJbh95WHbn1OTnp9KqTXd1eanO1sjtiIwmGFQI1HcITkD3PX0NUbOK2imMiyi43zbCqy8Jt+Y8Y+7kZJzzWtPc/2SGa3eFJo7UyJGDuJBYnIPbrUWsyUijq1sLNHuftEkl1IPL8ooSrZHQD0HXI9KqXRneIyBI4hbxrG0rABA2wDt0ye3Wqkl41xdGeOOWSSdlXzc5MXB+7+PekkjjW6vEnkUBE2KrZ/eOwwTn+9k8ntVpFWRYvWewsnWC63R3EASYheQ45C/QZz+Iq1YXU8F7FLA0SXEaCGUzDzAu7lpGJ4zxj8apQc20Vrd+ZG0UmJIgM7yANpBHH1/CrVpKDbh5UUxW8hEoiOXZSDkknGBnGaGibdzS0q1nklFzJA8lqjMI2B/dsoOS3vjr+lLcWqfZrmdz9mh8nEUKuOJs9CfXHJPTpUymG7aFb66ka2eAjzJMoAoJIVcD5V9+c1E99eTxqtre/ZVcZMaIPkj5BKk9CQPw/Go1JfkJeRS3OmeeWht44rYRjZjEjjGT+LYy1QQeQLBFJKxwqJJZd2C0o6BT2TPrTLaezkcSLbNLBtFrbJI+48jO4evA9qswu0z27edHGqZESzQ43Hpgr6AimT5GeQktzJcXDM8ITfs+bBXI3MOc4Hqa2tP1G0fVrhoftTWUabImijVjICchjkHtWNNiWwZliWS4tfNNxMFJWUEqAijqq4J5xWvZ6ZYX0ccHm3KwxoDuh6MeAOuMYHGKH5lWsrsg1iSy0uNIYnMcoUWxVly7K3JODx/WsLUNUm1G0ttDjjCW5dHdYxtAAOcEelWL/AFe0lDSrB++MGwKwyUYnkbj296yII7iKQ3ErXAlkflimTtUenrnFUo6aktX3N6XTibhUSEM13wiyZAXtt56dOvpispZJH+UsxWJGjMO7IAUjDJ/nFSDzxIHAmeNgGkYsfkyfvH0+lFnI9nqKS26uULkYkXmJR1b360yl5kpu1uVkkfBZolIR+ArH+LA64/zzRHE7ZgiRZMSBS6yDLOQPWnatvgu8R2vzAjEi/dYHkHH0qvHmC9SRUl3hzhDGdyKRwMfXPNCDyJ4Y3sW8y3IE0cu3ymOS7f3snrgZ6cVNcB1ulmeP7WGcEzc7ZMdiPb1otUa8v4Cd3mphgrjKg9we4rTnjM99sTzre3Rjw/8Aqx+nGf8A61JvUTRn26pAquyIIZGMjPKCWXHTb3POeRUw1BJtTEl3K89vHlzujAc4GMemMkH1wKkvLZxDFJIshl3bCZFzsGeNoHXNU5LSSSRJna5ghZ/LkbaCgBOCOnFLRiLtjbSXaB4ZlMOGlKKxx04Zc/7XXPati0trG61Jp9QRpLiOMArbBnimPoT3xx09ap6SF+13gtYzJDbRsI2K7RJtGBgenHTvWlcandLbmG5iaJhKjxTFQmMj5lCgdFwM/Wod7hzPZA+jRWN4swvJllnAeMMoZFJU8N3xz+BxXPAO8z2s0PlAFommwUWRz3PrweprrdLuY5p5JIRLslDK124+Z177VPG3OMVQaGW8ubr9/uj8vG+YZ5HAAHfjHTp70k2txKV3qZxMyW8i6hIyxxIfK8vAOeOcdQp4/KszVYpBFAZDE/2gmWXY/IJ5wMcgenfFaWn2lyhiuLlMxrE0g3AuzKTgAL/L8ahjsHuZ5bSxDSPCUYyohAcY5Lk+h5wMdKtbmiMm6Ns93Ez7DDGgzPcEkHHJBPUHtg9arWZt5p1V3aK1AYsrD7y/w7c8469K6S/s7a9uYls5bQ2lsojeWZSVeVifmb19van62Leyt4rGymMtmoEs90tvw0nQADrgZPA9aal0NLmL5iWVvIbdoSjsjZEOAq8cOcYHPXNZsnmT3MQMioR90qSQiknLnHJ+h/lV+ZLyRmkjtQVtmJ8yXhGAGeV7kHt61HcK0qwRywwwfaEGwopIK5JYye/PFUhuRSs/MsLsXNwGlRhwqkAuO3HYd61Zjam6kuSDcBwuwSOckbfmyO2OakRLW2a4NqomW0RjGxbCzyEgbhkfd5zVaRZUs5Ly1R3MCAM6R8M54YjPpRe4aDk1C0jjkhhUiUk5iR8Ryjv06Z459qqPdPeGSIQo8siniPcI1GQN2RyQKhkiVzLJDDO58tWWQJwD/dx6n0rThtLiKC6kvisYUq1xDbjGwt8qoPXkglR0xRoiXJGhpjSJfpHK8z6fFH5SmctumOMbUz2z37Ck1e4tC0PlW/ETKzOj53NzhF7Njnk02c3IuPsVuFE1mQG3KWijBUDk54ye1ZEy73dobx9zRFpCU+UN/cQf3jjr2/GpSu7kHQaZDBe2hklVYkiVpgkcfK85ypI7jr9apG8eWZb5mZ5UxkkkGBCcDYOrH+Rq1HayDQTeJEzTFlWS3QMDDkgkEZzg9f8ACrllHcXgkDCMEF2jKJsfGMAgHOArZPOanzJ82xIdzyzXIaQW8aLDOwIEjoOiBepOT260w3NzpF5HN5EsrzRsC0kBEY+bgKMZP1pbNbFLO4fz3lVAIvlQ5un54Q+5x+RrS060bV4bcNDcGe3Ro51kl2Qq+7omck46HmjRb7ESl9x//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodules larger than those typically seen in follicular lymphoma are present in this lymph node section.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19874=[""].join("\n");
var outline_f19_26_19874=null;
var title_f19_26_19875="Penile length 0 to 5yrs";
var content_f19_26_19875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Penile length of boys aged 0 to 5 years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 587px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Camurdan AD, Oz MO, Ilhan MN, et al. Current stretched penile length: Cross-sectional study of 1040 healthy Turkish children aged 0 to 5 years. Urology 2007; 70:572. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19875=[""].join("\n");
var outline_f19_26_19875=null;
var title_f19_26_19876="Anterior neck muscles A";
var content_f19_26_19876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Anterior neck muscles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior neck muscles include the platysma, sternocleidomastoid (SCM), anterior vertebral muscles, and the lateral vertebral muscles. The platysma is a broad, thin muscle that overlies the other muscles and neck structures. The SCM arises from the sternum and the medial third of the clavicle and passes obliquely across the side of the neck to insert into the mastoid process. The anterior vertebral muscles include the longus capitis, longus colli, rectus capitis anterior, and rectus capitis lateralis (only the longus capitus is visible on this view). The lateral vertebral muscles (scalene muscles), attach from the cervical vertebrae to the first or second ribs. The nerves of the brachial plexus pass between the anterior and middle scalene muscles en route to the subclavian area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19876=[""].join("\n");
var outline_f19_26_19876=null;
var title_f19_26_19877="Dennie-Morgan fold";
var content_f19_26_19877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dennie-Morgan fold in atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An extra skin fold is present under the eyes in this patient with facial atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19877=[""].join("\n");
var outline_f19_26_19877=null;
var title_f19_26_19878="Balkan endemic nephropathy";
var content_f19_26_19878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Balkan endemic nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/26/19878/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19878/contributors\">",
"     Marc E De Broe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/26/19878/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19878/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/26/19878/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19878/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/26/19878/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balkan endemic nephropathy (BEN) is a chronic tubulointerstitial disease associated with a high frequency of urothelial atypia, occasionally culminating in tumors of the renal pelvis and urethra.",
"   </p>",
"   <p>",
"    Affected patients most commonly reside in southeastern Europe, including the areas traditionally considered to comprise the Balkans: Serbia, Bosnia and Herzegovina, Croatia, Romania, and Bulgaria. More specifically, BEN is most likely to occur among those living along the confluence of the Danube River, a region in which the plains and low hills generally have high humidity and rainfall.",
"   </p>",
"   <p>",
"    This topic reviews Balkan endemic nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated prevalence of BEN in endemic areas ranges between 0.5 to 4.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/1\">",
"     1",
"    </a>",
"    ]. It has been suggested that the prevalence would be as high as 20 percent if aggressive screening were to be performed in at-risk populations; a striking observation is that nearly all affected patients were farmers. In some regions in Bosnia, approximately 10 percent of the patients on dialysis have BEN as the cause of end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent reports, however, suggest that the incidence of BEN may be decreasing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/3\">",
"     3",
"    </a>",
"    ]. Since the early 1990s, the few new cases in one region in Serbia were only seen in previously affected families [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the years an impressive number of potential etiological agents and genetic factors have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that it is endemic to a specific geographic area, toxins and environmental exposures that are found in the Balkans",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are unique to that area have been considered. Many suspect agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    general group of compounds or organisms have been implicated, but none have been definitively linked. These include trace elements (lead, cadmium, silica,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    ), viruses, plant toxins, fungi (ochratoxin A, a mycotoxin),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aromatic hydrocarbons [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The following are the observations upon which a few of these putative associations were based:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ochratoxin A, a mycotoxin which induces oxidative DNA damage and causes nephrotoxicity in experimental models, has been found in much higher levels in the blood and urine of individuals in areas endemic for BEN and affected with BEN [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. However, similarly high exposure occurs throughout the world in farming communities, which are largely free of chronic kidney diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polycyclic aromatic hydrocarbons or other toxins leached from coal into the water supply were found in higher levels in affected areas in one study, but a larger study failed to find higher levels of these hydrocarbons or other dissolved organic compounds in the water supply of endemic villages compared to nonendemic villages [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aristolochic acid, a mutagenic and nephrotoxic alkaloid found in the plant Aristolochia clematis, most likely underlie both Chinese herbal nephropathy and BEN [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. There are striking pathologic and clinical similarities between BEN and the progressive interstitial fibrosis observed in young women who have been on a slimming regimen including Chinese herbs (as well as other agents) (",
"      <a class=\"graphic graphic_table graphicRef83518 \" href=\"UTD.htm?0/62/1005\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using ultrasensitive methods utilizing liquid chromatography and mass spectroscopy, aristolactam-DNA adducts were demonstrated in the renal cortex of individuals with BEN, and in urothelial tumors from individuals from endemic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/19\">",
"     19",
"    </a>",
"    ]. Characteristic A:T&rarr;T:A mutations of the TP53 tumor-suppressor gene were also identified in urothelial tumors from residents of BEN-endemic villages. In a follow-up study, aristolactam-DNA adducts were demonstrated in 70 percent of 67 individuals with urothelial tumors who resided in BEN-endemic areas. The aristolactam-DNA adducts were present in 94 percent of individuals who had A:T&rarr;T:A mutations in TP53. By contrast, neither the aristolactam-DNA adducts nor A:T&rarr;T:A mutations were detected in urothelial tumors of 10 patients residing in non-endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6933?source=see_link\">",
"     \"Nephropathy induced by aristolochic acid (AA) containing herbs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These clinical, histopathological, epidemiological, and toxicological data suggest that long-term exposure to AA is the etiological factor in BEN [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/18,22\">",
"     18,22",
"    </a>",
"    ]. Aristolochic acid nephropathy has been proposed as a more correct term for BEN [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A genetic predisposition to BEN has been proposed by some investigators. Support for this hypothesis includes observations that the disease clearly affects specific families and that some ethnic populations who have lived in the area for generations (such as Gypsies) do not suffer from BEN. Although a mode of inheritance has not been established, polygenetic inheritance appears to be most plausible.",
"   </p>",
"   <p>",
"    The reported prevalence of BEN is 3 to 7 percent in the exposed population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/23\">",
"     23",
"    </a>",
"    ]. Genetically determined interindividual variability may contribute to the risk of developing BEN and urothelial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/23\">",
"     23",
"    </a>",
"    ]. Polymorphisms that effect susceptibility to BEN and urothelial tumors are likely to be found in genes responsible for the absorption, bioactivation metabolism, detoxification (cytochrome P450-mediated O-methylation), excretion and transport of AA.",
"   </p>",
"   <p>",
"    A possible causative gene(s) has not been identified. Candidate genes have been localized to the region between 3q24 and 3q26 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/24\">",
"     24",
"    </a>",
"    ]. Given the association with bladder cancer, a correlation with mutations in the p53 tumor suppressor gene has also been explored [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/25\">",
"     25",
"    </a>",
"    ]. Whether this gene predisposes to BEN or bladder cancer in these patients is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=see_link&amp;anchor=H14#H14\">",
"     \"Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer\", section on 'p53 status for risk-directed clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A unifying hypothesis may be that BEN develops in genetically predisposed individuals who are chronically exposed to a causative (but as yet unidentified) agent found within endemic areas. This possibility was suggested by a study of 100 adult offspring (mean age 49 years) of individuals with BEN, who were compared to adults from unaffected families (most of whom were from endemic villages) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/26\">",
"     26",
"    </a>",
"    ]. Individuals whose mothers had BEN had slightly smaller kidneys and somewhat greater degree of proteinuria, microalbuminuria, and &szlig;2-microglobinuria. These individuals probably represent early cases of BEN and suggest a maternal association with BEN risk. Whether this reflects an X-linked genetic factor or exposure to environmental toxins in-utero is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the following observations are inconsistent with a genetic basis or in-utero exposure as a sole explanation for the disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BEN has been observed in individuals who have migrated from nonendemic into endemic areas and in previously unaffected families who have lived for at least 15 years in endemic areas.",
"     </li>",
"     <li>",
"      BEN does",
"      <strong>",
"       not",
"      </strong>",
"      develop in individuals who left endemic areas early in life, despite being from previously affected families, or who spent less than 15 years in high incidence areas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;With early disease, renal histology reveals cortical focal tubular atrophy, interstitial edema, and peritubular and glomerular sclerosis with limited mononuclear cell infiltration. Narrowing and endothelial swelling of interstitial capillaries (eg, capillarosclerosis) are also described.",
"   </p>",
"   <p>",
"    In advanced cases, marked tubular atrophy and interstitial fibrosis develop along with focal segmental glomerular changes and global sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/28\">",
"     28",
"    </a>",
"    ]. As mentioned, there is also an extremely high incidence of cellular atypia and urothelial carcinoma of the genitourinary tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;BEN is a slowly progressive tubulointerstitial disease that may culminate in ESRD. Clinical manifestations first appear in patients 30 to 50 years of age; findings prior to the age of 20 are extremely rare.",
"   </p>",
"   <p>",
"    One of the first signs of BEN, detected only when prospective monitoring is performed, is tubular dysfunction. This is characterized by increased excretion of low molecular weight proteins (such as &szlig;2-microglobulin and neopterin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/4\">",
"     4",
"    </a>",
"    ]) that are not detected on the urine dipstick for protein [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]. As an example, among offspring of patients with BEN who had no clinical renal abnormalities, 6 percent had elevated &szlig;2-microglobulin levels, compared to 1 percent in the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early tubular injury can also lead to renal glucosuria, aminoaciduria, and diminished ability to handle an acid load. Over more than twenty years, there is a progressive decrease in concentrating ability (possibly resulting in polyuria) and in the glomerular filtration rate (GFR). Many patients eventually progress to ESRD. As an example, among 18 patients with BEN followed for a mean of 15 years, six progressed to requiring dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional clinical features include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are usually normotensive and without edema; hypertension only develops with end-stage disease.",
"     </li>",
"     <li>",
"      A normochromic normocytic anemia occurs with early disease, which becomes increasingly pronounced as the disorder progresses.",
"     </li>",
"     <li>",
"      Urinary tract infection is rarely observed [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The kidneys are usually of normal size early in the course of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/32\">",
"       32",
"      </a>",
"      ]. A symmetric reduction of kidney size with a smooth outline and normal pelvicaliceal system is subsequently observed with late-stage disease. Intrarenal calcifications are not observed.",
"     </li>",
"     <li>",
"      High incidence of transitional cell carcinoma, predominantly of the renal pelvis, ureter, but also involving the urinary bladder, in BEN-endemic areas (2 to 50 percent, which is a two- to tenfold higher incidence than in nonendemic areas) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/2,33-36\">",
"       2,33-36",
"      </a>",
"      ]. These tumors are generally superficial and slow-growing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=see_link\">",
"       \"Malignancies of the renal pelvis and ureter\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link\">",
"       \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of BEN is typically considered in a patient with slowly progressive chronic kidney disease who is living in or recently moved from an endemic area, particularly if the family history is positive for BEN.",
"   </p>",
"   <p>",
"    The diagnosis is based upon the presence of some combination of the following findings (",
"    <a class=\"graphic graphic_table graphicRef83518 \" href=\"UTD.htm?0/62/1005\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symmetrically shrunken, smooth kidneys without intrarenal calcifications",
"     </li>",
"     <li>",
"      Mild tubular proteinuria, hyposthenuria, and glucosuria",
"     </li>",
"     <li>",
"      Normochromic hypochromic anemia out of proportion with the decrease in GFR",
"     </li>",
"     <li>",
"      Urothelial atypia",
"     </li>",
"     <li>",
"      Characteristic histologic findings on renal biopsy, although a renal biopsy is not necessary if the above findings are present in a patient from an endemic area or with a positive family history. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course and histologic appearance of BEN can resemble that of other chronic interstitial nephropathies, including analgesic nephropathy and Chinese herb nephropathy. The history typically reveals ingestion of the potential causative substance in the latter disorders, and these can be further differentiated from BEN by the absence of a positive family history and the finding of shrunken kidneys with irregular contours on ultrasonography (versus smooth contour) (",
"    <a class=\"graphic graphic_table graphicRef83518 \" href=\"UTD.htm?0/62/1005\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27318?source=see_link\">",
"     \"Clinical manifestations and diagnosis of analgesic nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6933?source=see_link\">",
"     \"Nephropathy induced by aristolochic acid (AA) containing herbs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with many other chronic tubulointerstitial diseases of unclear origin, there is no specific prevention or treatment for BEN. Therefore, therapy is largely supportive, including implementation of strategies to delay progression and manage the complications of chronic kidney disease. Patients who progress to ESRD may be treated with dialysis or kidney transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=see_link\">",
"     \"Indications for initiation of dialysis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the high incidence of cellular atypia of the genitourinary tract, we advocate surveillance with urine sent for cytology once a year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19878/abstract/37\">",
"     37",
"    </a>",
"    ]. For patients who are considering or have undergone transplantation, screening with urine cytologies every six months is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=see_link\">",
"     \"Malignancies of the renal pelvis and ureter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether bilateral native nephroureterectomies are advisable in those who have progressed to ESRD, particularly those undergoing renal transplantation, is unclear. A similar problem faces patients with Chinese herbal nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6933?source=see_link\">",
"     \"Nephropathy induced by aristolochic acid (AA) containing herbs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Balkan endemic nephropathy (BEN) is a chronic tubulointerstitial disease of unknown etiology, most commonly reported in patients who reside in southeastern Europe. The estimated prevalence is between 0.5 and &lt;5 percent, with most cases reported in farmers. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      BEN is likely caused by exposure to aristolochic acid. Aristolochic acid nephropathy has been proposed as a more correct term for BEN. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal histology with early disease reveals cortical focal tubular atrophy, interstitial edema, and peritubular and glomerular sclerosis with limited mononuclear cell infiltration. In advanced cases, marked tubular atrophy, interstitial fibrosis, and focal segmental glomerulosclerosis are seen. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early clinical manifestations include clinically silent tubular dysfunction (eg, glucosuria, aminoaciduria). More advanced disease leads to decreased concentrating ability and GFR, and progression to ESRD. Patients with BEN have anemia out of proportion to the degree of reduced GFR, and they have a high risk of urothelial malignancy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical Features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kidney ultrasound is normal with early disease; more advanced disease is characterized by a symmetric reduction of kidney size with a smooth outline and normal pelvicaliceal system, without intrarenal calcifications. The diagnosis of BEN is typically based upon some combination of the associated clinical findings and the appearance of the kidneys on ultrasound. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical Features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific prevention or treatment for BEN. Therapy is therefore largely supportive, including implementation of strategies to delay progression and manage the complications of chronic kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"       \"Overview of the management of chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Given the high incidence of cellular atypia of the genitourinary tract, we suggest regular surveillance with urine sent for cytology once or twice per year. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/1\">",
"      Ceovi S, Hrabar A, Sari M. Epidemiology of Balkan endemic nephropathy. Food Chem Toxicol 1992; 30:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/2\">",
"      Djukanovi L, Radovi M, Bakovi J, et al. Epidemiology of end-stage renal disease and current status of hemodialysis in Yugoslavia. Int J Artif Organs 2002; 25:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/3\">",
"      Dimitrov PS, Simeonov VA, Ganev VS, Karmaus WJ. Is the incidence of Balkan endemic nephropathy decreasing? Pathol Biol (Paris) 2002; 50:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/4\">",
"      Bukvi D, Jankovi S, Arsenovi A, Djukanovi L. Balkan endemic nephropathy is still present in the Kolubara region, Serbia. Ren Fail 2005; 27:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/5\">",
"      Arsenovi A, Bukvi D, Trbojevi S, et al. Detection of renal dysfunctions in family members of patients with Balkan endemic nephropathy. Am J Nephrol 2005; 25:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/6\">",
"      Stefanovic V, Toncheva D, Atanasova S, Polenakovic M. Etiology of Balkan endemic nephropathy and associated urothelial cancer. Am J Nephrol 2006; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/7\">",
"      Bamias G, Boletis J. Balkan nephropathy: evolution of our knowledge. Am J Kidney Dis 2008; 52:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/8\">",
"      Radovanovic Z. Aetiology of Balkan nephropathy: a reappraisal after 30 years. Eur J Epidemiol 1989; 5:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/9\">",
"      Riquelme C, Escors D, Ortego J, et al. Nature of the virus associated with endemic Balkan nephropathy. Emerg Infect Dis 2002; 8:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/10\">",
"      Puntari D, Bosnir J, Smit Z, et al. Ochratoxin A in corn and wheat: geographical association with endemic nephropathy. Croat Med J 2001; 42:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/11\">",
"      Hassen W, Abid S, Achour A, et al. Ochratoxin A and beta2-microglobulinuria in healthy individuals and in chronic interstitial nephropathy patients in the centre of Tunisia: a hot spot of Ochratoxin A exposure. Toxicology 2004; 199:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/12\">",
"      Kamp HG, Eisenbrand G, Schlatter J, et al. Ochratoxin A: induction of (oxidative) DNA damage, cytotoxicity and apoptosis in mammalian cell lines and primary cells. Toxicology 2005; 206:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/13\">",
"      Castegnaro M, Canadas D, Vrabcheva T, et al. Balkan endemic nephropathy: role of ochratoxins A through biomarkers. Mol Nutr Food Res 2006; 50:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/14\">",
"      Vrabcheva T, Petkova-Bocharova T, Grosso F, et al. Analysis of ochratoxin A in foods consumed by inhabitants from an area with balkan endemic nephropathy: a 1 month follow-up study. J Agric Food Chem 2004; 52:2404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/15\">",
"      Voice TC, McElmurry SP, Long DT, et al. Evaluation of the hypothesis that Balkan endemic nephropathy is caused by drinking water exposure to contaminants leaching from Pliocene coal deposits. J Expo Sci Environ Epidemiol 2006; 16:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/16\">",
"      Ivic, M. The problem of etiology of endemic nephropathy. Acta Fac Med Naiss 1970; 1:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/17\">",
"      Cosyns JP, Jadoul M, Squifflet JP, et al. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int 1994; 45:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/18\">",
"      De Broe ME. Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney Int 2012; 81:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/19\">",
"      Grollman AP, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A 2007; 104:12129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/20\">",
"      Arlt VM, Schmeiser HH, Pfeifer GP. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 2001; 22:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/21\">",
"      Jelakovi B, Karanovi S, Vukovi-Lela I, et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012; 81:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/22\">",
"      Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008; 74:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/23\">",
"      Li X, Wang H. Aristolochic acid nephropathy: what we know and what we have to do. Nephrology (Carlton) 2004; 9:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/24\">",
"      Toncheva D, Dimitrov T, Tzoneva M. Cytogenetic studies in Balkan endemic nephropathy. Nephron 1988; 48:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/25\">",
"      Krasteva ME, Georgieva EI. Germline p53 single-base changes associated with Balkan endemic nephropathy. Biochem Biophys Res Commun 2006; 342:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/26\">",
"      Dimitrov P, Tsolova S, Georgieva R, et al. Clinical markers in adult offspring of families with and without Balkan Endemic Nephropathy. Kidney Int 2006; 69:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/27\">",
"      Batuman V. Fifty years of Balkan endemic nephropathy: daunting questions, elusive answers. Kidney Int 2006; 69:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/28\">",
"      Stefanovi V, Polenakovi MH. Balkan nephropathy. Kidney disease beyond the Balkans? Am J Nephrol 1991; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/29\">",
"      Toncheva D, Galabov AS, Laich A, et al. Urinary neopterin concentrations in patients with Balkan endemic nephropathy (BEN). Kidney Int 2003; 64:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/30\">",
"      Cukuranovic R, Savic V, Stefanovic N, Stefanovic V. Progression of kidney damage in Balkan endemic nephropathy: a 15-year follow-up of patients with kidney biopsy examination. Ren Fail 2005; 27:701.",
"     </a>",
"    </li>",
"    <li>",
"     Polenakovic, MH, Stefanovic, V. Balkan nephropathy. In: Oxford Textbook of Clinical Nephrology, 2nd edition, Davison, AM, Cameron, JS, Gr&uuml;nfeld, JP, et al (Eds), Oxford Medical Publications 1998. p.1203.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/32\">",
"      Djukanovic L, Bukvic D, Maric I. Creatinine clearance and kidney size in Balkan endemic nephropathy patients. Clin Nephrol 2004; 61:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/33\">",
"      Petroni VJ, Bukurov NS, Djoki MR, et al. Balkan endemic nephropathy and papillary transitional cell tumors of the renal pelvis and ureters. Kidney Int Suppl 1991; 34:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/34\">",
"      Sattler TA, Dimitrov T, Hall PW. Relation between endemic (Balkan) nephropathy and urinary-tract tumours. Lancet 1977; 1:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/35\">",
"      Cukuranovi R, Ignjatovi M, Stefanovi V. Urinary tract tumors and Balkan nephropathy in the South Morava River basin. Kidney Int Suppl 1991; 34:S80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19878/abstract/36\">",
"      Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003; 14:197.",
"     </a>",
"    </li>",
"    <li>",
"     Djukanovic, L, Radovanovic, Z. Balkan endemic nephropathy. In: Clinical nephrotoxins - renal injury from drugs and chemicals. De Broe, ME, Porter, GA, Bennett, WM, Verpooten, GA (Eds), Kluwer Academic Publications, Dordrecht 2003, p. 587.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7193 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.22.229.50-C760863B48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19878=[""].join("\n");
var outline_f19_26_19878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7193\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7193|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/62/1005\" title=\"table 1\">",
"      Diff diag chronic tubulo neph assoc uroth carc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27318?source=related_link\">",
"      Clinical manifestations and diagnosis of analgesic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=related_link\">",
"      Indications for initiation of dialysis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=related_link\">",
"      Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6933?source=related_link\">",
"      Nephropathy induced by aristolochic acid (AA) containing herbs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_26_19879="Rocuronium: Drug information";
var content_f19_26_19879=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rocuronium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/52/27459?source=see_link\">",
"    see \"Rocuronium: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"    see \"Rocuronium: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zemuron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rocuronium Bromide Injection;",
"     </li>",
"     <li>",
"      Zemuron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F219099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Neuromuscular Blocker Agent, Nondepolarizing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F219073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose to effect; doses will vary due to interpatient variability. Dosing also dependent on anesthetic technique and age of patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Rapid sequence intubation:",
"     </b>",
"     I.V.: 0.6-1.2 mg/kg;",
"     <b>",
"      Note:",
"     </b>",
"     In adult patients with morbid obesity (BMI &gt;40 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ), the use of 1.2 mg/kg using ideal body weight (IBW) provided a short onset of action and excellent or good intubating conditions at 60 seconds in one study (Gaszynski, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Tracheal intubation:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     May use ideal body weight (IBW) for morbidly obese (BMI &gt;40 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) adult patients (Leykin, 2004); onset time may be slightly delayed using IBW. The manufacturer recommends dosing based on actual body weight in all obese patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     0.45-0.6 mg/kg; administration of 0.3 mg/kg may also provide optimal conditions for tracheal intubation (Barclay, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Maintenance for continued surgical relaxation:",
"     </i>",
"     0.1-0.2 mg/kg; repeat as needed",
"     <b>",
"      or",
"     </b>",
"     a continuous infusion of 8-12",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute only after recovery of neuromuscular function is evident; infusion rates have ranged from 4-16",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Inhaled anesthetic agents prolong the duration of action of rocuronium. Use lower end of the dosing range; redosing interval guided by monitoring with a peripheral nerve stimulator.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Preinduction defasciculating dose:",
"     </b>",
"     I.V.: 0.03-0.06 mg/kg given 1.5-3 minutes before administration of succinylcholine (Harvey, 1998; Martin, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      ICU paralysis (eg, facilitate mechanical ventilation) in selected adequately sedated patients",
"     </b>",
"     (Murray, 2002; Rudis, 1996; Sparr, 1997; Warr, 2011): Initial bolus dose: 0.6-1 mg/kg, then a continuous I.V. infusion of 8-12",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute; monitor depth of blockade every 2-3 hours initially until stable dose, then every 8-12 hours; adjust rate of administration by 10% increments according to peripheral nerve stimulation response or desired clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When possible, minimize depth and duration of paralysis. Stopping the infusion for some time until forced to restart based on patient condition is recommended to reduce post-paralytic complications (eg, acute quadriplegic myopathy syndrome [AQMS]) (Murray, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Intermittent dosing",
"     </i>",
"     has also been described with an initial loading dose of 50 mg followed by 25 mg given when peripheral nerve stimulation returns (Sparr, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F219085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"      see \"Rocuronium: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose to effect; doses will vary due to interpatient variability. Dosing also dependent on anesthetic technique and age of patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants 28 days to 3 months and Children &ge;3 months:",
"     <b>",
"      Note:",
"     </b>",
"     In general, onset is shortened and duration is prolonged as dose increases. Duration is shortest in children &gt;2 to &le;11 years and longest in neonates and infants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rapid sequence intubation (unlabeled use):",
"     </b>",
"     I.V.: 0.9 mg/kg or 1.2 mg/kg. Not recommended, per the manufacturer, for rapid sequence intubation in pediatric patients; however, it has been used successfully in clinical trials for this indication in children &gt;1 year of age (Cheng, 2002; Fuchs-Buder, 1996; Mazurek, 1998; Naguib, 1997).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tracheal intubation:",
"     </b>",
"     I.V.: 0.45 mg/kg or 0.6 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance for continued surgical relaxation:",
"     </i>",
"     I.V.: 0.075-0.15 mg/kg; redosing interval is guided by monitoring with a peripheral nerve stimulator",
"     <b>",
"      or",
"     </b>",
"     7-12",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute as a continuous infusion; use lower end of the continuous infusion dosing range for neonates and infants up to age 28 days and the upper end for children &gt;2 to &le;11 years of age",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F219074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7282609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustments required; duration of neuromuscular blockade may vary in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7282610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reductions may be necessary in patients with liver disease; duration of neuromuscular blockade may be prolonged due to increased volume of distribution. When rapid sequence intubation is required in adult patients with ascites, a dose on the higher end of the dosage range may be necessary to achieve adequate neuromuscular blockade.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as bromide: 10 mg/mL (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zemuron&reg;: 10 mg/mL (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as bromide [preservative free]: 10 mg/mL (5 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F219054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. only; may be administered undiluted as a bolus injection or via a continuous infusion using an infusion pump",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F7282116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS; do not mix with alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Dexmedetomidine, fenoldopam, hetastarch in lactate electrolyte injection (Hextend&reg;), milrinone, palonosetron.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Micafungin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Midazolam, morphine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F219052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Facilitate both rapid sequence and routine endotracheal intubation and to relax skeletal muscles during surgery; to facilitate mechanical ventilation in ICU patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F219106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zemuron&reg; may be confused with Remeron&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"       - Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"       - Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F219097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;1%: Cardiovascular: Hypertension (&le;2%), hypotension (transient; &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal ECG, anaphylactoid reaction, anaphylaxis, arrhythmia, bronchospasm, injection site edema, hiccups, pruritus, nausea, pulmonary vascular resistance (increased), rash, rhonchi, shock, tachycardia, vomiting, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F219057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, anaphylaxis) to rocuronium, other neuromuscular-blocking agents, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F219041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use is contraindicated in patients with previous anaphylactic reactions to other neuromuscular blockers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged paralysis: Some patients may experience prolonged recovery of neuromuscular function after administration (especially after prolonged use). Patients should be adequately recovered prior to extubation. Other factors associated with prolonged recovery should be considered (eg, corticosteroid use, patient condition).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Burn injury: Resistance may occur in burn patients (&gt;30% of body) for period of 5-70 days postinjury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure); onset of action may be delayed and duration of action may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may",
"     <i>",
"      antagonize",
"     </i>",
"     neuromuscular blockade: Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, and muscle trauma may result in antagonism of neuromuscular blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may",
"     <i>",
"      potentiate",
"     </i>",
"     neuromuscular blockade: Electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, cachexia, neuromuscular diseases, metabolic acidosis, metabolic alkalosis, Eaton-Lambert syndrome, and myasthenia gravis may result in potentiation of neuromuscular blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clinical duration may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary hypertension:  Use with caution in patients with pulmonary hypertension; use may increase pulmonary vascular resistance worsening symptoms of right heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Valvular heart disease: Use with caution in patients with valvular heart disease; use may increase pulmonary vascular resistance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; Corticosteroids: In addition to prolonging recovery from neuromuscular blockade, concomitant use with corticosteroids has been associated with development of acute quadriplegic myopathy syndrome (AQMS). Current guidelines recommend neuromuscular blockers be discontinued as soon as possible in patients receiving corticosteroids or interrupted daily until necessary to restart them based on clinical condition (Murray, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; High potential for interactions: Numerous drugs either",
"     <i>",
"      antagonize",
"     </i>",
"     (eg, acetylcholinesterase inhibitors) or",
"     <i>",
"      potentiate",
"     </i>",
"     (eg, calcium channel blockers, certain antimicrobials, inhalation anesthetics, lithium, magnesium salts, procainamide, and quinidine) the effects of neuromuscular blockade; use with caution in patients receiving these agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly, effects and duration are more variable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immobilized patients: Resistance may occur in patients who are immobilized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not recommended by the manufacturer for rapid sequence intubation in pediatric patients; however, it has been used successfully in clinical trials for this indication (Cheng, 2002; Fuchs-Buder, 1996; Mazurek, 1998; Naguib, 1997).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical.  Rocuronium does not relieve pain or produce sedation; use should include appropriate anesthesia, pain control, and sedation. In patients requiring long-term administration in the ICU, use of a peripheral nerve stimulator to monitor drug effects is strongly recommended. Additional doses of rocuronium or any other neuromuscular-blocking agent should be avoided unless definite excessive response to nerve stimulation is present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced personnel: Should be administered by adequately trained individuals familiar with its use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: If extravasation occurs, local irritation may ensue; discontinue administration immediately and restart in another vein.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F219060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Rocuronium crosses the placenta; umbilical venous plasma levels are ~18% of the maternal concentration following a maternal dose of 0.6 mg/kg  (Abouleish, 1994). The manufacturer does not recommend use for rapid sequence induction during cesarean section.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15683458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Information related to rocuronium use and breast-feeding has not been located. If present in breast milk, oral absorption by a nursing infant would be expected to be minimal (Lee, 1993).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rocuronium Bromide Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (5 mL): $5.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/10 mL (10 mL): $8.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zemuron Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (5 mL): $25.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/10 mL (10 mL): $48.79",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F219049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Peripheral nerve stimulator measuring twitch response, heart rate, blood pressure, assisted ventilation status",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F219061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Esmero-N (MX);",
"     </li>",
"     <li>",
"      Esmeron (AE, AT, AU, BE, BG, BH, BR, CH, CL, CN, CR, CY, CZ, DE, DK, DO, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IQ, IR, IT, JO, KP, KW, LB, LY, MT, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PT, QA, RU, SA, SE, SG, SK, SV, SY, TH, TR, TW, VE, YE);",
"     </li>",
"     <li>",
"      Noveron (ID);",
"     </li>",
"     <li>",
"      Roculax (ID);",
"     </li>",
"     <li>",
"      Rocur (UY);",
"     </li>",
"     <li>",
"      Rocuronio (CO);",
"     </li>",
"     <li>",
"      Zemuron (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F219040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks acetylcholine from binding to receptors on motor endplate inhibiting depolarization",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F219056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Good intubation conditions within 1-2 minutes (depending on dose administered); maximum neuromuscular blockade within 4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: ~30 minutes (with standard doses, increases with higher doses and inhalational anesthetic agents; patient age dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~0.25 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic; 17-desacetylrocuronium (5% to 10% activity of parent drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 60-144 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (50%); urine (30%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abouleish E, Abboud T, Lechevalier T, et al, \"Rocuronium (Org 9426) for Caesarean Section,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1994, 73(3):336-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/7946860/pubmed\" id=\"7946860\" target=\"_blank\">",
"        7946860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barclay K, Eggers K, and Asai T, &ldquo;Low-Dose Rocuronium Improves Conditions for Tracheal Intubation After Induction of Anaesthesia With Propofol and Alfentanil,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1997, 78(1):92-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/9059214/pubmed\" id=\"9059214\" target=\"_blank\">",
"        9059214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartkowski RR, Witkowski TA, Azad S, et al, &ldquo;Rocuronium Onset of Action: A Comparison With Atracurium and Vecuronium,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1993, 77(3):574-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/8103649/pubmed\" id=\"8103649\" target=\"_blank\">",
"        8103649",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheng CA, Aun CST, and Gin T, &ldquo;Comparison of Rocuronium and Suxamethonium for Rapid Tracheal Intubation in Children,&rdquo;",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2002, 12(2):140-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/11882225/pubmed\" id=\"11882225\" target=\"_blank\">",
"        11882225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheymol G, &ldquo;Effects of Obesity on Pharmacokinetics: Implications for Drug Therapy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2000, 39(3):215-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/11020136/pubmed\" id=\"11020136\" target=\"_blank\">",
"        11020136",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL, &ldquo;Dosing of Medications in Morbidly Obese Patients in the Intensive Care Unit Setting,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2004, 30(1):18-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/14625670/pubmed\" id=\"14625670\" target=\"_blank\">",
"        14625670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuchs-Buder T and Tassonyi E, &ldquo;Intubating Conditions and Time Course of Rocuronium-Induced Neuromuscular Block in Children,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1996, 77(3):335-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/8949805/pubmed\" id=\"8949805\" target=\"_blank\">",
"        8949805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaszynski TM, Szewczyk T. &ldquo;Rocuronium for Rapid Sequence Induction in Morbidly Obese Patients: A Prospective Study for Evaluation of Intubation Conditions After Administration 1.2 mg kg",
"      <sup>",
"       -1",
"      </sup>",
"      Ideal Body Weight of Rocuronium,&rdquo;",
"      <i>",
"       Eur J Anaesthesiol",
"      </i>",
"      , 2011, 28(8):609-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/21562423/pubmed\" id=\"21562423\" target=\"_blank\">",
"        21562423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harvey SC, Roland P, Bailey MK, et al, \"A Randomized, Double-Blind Comparison of Rocuronium, d-Tubocurarine, and 'Mini-Dose' Succinylcholine for Preventing Succinylcholine-Induced Muscle Fasciculations,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1998, 87(3):719-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/9728861/pubmed\" id=\"9728861\" target=\"_blank\">",
"        9728861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khuenl-Brady KS, Sparr H, Puhringer F, et al, &ldquo;Rocuronium Bromide in the ICU: Dose Finding and Pharmacokinetics,&rdquo;",
"      <i>",
"       Eur J Anaesthesiol Suppl",
"      </i>",
"      , 1995, 11:79-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/8557012/pubmed\" id=\"8557012\" target=\"_blank\">",
"        8557012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee JJ and Rubin AP, \"Breast Feeding and Anaesthesia,\"",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 1993, 48(7):616-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/8346780/pubmed\" id=\"8346780\" target=\"_blank\">",
"        8346780",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leykin Y, Pellis T, Lucca M, et al, &ldquo;The Pharmacodynamic Effects of Rocuronium When Dosed According to Real Body Weight or Ideal Body Weight in Morbidly Obese Patients,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2004, 99(4):1086-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/15385355/pubmed\" id=\"15385355\" target=\"_blank\">",
"        15385355",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin R, Carrier J, Pirlet M, et al, \"Rocuronium is the Best Non-Depolarizing Relaxant to Prevent Succinylcholine Fasciculations and Myalgia,\"",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 1998, 45(6):521-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/9669004/pubmed\" id=\"9669004\" target=\"_blank\">",
"        9669004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mazurek AJ, Rae B, Hann S, et al, &ldquo;Rocuronium versus Succinylcholine: Are They Equally Effective During Rapid-Sequence Induction of Anesthesia?&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1998, 87:1259-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/9842809/pubmed\" id=\"9842809\" target=\"_blank\">",
"        9842809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meretoja OA, Taivainen T, Jalkanen L, et al, &ldquo;Synergism Between Atracurium and Vecuronium in Infants and Children During Nitrous Oxide-Oxygen-Alfentanil Anaesthesia,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1994, 73(5):605-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/7826787/pubmed\" id=\"7826787\" target=\"_blank\">",
"        7826787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murray MJ, Cowen J, DeBlock H, et al, &ldquo;Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):142-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/11902255/pubmed\" id=\"11902255\" target=\"_blank\">",
"        11902255",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naguib M, Samarkandi AH, Ammar A, et al, &ldquo;Comparison of Suxamethonium and Different Combinations of Rocuronium and Mivacurium for Rapid Tracheal Intubation in Children,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1997, 79(4):450-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/9389261/pubmed\" id=\"9389261\" target=\"_blank\">",
"        9389261",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Puhringer FK, Khuenl-Brady KS, and Mitterschiffthaler G, &ldquo;Rocuronium Bromide: Time-Course of Action in Underweight, Normal Weight, Overweight and Obese Patients,&rdquo;",
"      <i>",
"       Eur J Anaesthesiol Suppl",
"      </i>",
"      , 1995, 11:107-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/8556996/pubmed\" id=\"8556996\" target=\"_blank\">",
"        8556996",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rudis MI, Guslits BG, and Zarowitz BJ, &ldquo;Technical and Interpretive Problems of Peripheral Nerve Stimulation in Monitoring Neuromuscular Blockade in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(2):165-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/8835051/pubmed\" id=\"8835051\" target=\"_blank\">",
"        8835051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sparr HJ, Wierda JM, Proost JH, et al, &ldquo;Pharmacodynamics and Pharmacokinetics of Rocuronium in Intensive Care Patients,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1997, 78(3):267-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/9135303/pubmed\" id=\"9135303\" target=\"_blank\">",
"        9135303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warr J, Thiboutot Z, Rose L, et al, &ldquo;Current Therapeutic Uses, Pharmacology, and Clinical Considerations of Neuromuscular Blocking Agents for Critically Ill Adults,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2011, 45(9):1116-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/26/19879/abstract-text/21828347/pubmed\" id=\"21828347\" target=\"_blank\">",
"        21828347",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9872 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19879=[""].join("\n");
var outline_f19_26_19879=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219069\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219070\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219099\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219073\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219085\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219074\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7282609\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7282610\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219051\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219037\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219054\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7282116\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219052\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219106\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219097\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219057\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219041\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300012\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219045\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219047\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219060\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15683458\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323798\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219049\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219061\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219040\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219056\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9872\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9872|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/52/27459?source=related_link\">",
"      Rocuronium: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=related_link\">",
"      Rocuronium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_26_19880="Overview of the treatment of myelodysplastic syndromes";
var content_f19_26_19880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of myelodysplastic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/26/19880/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19880/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19880/contributors\">",
"     Elihu H Estey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/26/19880/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19880/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/26/19880/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19880/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/26/19880/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H515103\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelodysplastic syndromes (MDS) encompass a series of hematologic conditions characterized by chronic cytopenias (anemia, neutropenia, thrombocytopenia) accompanied by abnormal cellular maturation. As a result, patients with MDS are at risk for symptomatic anemia, infection, and bleeding, as well as progression to acute myeloid leukemia (AML), which is often refractory to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with MDS, particularly those with lower risk disease, die because of the consequences of bone marrow failure rather than transformation to AML. Thus, use of terms such as \"pre-leukemia\" or \"smoldering leukemia\" can be misleading if taken to imply that death or morbidity from MDS results only when AML develops. Indeed, the distinction between MDS and AML is itself arbitrary, as patients with 20 to 30 percent blasts are considered to have MDS by French-American-British (FAB) criteria, but AML by the World Health Organization (WHO) classification.",
"   </p>",
"   <p>",
"    For many years, transfusion with packed red blood cells and platelets and the use of erythropoiesis stimulating agents were the only therapy available. More recently, chemotherapy agents directed at the underlying disorder have been developed and continue to be studied for patients with MDS (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ). However, due to the advanced age of most patients, the chronicity of the disease, and its attendant morbidities, supportive care remains a central component of the management of all patients with MDS. Patients should be treated as needed with antibiotics for infection and platelet transfusions for bleeding in the setting of thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link\">",
"     \"Management of the complications of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general overview of the treatment of MDS will be reviewed here. More detailed discussions of the following issues are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of very low, low or intermediate risk MDS (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment of high or very high risk MDS (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9049?source=see_link\">",
"       \"Treatment of high or very high risk myelodysplastic syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Management of the complications of MDS (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link\">",
"       \"Management of the complications of the myelodysplastic syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The use of hematopoietic cell transplantation in MDS (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=see_link\">",
"       \"Hematopoietic cell transplantation in myelodysplastic syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The prognosis of MDS (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=see_link\">",
"       \"Prognosis of the myelodysplastic syndromes in adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515110\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with MDS require immediate treatment. This is principally because:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MDS is a heterogeneous disease with certain subsets of patients surviving for a decade or more with supportive care alone.",
"     </li>",
"     <li>",
"      With the exception of allogeneic hematopoietic cell transplantation (HCT), MDS cannot be cured by current treatment options.",
"     </li>",
"     <li>",
"      The main goals of therapy for most patients with MDS are to control symptoms and to improve quality of life, which includes minimizing the toxicity of therapy.",
"     </li>",
"     <li>",
"      There is no evidence that the treatment of asymptomatic patients improves long term survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immediate treatment is indicated for patients with the following disease-related complications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptomatic anemia",
"     </li>",
"     <li>",
"      Symptomatic thrombocytopenia",
"     </li>",
"     <li>",
"      Recurrent infections in the setting of neutropenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some physicians may choose to intervene in cases of asymptomatic severe anemia (eg, hemoglobin &lt;10",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    or asymptomatic severe thrombocytopenia (eg, platelets",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL).",
"    </span>",
"    It is unclear that the treatment of neutropenia without a history of infection is of benefit. Studies of granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) in this setting have demonstrated that these agents can increase neutrophil counts, but do not improve clinically significant endpoints such as infection rates and survival. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H7196900#H7196900\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Myeloid growth factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515117\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ASYMPTOMATIC MDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients may be followed expectantly with serial examinations and laboratory studies in order to evaluate the disease tempo. This also allows for the more detailed evaluation of cytopenias and exclusion of reversible causes of the cytopenias (eg, vitamin B12 deficiency, iron deficiency, copper deficiency). This is also an opportunity to bring vaccinations up to date, especially against respiratory pathogens such as pneumococcus, haemophilus influenza B, pertussis, and influenza. Smoking cessation should also be emphasized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H7193969#H7193969\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H1063596#H1063596\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients present with a history of documented complete blood counts, which can provide insight into the disease tempo. Less commonly, a patient with little information regarding prior blood counts should be initially scheduled for monthly visits. At these visits, we perform a focused history and physical examination, complete blood count with differential, and evaluate the peripheral blood smear. If the patient remains asymptomatic for several months and the blood counts are stable, the length of time between visits is gradually lengthened. Patients are educated regarding the potential complications of MDS and told to call the office immediately if they develop a fever or bleeding. When patients develop a transfusion requirement or recurrent infections, then it is time to consider treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H516641\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with MDS should have a history and physical examination that includes documentation of their transfusion history. In addition, it is our practice to perform the following pretreatment studies in patients with MDS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, reticulocyte count, pre-transfusion serum erythropoietin level, RBC folate, serum vitamin B12 level, serum ferritin, iron, total iron binding capacity, serum copper level, and serology for HIV infection. Human leukocyte antigen (HLA) typing should be performed for patients who are candidates for hematopoietic cell transplantation (HCT) and for those who require HLA-matched platelets. HLA-DR15 typing may identify patients with low or intermediate-1 risk MDS likely to respond to immunosuppressive agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2447560#H2447560\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Immunosuppressive therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unilateral bone marrow aspiration with biopsy is recommended for all patients. This sample should be sent for pathologic review with iron staining and fluorescence in situ hybridization (FISH) to evaluate for common cytogenetic abnormalities in MDS and those that might affect therapy such as 5q minus, 7q minus, +8, MLL (11q23) rearrangements, 13q minus, 20q minus, and inv(3). Although fluorescence in situ hybridization (FISH) is often performed, it is unclear whether an abnormality detected only on FISH has the same significance as the same abnormality detected on routine cytogenetics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphocytotoxic (anti-HLA) antibody screen for multiparous women and multiply-transfused patients.",
"     </li>",
"     <li>",
"      Patients with chronic myelomonocytic leukemia (CMML) should be evaluated for 5q31-33 translocations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PDGFRbeta gene rearrangements. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2444494#H2444494\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Chronic myelomonocytic leukemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      JAK2 mutation analysis should be considered for patients with thrombocytosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link&amp;anchor=H24#H24\">",
"       \"Diagnostic approach to the patient with suspected polycythemia vera\", section on 'JAK2 mutations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Flow cytometry of the peripheral blood can evaluate for a paroxysmal nocturnal hemoglobinuria (PNH) clone in patients with hypoplastic MDS and assess the possibility of large granular lymphocytic disease in patients with large granular lymphocytes on the peripheral smear. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2816177#H2816177\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'PNH-positive cells'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=see_link&amp;anchor=H458743514#H458743514\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Performance status should be evaluated using either the Eastern Cooperative Oncology Group (ECOG) performance scale (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      ), or the Karnofsky performance scale (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The International Prognostic Scoring System (IPSS) (",
"      <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) and revised IPSS (R-IPSS) (",
"      <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"       table 4",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) should be used to incorporate information on bone marrow blast percentage, karyotype, and cytopenias for the purpose of stratifying the MDS into risk groups to guide management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=see_link&amp;anchor=H2102498#H2102498\">",
"       \"Prognosis of the myelodysplastic syndromes in adults\", section on 'International prognostic scoring systems (IPSS and IPSS-R)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515265\">",
"    <span class=\"h1\">",
"     SELECTION OF INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding a standard treatment approach for patients with symptomatic MDS, and patients should be encouraged to enroll on clinical trials whenever available. Our treatment approach is similar to that proposed by the MDS Panel for Practice Guidelines of the National Comprehensive Cancer Network (NCCN). This approach incorporates knowledge of the patient&rsquo;s performance status, the International Prognostic Scoring System (IPSS) (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 3",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and revised IPSS (IPSS-R) (",
"    <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"     table 4",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) MDS risk categories, and other disease characteristics (ie, cytopenias present, serum erythropoietin level) to help guide management decisions. However, despite the increased availability of treatment guidelines, it is important to individualize care for the patient with MDS.",
"   </p>",
"   <p>",
"    Treatment options for patients with MDS typically fall into one of three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive care includes the use of antibiotics for infection and red cell and platelet transfusions in the setting of symptomatic anemia and thrombocytopenia, respectively. Prophylactic antibiotics are generally not helpful and this strategy may select for antibiotic resistance. Supportive care is an important adjunct to the management of all patients with MDS and can be considered as the sole treatment modality for a subset of patients with lower risk MDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link\">",
"       \"Management of the complications of the myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low intensity therapies include hematopoietic growth factors, DNA hypomethylating agents, immunosuppressive therapy, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      . These can be administered in the outpatient setting and have a low risk of treatment-related morbidity and mortality. Low intensity treatments can improve symptoms and quality of life, but are not curative.",
"     </li>",
"     <li>",
"      High intensity therapies include intensive combination chemotherapy and allogeneic hematopoietic cell transplantation (HCT). They require hospitalization and entail significant risk of treatment-related mortality. However, these treatments may improve blood counts more quickly than less intensive therapy, reduce the risk of death from MDS, and may alter the MDS disease course. As in AML, combinations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      should be reserved for patients with normal cytogenetics and de novo MDS. Use of combination chemotherapy in other patients, particularly those with unfavorable cytogenetics should be restricted to investigational regimens being studied in clinical trials. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=see_link\">",
"       \"Hematopoietic cell transplantation in myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High intensity therapies are generally reserved for patients with intermediate-2 or high risk IPSS scores. This allows for the avoidance of treatment-related morbidity and mortality in most patients with a relatively good prognosis, and allows for the aggressive treatment of disease in those with a poor prognosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a very low (&le;1.5 points) or low (&gt;1.5 to 3 points) IPSS-R score are primarily treated with supportive care or low intensity therapies such as DNA hypomethylating agents or immunosuppressive therapy. This approach is also appropriate for patients with a low (0 points) or intermediate-1 (0.5 to 1.0 points) risk IPSS score. A choice among these options is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H519324#H519324\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Choice of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a high (&gt;4.5 to 6 points) or very high (&gt;6 points) IPSS-R score with a good performance status are primarily treated with combination chemotherapy or allogeneic hematopoietic cell transplantation (HCT) in an attempt to alter the disease course. This approach is also appropriate for patients with an intermediate-2 (1.5 to 2.0 points) or high (2.5 to 3.5 points) risk IPSS score. A choice among these options is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9049?source=see_link&amp;anchor=H48546540#H48546540\">",
"       \"Treatment of high or very high risk myelodysplastic syndromes\", section on 'Choice of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Either of these approaches is reasonable for a patient with an intermediate (&gt;3 to 4.5 points) IPSS-R score. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9049?source=see_link\">",
"       \"Treatment of high or very high risk myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Supportive care is an important adjunct to the management of",
"      <strong>",
"       all",
"      </strong>",
"      patients with MDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link\">",
"       \"Management of the complications of the myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, there are certain patient populations that require special attention and modification of this approach. As an example, patients with therapy-related MDS have a particularly poor prognosis and are treated in a similar fashion to those with therapy-related acute myeloid leukemia (AML) or may be considered for palliative",
"    <span class=\"nowrap\">",
"     care/hospice,",
"    </span>",
"    depending upon the diagnosis, IPSS-R, and comorbidities. In addition, patients with 5q deletion and those with chronic myelomonocytic leukemia demonstrating a platelet-derived growth factor receptor beta (PDGFRB) fusion gene have superior outcomes when treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with MDS requires consideration of the often-confounding issues of comorbid conditions in these generally elderly individuals (average age 65 to 70), who present clinically with single or multiple cytopenias or their sequelae, and often do not tolerate or respond to conventional chemotherapy. Although transformation to AML is less frequent than bone marrow failure as a cause of death in MDS, significant numbers of patients with MDS undergo evolution to a form of AML which is often less responsive to standard treatment than is de novo AML. Advanced age makes these patients less likely to tolerate standard combination chemotherapy with or without hematopoietic cell transplantation. The adverse biologic characteristics of the transformed cells are also a major contributor to this poor prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=see_link\">",
"     \"Hematopoietic cell transplantation in myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of specific therapeutic approaches has been reviewed in detail [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19880/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Some of these treatments are still considered to be experimental. Comparative clinical trials using the above patient- and disease-related stratifications are needed in order to determine the relative value of each therapeutic modality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515592\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are followed longitudinally to assess disease response to therapy and to monitor for disease progression. Standardized response criteria have been developed that use bone marrow and peripheral blood analysis to allow better comparisons between published studies and to help guide treatment.",
"   </p>",
"   <p>",
"    However, outside of a clinical trial, the examinations included in the response assessment depend at least partially upon the goals of therapy and how treatment decisions may change based upon the results. We follow all patients with complete blood counts in order to assess hematologic improvement. A bone marrow aspirate with or without biopsy is performed if cell counts deteriorate more than anticipated to evaluate for possible progression to higher risk MDS or acute myeloid leukemia. Alternatively, some clinicians perform a bone marrow biopsy and aspirate after two to four cycles of chemotherapy to help guide further treatment for patients receiving active therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515600\">",
"    <span class=\"h2\">",
"     Response criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Responses are categorized according to the International Working Group (IWG) standardized response criteria for evaluating clinically significant responses in MDS first published in 2000 and modified in 2006. [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19880/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Response criteria for hematologic improvement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythroid response &mdash; Patients with a pretreatment hemoglobin &lt;11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      demonstrate erythroid response if their hemoglobin increases by &ge;1.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      for at least eight weeks, and there is a reduction in the units of red cell transfusions by an absolute number of at least four red cell transfusions per eight weeks compared with the pretreatment transfusion number in the previous eight weeks. Only red cell transfusions given for a hemoglobin &le;9",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      pretreatment will count in the red cell transfusion response evaluation.",
"     </li>",
"     <li>",
"      Platelet response &mdash; Patients with a pretreatment platelet count &lt;100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      demonstrate a platelet response if there is an absolute platelet increase of &ge;30 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      for patients starting with &gt;20 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      platelets. For those with an increase from 10 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      to &gt;20 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      must have an increase of at least 100 percent.",
"     </li>",
"     <li>",
"      Neutrophil response &mdash; Patients with a pretreatment neutrophil count &lt;1 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      demonstrate a neutrophil response if they have an at least 100 percent increase and an absolute increase &gt;0.5 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although intuitively sensible, it remains unclear whether achievement of hematologic improvement prolongs survival.",
"   </p>",
"   <p>",
"    Bone marrow response must persist for a minimum duration of four weeks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete remission (CR) &mdash; Bone marrow with &le;5 percent myeloblasts with normal maturation of all cell lines. Dysplastic changes may be seen, but should be considered within the normal range of dysplastic changes. Peripheral blood demonstrates hemoglobin &ge;11",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      platelets &ge;100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L,",
"      </span>",
"      neutrophils &ge;1 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L,",
"      </span>",
"      and no circulating blasts. Patients who achieve a CR have improved survival. This survival advantage appears to be due to the achievement of a CR rather than an inherently better prognosis.",
"     </li>",
"     <li>",
"      Partial remission &mdash; Criteria for complete remission except bone marrow blasts decreased by &ge;50 percent over pretreatment, but are still &gt;5 percent. The cellularity and morphology of the bone marrow is not relevant.",
"     </li>",
"     <li>",
"      Marrow complete remission &mdash; Marrow complete remission was developed to describe patients who have achieved a complete remission in the bone marrow, but have not recovered peripheral blood counts. The bone marrow demonstrates &le;5 percent myeloblasts and the percent of myeloblasts has decreased by &ge;50 percent over pretreatment. If peripheral blood demonstrates a hematologic improvement response, this should be noted in addition to marrow complete remission. As with hematologic improvement, the clinical significance of response marrow complete remission is not well established.",
"     </li>",
"     <li>",
"      Stable disease &mdash; Failure to achieve at least partial remission, but no evidence of progression for at least eight weeks. As with hematologic improvement, the clinical significance of stable disease is not well established.",
"     </li>",
"     <li>",
"      Disease progression &mdash; Defined by the percent blasts: those with &lt;5 percent blasts have a &ge;50 percent increase in blasts to &gt;5 percent blasts; those with 5 to 10 percent blasts have a &ge;50 percent increase in blasts to &gt;10 percent; those with 10 to 20 percent blasts have a &ge;50 percent increase to &gt;20 percent; those with 10 to 30 percent blasts have a &ge;50 percent increase to &gt;30 percent. Disease progression can also be defined by an at least 50 percent decrement from maximum",
"      <span class=\"nowrap\">",
"       remission/response",
"      </span>",
"      in granulocytes or platelets, reduction in hemoglobin by &ge;2",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      or transfusion dependence.",
"     </li>",
"     <li>",
"      Cytogenetic response &mdash; Complete if the previous chromosomal abnormality disappears without the appearance of new ones, partial if there is an at least 50 percent reduction in the chromosomal abnormality. At least 20 analyzable metaphases by conventional cytogenetic studies are required to diagnose or exclude the presence of any cytogenetic abnormality. Patients who achieve a complete remission (CR) but have persistent cytogenetic abnormalities are more likely to relapse than patients whose CR is characterized by disappearance of the initial cytogenetic abnormality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515607\">",
"    <span class=\"h2\">",
"     Disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most treatment regimens are often continued until disease progression. However, it is not clear that continuous cycles of therapy lead to a better long-term outcome than stopping treatment after several months in CR and then resuming when the disease recurs. Second responses to the same drug do occur. Disease progression is characterized by worsening cytopenias, an increase in the percentage of bone marrow blasts, or progression to a more advanced MDS French-American-British (FAB) subtype. Progression is categorized according to the International Working Group (IWG) standardized response criteria for evaluating clinically significant responses in MDS first published in 2000 and modified in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19880/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapse after complete or partial remission requires at least one of the following: return to pretreatment bone marrow blast percentage, decrement of &ge;50 percent from maximum",
"      <span class=\"nowrap\">",
"       remission/response",
"      </span>",
"      levels in granulocytes or platelets; reduction in hemoglobin concentration by &ge;1.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or transfusion dependence.",
"     </li>",
"     <li>",
"      Hematologic progression or relapse after hematologic improvement is defined by at least one of the following: at least 50 percent decrement from maximum response levels in granulocytes or platelets; reduction in hemoglobin by &ge;1.5",
"      <span class=\"nowrap\">",
"       g/L;",
"      </span>",
"      or transfusion dependence. In the absence of another explanation such as acute infection, repeated courses of chemotherapy, gastrointestinal bleeding, hemolysis, or other.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515614\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT OR REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a general lack of effective treatments for the management of recurrent or refractory MDS and patients should be encouraged to participate in clinical trials, whenever available. The importance of enrolling these patients on a clinical trial was illustrated in a retrospective analysis of 435 patients with relapsed or refractory MDS following initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    for high-risk MDS or refractory anemia with excess blasts in transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19880/abstract/7\">",
"     7",
"    </a>",
"    ]. After a median follow-up after azacitidine failure of 15 months, the median overall survival was 5.6 months and the overall survival at two years was 15 percent. Patients who underwent allogeneic hematopoietic cell transplantation or were enrolled on a clinical trial appeared to have better outcomes when compared with those treated with conventional care. (See",
"    <a class=\"local\" href=\"#H515621\">",
"     'Clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Outside of a clinical trial, the management of patients with recurrent or refractory MDS is largely dependent upon the patient&rsquo;s prior therapy. Patients who have not yet been treated with DNA hypomethylating agents (ie, those initially treated with transplantation or immunosuppressive therapy) may be offered a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    . There is a paucity of data regarding the use of a DNA hypomethylating agent after the failure of another DNA hypomethylating agent (eg, the use of decitabine after failure of azacitidine or vice versa). Despite their name, it is also unclear whether clinical response to hypomethylating agents parallels the hypomethylation induced by these drugs.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    is not approved by the US Food and Drug Administration for use in MDS without del(5q), however there is some evidence of activity in this setting, although much lower than that seen with del(5q):",
"   </p>",
"   <p>",
"    The safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    were initially tested in a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trial in patients with MDS (with or without 5q minus) and red cell transfusion-dependent disease or symptomatic anemia, the majority of whom had failed prior treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erythropoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19880/abstract/8\">",
"     8",
"    </a>",
"    ]. Initial results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-one of the 43 evaluable patients (49 percent) had either a &gt;2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      increase in hemoglobin level or became red cell transfusion independent. Increases in platelet count (10 percent of patients) and neutrophils (17 percent of patients) were less frequently noted.",
"     </li>",
"     <li>",
"      Restoration of a normal karyotype was noted in 10 of 20 informative patients and in 9 of 12 with the 5q minus (5q-) syndrome",
"     </li>",
"     <li>",
"      Erythroid response was highest in patients with",
"      <span class=\"nowrap\">",
"       Low/Int-1",
"      </span>",
"      IPSS scores (60 percent) and in those with the 5q- syndrome (83 percent). In the latter patients, hematologic improvement was associated with resolution of megakaryocytic dysplasia on bone marrow examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H359933#H359933\">",
"       \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'MDS with isolated del(5q)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dose-dependent myelosuppression was the most common adverse event and required treatment interruption or dose reduction in 58 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A phase II study evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    treatment in 214 transfusion-dependent patients with low- or intermediate-1 IPSS MDS without the 5q- deletion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19880/abstract/9\">",
"     9",
"    </a>",
"    ]. Eligible patients had a platelet count",
"    <span class=\"nowrap\">",
"     &ge;50,000/microL",
"    </span>",
"    and required &ge;2 units of red cells within the previous eight weeks. They received either 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of lenalidomide or 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    on days 1 through 21 of a 28-day cycle. Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-six percent of patients (56 of 214) achieved transfusion independence (TI) after a median of 4.8 weeks of treatment. TI continued for a median duration of 41 weeks. The median rise in hemoglobin was 3.2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (range 1.0 to 9.8",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      for those achieving TI.",
"     </li>",
"     <li>",
"      A &ge;50 percent reduction in transfusion requirement was noted in an additional 37 patients (17 percent), yielding an overall rate of hematologic improvement of 43 percent.",
"     </li>",
"     <li>",
"      The most common grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      adverse events were neutropenia (30 percent) and thrombocytopenia (25 percent). Fifty-five percent of patients required a dose adjustment at a median treatment time of seven weeks. There were no differences in hematologic toxicity between the two treatment schedules.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515621\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ). For interested patients, relatives, and physicians, the Aplastic Anemia and MDS International Foundation maintains a website (",
"    <a class=\"external\" href=\"file://www.aamds.org/\">",
"     www.aamds.org",
"    </a>",
"    ), which contains additional information as well as a listing of clinical trials in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19880/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       \"Patient information: Bone marrow transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H516101\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate treatment is indicated for patients with symptomatic cytopenia (anemia, thrombocytopenia, neutropenia with recurrent infections). Asymptomatic patients with lower risk MDS may be followed expectantly with serial examinations and laboratory studies. Immunizations should be updated and smoking ceased. (See",
"      <a class=\"local\" href=\"#H515110\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With the probable exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      in RBC transfusion-dependent patients with deletion 5q and low or intermediate 1 MDS, there is no agreed upon standard treatment approach for patients with symptomatic myelodysplastic syndrome (MDS) and patients should be encouraged to enroll in clinical trials whenever available. Our treatment approach incorporates knowledge of the patient&rsquo;s performance status, the International Prognostic Scoring System (IPSS) (",
"      <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) and revised IPSS (IPSS-R) (",
"      <a class=\"graphic graphic_table graphicRef85832 \" href=\"UTD.htm?20/16/20749\">",
"       table 4",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) MDS risk categories, and other disease characteristics (ie, cytopenias present, serum erythropoietin level) to help guide management decisions. (See",
"      <a class=\"local\" href=\"#H515265\">",
"       'Selection of initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive care is an important adjunct to the management of",
"      <strong>",
"       all",
"      </strong>",
"      patients with MDS and can be considered as the sole treatment modality for a subset of patients with lower risk MDS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link\">",
"       \"Management of the complications of the myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a very low (&le;1.5 points) or low (&gt;1.5 to 3 points) IPSS-R score are primarily treated with supportive care or low intensity therapies, such as DNA hypomethylating agents or immunosuppressive therapy. This approach is also appropriate for patients with a low (0 points) or intermediate-1 (0.5 to 1.0 points) risk IPSS score. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H519324#H519324\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Choice of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a high (&gt;4.5 to 6 points) or very high (&gt;6 points) IPSS-R score with a good performance status are primarily treated with combination chemotherapy or allogeneic hematopoietic cell transplantation (HCT) in an attempt to alter the disease course. This approach is also appropriate for patients with an intermediate-2 (1.5 to 2.0 points) or high (2.5 to 3.5 points) risk IPSS score. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9049?source=see_link&amp;anchor=H48546540#H48546540\">",
"       \"Treatment of high or very high risk myelodysplastic syndromes\", section on 'Choice of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Either of these approaches is reasonable for a patient with an intermediate (&gt;3 to 4.5 points) IPSS-R score. A choice among therapies must take into account the patient&rsquo;s interpretation of expected outcomes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients are followed longitudinally to assess disease response to therapy and to monitor for disease progression. Standardized response criteria have been developed that use bone marrow and peripheral blood analysis to allow better comparisons between published studies and to help guide treatment. (See",
"      <a class=\"local\" href=\"#H515592\">",
"       'Patient follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a general lack of effective treatments for the management of recurrent or refractory MDS, and patients should be encouraged to participate in clinical trials. Outside of a clinical trial, the management of patients with recurrent or refractory MDS is largely dependent upon the patient&rsquo;s prior therapy. Patients who have not yet been treated with DNA hypomethylating agents may be offered a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H515621\">",
"       'Clinical trials'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H515614\">",
"       'Treatment of recurrent or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19880/abstract/1\">",
"      Golshayan AR, Jin T, Maciejewski J, et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 2007; 137:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19880/abstract/2\">",
"      Atallah E, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. Cancer Invest 2008; 26:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19880/abstract/3\">",
"      Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009; 113:6296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19880/abstract/4\">",
"      Greenberg PL. Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol 2010; 150:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19880/abstract/5\">",
"      Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96:3671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19880/abstract/6\">",
"      Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19880/abstract/7\">",
"      Pr&eacute;bet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29:3322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19880/abstract/8\">",
"      List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19880/abstract/9\">",
"      Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111:86.",
"     </a>",
"    </li>",
"    <li>",
"     www.aamds.org/aplastic (Accessed on July 12, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16122 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19880=[""].join("\n");
var outline_f19_26_19880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H516101\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H515103\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H515110\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H515117\">",
"      MANAGEMENT OF ASYMPTOMATIC MDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H516641\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H515265\">",
"      SELECTION OF INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H515592\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H515600\">",
"      Response criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H515607\">",
"      Disease progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H515614\">",
"      TREATMENT OF RECURRENT OR REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H515621\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H516101\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/16122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16122|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/37/27228\" title=\"table 3\">",
"      IPSS in MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/16/20749\" title=\"table 4\">",
"      IPSS-R in MDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=related_link\" title=\"calculator 1\">",
"      Calculator: Myelodysplastic syndrome international prognostic scoring system (Original IPSS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?41/54/42849?source=related_link\" title=\"calculator 2\">",
"      Calculator: Revised International Prognostic Scoring System (IPSS-R) in myelodysplastic syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=related_link\">",
"      Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=related_link\">",
"      Hematopoietic cell transplantation in myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=related_link\">",
"      Prognosis of the myelodysplastic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9049?source=related_link\">",
"      Treatment of high or very high risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_26_19881="Periorificial dermatitis - perinasal";
var content_f19_26_19881=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51230%7EDERM%2F70512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51230%7EDERM%2F70512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Periorificial dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules and mild scale are present on the perinasal skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission of Edizioni Minerva Medica from G Ital Dermatol Venereol 2010; 145:433. Copyright &copy; 2010. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Periorificial dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules are present in the periorbital region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19881=[""].join("\n");
var outline_f19_26_19881=null;
var title_f19_26_19882="Myotonic dystrophy: Etiology, clinical features, and diagnosis";
var content_f19_26_19882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/26/19882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19882/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19882/contributors\">",
"     David A Chad, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/26/19882/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19882/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19882/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/26/19882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/26/19882/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/26/19882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myotonic dystrophy (DM) is a clinically and genetically heterogeneous disorder. There are two major forms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      DM1, for a century known as Steinert's disease",
"     </li>",
"     <li>",
"      DM2, recognized in 1994 as a milder version of DM1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of DM is 1 in 8000 in the general population, but the proportions of myotonic dystrophy caused by DM1 and DM2 are unknown.",
"   </p>",
"   <p>",
"    These autosomal dominant conditions are among the most common forms of adult-onset muscular dystrophy. However, DM is more than simply a muscular dystrophy per se, since affected individuals may show cataracts, cardiac conduction abnormalities, infertility, and insulin resistance. Furthermore, there is a severe congenital form of DM1 with marked developmental disability.",
"   </p>",
"   <p>",
"    One consequence of the multisystemic nature of this disorder is that individuals affected by DM1 or DM2 may first present to internists, cardiologists, ophthalmologists, endocrinologists, and pediatricians (in the case of DM1), before they see a neurologist.",
"   </p>",
"   <p>",
"    The genetics, pathophysiology, clinical features, and diagnosis of myotonic dystrophy will be reviewed here. The prognosis and management of myotonic dystrophy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18057?source=see_link\">",
"     \"Myotonic dystrophy: Prognosis and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other muscular dystrophies are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21415?source=see_link\">",
"     \"Emery-Dreifuss muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=see_link\">",
"     \"Limb-girdle muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=see_link\">",
"     \"Oculopharyngeal, distal, and congenital muscular dystrophies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic heterogeneity of myotonic dystrophy (",
"    <a class=\"graphic graphic_table graphicRef65850 \" href=\"UTD.htm?32/41/33435\">",
"     table 1",
"    </a>",
"    ) was apparent by 1992, when genetic testing became available for myotonic dystrophy type 1 (DM1). This has turned out to be the most common form of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second multisystemic myotonic disorder, with both similarities to and differences from DM1, had been recognized clinically as early as 1994. However, it was not until 2001 that investigators established the genetic basis for this disorder, which has since become known as myotonic dystrophy type 2 (DM2) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DM1 results from an expansion of a CTG trinucleotide repeat in the 3'-untranslated region of the dystrophia myotonica protein kinase gene (DMPK gene) on chromosome 19q 13.3 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/1-5\">",
"       1-5",
"      </a>",
"      ]. Wild-type individuals have 5 to 34 CTG repeats at this locus, whereas individuals with DM1 have repeats in the hundreds to thousands [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/7\">",
"       7",
"      </a>",
"      ]. In DM1, a new mutation, which is the expansion of a normal allele (&lt;35 repeats) into the abnormal range, is rare.",
"     </li>",
"     <li>",
"      DM2 is caused by an expanded CCTG tetranucleotide repeat expansion located in intron 1 of the zinc finger protein 9 gene (ZNF9 gene, also known as the CNBP gene) on chromosome 3q 21.3 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/6\">",
"       6",
"      </a>",
"      ]. On normal alleles, there are 11 to 26 tetranucleotide repeats; on pathogenic alleles, the number of repeats ranges from 75 to more than 11,000, with a mean of 5000 repeats [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both DM1 and DM2, the repeat expansion is transcribed into RNA but remains untranslated. The marked intergenerational instability of the size of the repeat expansion may explain the phenomenon of anticipation, at least in DM1, in which increased size of the expansion is associated with an earlier age of onset and more severe clinical phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Intergenerational contraction of the CTG repeat has also been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/11\">",
"     11",
"    </a>",
"    ]. In DM2, there is no definite correlation between repeat length and disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the severity of the DM1 phenotype correlates with the CTG repeat size, but there is considerable variability and overlap between phenotypes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with a repeat size between 35 and 49, designated premutation status or mutable normal, are asymptomatic.",
"     </li>",
"     <li>",
"      In DM1, a mutation of 50 to approximately 150 CTG repeats is associated with a mild disease phenotype, typically characterized by cataracts and mild myotonia [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/8,13\">",
"       8,13",
"      </a>",
"      ]. Age at onset is between 20 to 70 years, and life expectancy is normal or moderately reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Longer repeats, in the range of 100 to 1000, are seen in individuals with the classic myotonic dystrophy phenotype (onset between 12 and 30 years of age) with muscle wasting and weakness, myotonia, cataracts, balding, and cardiac conduction defects. In these patients, average lifespan is reduced.",
"     </li>",
"     <li>",
"      With CTG repeat length &gt;1000, myotonic dystrophy may manifest at birth with infantile hypotonia, respiratory dysfunction, and the emergence of mental retardation &ndash; so-called congenital myotonic dystrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Congenital myotonic dystrophy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inheritance of congenital DM1 is overwhelmingly maternal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/7\">",
"     7",
"    </a>",
"    ]. This phenomenon stems from the much greater likelihood for anticipation (ie, expansions of CTG repeats) to occur in maternal compared with paternal transmissions.",
"   </p>",
"   <p>",
"    As mentioned earlier, there is no correlation in DM2 between CCTG repeat size and age of onset of weakness or other measures of disease severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myotonic dystrophy provides an example of a novel mechanism of disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In myotonic dystrophy type 1 (DM1), the expanded trinucleotide repeat is located in the 3'-untranslated region of the DMPK gene, and also happens to be located within the promoter region of the adjacent SIX5 gene.",
"     </li>",
"     <li>",
"      In myotonic dystrophy type 2 (DM2), the expanded tetranucleotide repeat is located within the first intron of the ZNF9 (CNBP) gene.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In each instance, the gene is transcribed into RNA but is not translated. It is notable that DMPK, a serine-threonine kinase, shows no functional similarity to ZNF9, a 7 zinc finger protein thought to bind RNA. The fact that both genes were associated by repeat expansions in transcribed but untranslated regions suggests that the mutant RNA might have a significant role in the disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current understanding of the pathophysiology of this disease posits what is known as a \"trans\" effect, in which the repeat expansions exert a dominant toxic effect on other genes not localized to either the DM1 or DM2 loci. This effect is mediated by two RNA-binding protein families [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Muscleblind-like (MBNL)",
"     </li>",
"     <li>",
"      CUG-BP- and ETR-3-like-factors (CELF)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to this theory, for which there is some experimental support, the CUG and CCUG RNA expansions fold into a hairpin structure, and these mutant RNAs accumulate in the nucleus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/17\">",
"     17",
"    </a>",
"    ]. In DM1, the mutant CUG repeat containing RNA sequesters MBNL1 and leads to loss of its function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mutant RNAs alter RNA binding protein activity, which in turn results in aberrant splicing and abnormal function of several genes, including the bridging integrator 1 gene (BIN1) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/18\">",
"     18",
"    </a>",
"    ], the skeletal muscle chloride channel [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/19\">",
"     19",
"    </a>",
"    ], the insulin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/20\">",
"     20",
"    </a>",
"    ], and cardiac troponin T [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/21\">",
"     21",
"    </a>",
"    ]. Muscle weakness may result from sequestration of MBNL1 by expanded CUG or CCUG repeats, leading to alternative splicing of BIN1 and skipping of muscle-specific exon 11 of BIN1 messenger RNA, which in turn causes disorganized T tubules and impairs excitation-contraction coupling (",
"    <a class=\"graphic graphic_figure graphicRef77706 \" href=\"UTD.htm?7/42/7843\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/18\">",
"     18",
"    </a>",
"    ]. Skeletal muscle chloride channel dysfunction is responsible for the myotonia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/16,22,23\">",
"     16,22,23",
"    </a>",
"    ] and is related to increased inclusion of exon 7A during misregulated alternative splicing of the CLCN1 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/16\">",
"     16",
"    </a>",
"    ]. Mutant RNA appears to induce expression of the cardiac transcription factor NKX2-5, which may account for the cardiac conduction disturbances associated with DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/24\">",
"     24",
"    </a>",
"    ]. Dysregulation of alpha-dystrobrevin splicing may also play a role in the muscle weakness and wasting found with DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are similar in that both are multisystem disorders characterized by skeletal muscle weakness and myotonia, cardiac conduction abnormalities, cataracts, testicular failure, hypogammaglobulinemia, and insulin resistance (",
"    <a class=\"graphic graphic_table graphicRef75472 \" href=\"UTD.htm?23/50/24363\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51888 \" href=\"UTD.htm?5/3/5180\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, DM2 is generally a less severe disease than DM1. In addition, there are congenital, juvenile, and adult onset forms of DM1, whereas adult onset (typically in the fourth decade) is the most common presentation for DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/10,26\">",
"     10,26",
"    </a>",
"    ]. Nevertheless, there is a wide range of symptom onset in DM2 for myotonia (range 13 to 67 years, median 30) and weakness (range 18 to 66 years, median 41) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Skeletal muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In DM1, weakness occurs most frequently in facial muscles, levator palpebrae superficialis, temporalis, sternocleidomastoids, distal muscles of the forearm, hand intrinsic muscles (leading to compromised finger dexterity), and ankle dorsiflexors (causing bilateral foot drop). Less commonly, weakness occurs in the quadriceps, respiratory muscles, palatal and pharyngeal muscles, tongue, and extraocular muscles. Muscles of the pelvic girdle, the hamstrings, and ankle plantar flexors are relatively spared in most cases of DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with DM1 often have a characteristic facial appearance due to the pattern and longstanding nature of the muscle weakness and wasting. The face is long and narrow and the palate is high arched. The cheeks are hollowed and the jaw sags. Ptosis and wasting of the sternocleidomastoid muscles are common in DM1 and typically absent in DM2.",
"   </p>",
"   <p>",
"    In DM2, neck flexors and finger flexors muscles are affected in the earliest stages [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/26\">",
"     26",
"    </a>",
"    ]. Prior to the identification of its genetic basis, DM2 went by various names, including proximal myotonic myopathy (PROMM) and proximal myotonic dystrophy (PDM) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. These terms underscore the fact that weakness in the hip girdle region is often the presenting feature of DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/12\">",
"     12",
"    </a>",
"    ]. Weakness of thigh, hip flexor, and extensor muscles frequently impairs the ability to arise from a squat, arise from a chair, or climb stairs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weakness of elbow extensors in DM2 typically develops along with proximal leg weakness. In patients with DM2 over 50 years old, triceps weakness affects approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/12\">",
"     12",
"    </a>",
"    ]. Although it is generally symmetrical in distribution, isolated weakness of one triceps has been reported in DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Facial weakness may occur in DM2, generally in later stages of the disease, involving approximately 13 percent of patients over age 50 in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/12\">",
"     12",
"    </a>",
"    ]. However, facial weakness is not as prominent in DM2 as it is in DM1. Neck flexor muscle involvement is universal in DM1 and nearly so in DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/12\">",
"     12",
"    </a>",
"    ]. Weakness of neck flexion and neck extension in DM2 is less severe than in DM1, where a \"dropped head posture\" is occasionally encountered.",
"   </p>",
"   <p>",
"    Differences between DM1 and DM2 with respect to muscle group involvement are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef70688 \" href=\"UTD.htm?5/6/5228\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Muscle pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle pain is a very common symptom in DM1. It does not clearly parallel myotonia, and in fact is more common in the legs, where myotonia cannot be demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain is also a major complaint and management concern in DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/10,33\">",
"     10,33",
"    </a>",
"    ], and is one of the symptoms (along with stiffness and fatigue) that can bring patients to medical attention before the onset of symptomatic weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/12\">",
"     12",
"    </a>",
"    ]. The pain is typically proximal in location, affects the legs more than the arms, is unrelated to myotonia, varies from day to day, and may be problematic at rest. Pain in DM2 may be induced by exercise, palpation, or temperature changes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/26,33,34\">",
"     26,33,34",
"    </a>",
"    ]. Chest pain may trigger a work-up for heart disease.",
"   </p>",
"   <p>",
"    The muscle pain and stiffness of DM2 have been likened to those of fibromyalgia. In one study of 63 randomly selected patients diagnosed with fibromyalgia, the DM2 mutation was identified in two (3 percent). [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Myotonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myotonia is a slowed relaxation following a normal muscle contraction. Most patients with myotonic dystrophy do not describe symptoms referable to the myotonia (unlike patients with myotonia congenita), and those who do often refer to it as muscle stiffness.",
"   </p>",
"   <p>",
"    Myotonia is most prominent in the early stages of the illness, is aggravated by cold and stress, and is seen most consistently in facial, jaw, tongue, and hand intrinsic muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/32\">",
"     32",
"    </a>",
"    ]. Myotonia is universally present in DM1, whereas myotonia is found in 75 percent of patients with DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/12\">",
"     12",
"    </a>",
"    ]. Myotonia is also more pronounced and relatively more constant in severity in DM1 than DM2. Myotonia varies in DM2, with patients reporting being free of symptoms for days or weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a clinical sign, myotonia is often best appreciated in the hand and fingers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To elicit grip myotonia, the patient is instructed to grip the examiner's fingers firmly and then to let go rapidly; in the presence of myotonia, the relaxation of the fingers is delayed.",
"     </li>",
"     <li>",
"      To demonstrate percussion myotonia, the examiner firmly percusses the thenar eminence (specifically the abductor pollicis brevis); in the presence of myotonia, the thumb will abduct and then relax slowly. Alternately, the examiner percusses the extensor digitorum; in the presence of myotonia, the third digit will extend and then relax slowly. Percussion myotonia can be elicited in other muscles as well.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with DM1 (but not DM2) tend to lose clinical myotonia (grip or percussion) as muscle weakness progresses over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In DM1, smooth muscle involvement is more common than in other muscular dystrophies and manifests particularly with gastrointestinal (GI) symptoms such as colicky abdominal pain, constipation, diarrhea, and pseudo-obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/36\">",
"     36",
"    </a>",
"    ]. Irritable bowel-like symptoms (abdominal pain, bloating, and changes in bowel habits) are common in DM1.",
"   </p>",
"   <p>",
"    Upper GI tract involvement is seen in most patients with classic DM1 and leads to dysphagia with resulting aspiration pneumonia, an important cause of morbidity and mortality in DM1. Gallstones also occur in DM1 because of increased tone of the gall bladder sphincter. The presence and severity of gastrointestinal disturbances in DM1 correlates poorly with the degree of skeletal muscle involvement, and correlates positively with the duration of skeletal muscle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although GI symptoms were previously considered uncommon in DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/26\">",
"     26",
"    </a>",
"    ], a later case-control study that evaluated 29 patients with genetically proven DM2 found that dysphagia for solid food, abdominal pain, and constipation were reported by 41, 62, and 62 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/38\">",
"     38",
"    </a>",
"    ]. These GI symptoms were significantly more frequent in patients with DM2 than in healthy controls, but were similar to rates found in patients with DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/38\">",
"     38",
"    </a>",
"    ]. A small companion study that evaluated the subgroup of patients with DM2 and dysphagia found that the dysphagia was relatively mild when assessed with swallowing studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, no patient with DM2 and dysphagia had a history of aspiration pneumonia or weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiac abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;DM1 and DM2 are associated with both cardiac conduction disturbances and structural heart abnormalities, which are potential causes of early mortality. While there is some risk of sudden death from cardiac arrhythmias in DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/40-43\">",
"     40-43",
"    </a>",
"    ] and DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/44\">",
"     44",
"    </a>",
"    ], the magnitude of this risk is not easily quantified based on the available data, which consists mainly of small observational studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18057?source=see_link&amp;anchor=H2#H2\">",
"     \"Myotonic dystrophy: Prognosis and management\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A comprehensive review of DM1 found that atrial flutter and fibrillation were the most common arrhythmias; ventricular arrhythmias were less common but represented major management problems [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/45\">",
"     45",
"    </a>",
"    ]. Clinical evidence of a generalized cardiomyopathy was unusual. In some but not all studies, the severity of conduction disturbances and tachyarrhythmias in DM1 correlated with both neuromuscular disease and length of the CTG repeat [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/45\">",
"     45",
"    </a>",
"    ]. However, arrhythmias or heart block may occasionally be very early manifestations of DM1, even when neuromuscular symptoms are mild or even unrecognized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Conduction disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiographic (ECG) abnormalities are common in patients with DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/40-43,46-50\">",
"     40-43,46-50",
"    </a>",
"    ]. Atrioventricular and intraventricular conduction disturbances are the most frequent abnormalities, indicating that the His-Purkinje system bears the brunt of the disease, with consequent prolongation of the PR interval and QRS complex [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In DM1, cardiac conduction abnormalities appear to be slowly progressive over time [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of the frequency of ECG abnormalities in patients with DM1 are based upon data from retrospective case series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/40,41,46\">",
"     40,41,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First degree atrioventricular block in 20 to 30 percent",
"     </li>",
"     <li>",
"      Bundle branch block in 10 to 15 percent",
"     </li>",
"     <li>",
"      Atrial flutter and atrial fibrillation in 2 to 11 percent, with a smaller proportion experiencing ventricular and supraventricular tachycardia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the actual prevalence is unknown, summing lower and upper estimates cited above for DM1 yields an overall estimate that cardiac conduction defects occur in 32 to 56 percent of patients.",
"   </p>",
"   <p>",
"    Overt symptoms related to these conduction disturbances appear to be less common. One of the most comprehensive studies addressing this issue evaluated a series of 17 patients with DM1 and reviewed the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/51\">",
"     51",
"    </a>",
"    ]. The percentage of patients with symptoms referable to the cardiovascular system was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      24 percent (four patients) in the series of 17 patients",
"     </li>",
"     <li>",
"      16 percent of 252 other published cases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the series of 17 patients, symptoms included palpitations, dyspnea, orthopnea, and pedal edema, but the specific symptoms in the larger number of patients from the literature review were not reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conduction disturbances also affect patients with DM2, although data are sparse. In one study that reported 44 patients with DM2, cardiac conduction abnormalities were seen in nine (20 percent), consisting of atrioventricular or intraventricular blocks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another small case-control study, cardiac conduction defects in DM2 were present in 37 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Structural abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural heart abnormalities have also been associated with DM1 and DM2.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report that evaluated 382 patients with DM1 using transthoracic echocardiography, the following structural abnormalities were noted [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/53\">",
"       53",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Left ventricular hypertrophy in 20 percent",
"     </li>",
"     <li>",
"      Left ventricular dilatation in 19 percent",
"     </li>",
"     <li>",
"      Left ventricular systolic dysfunction in 14 percent",
"     </li>",
"     <li>",
"      Regional wall motion abnormality in 11 percent",
"     </li>",
"     <li>",
"      Left atrial dilatation in 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart failure in DM1 was found in 2 percent based upon clinical history [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 100 patients with DM2 who were older than 50 years, a history of progressive cardiomyopathy in the absence of myocardial ischemia was found in 7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/12\">",
"       12",
"      </a>",
"      ]. In a study of 38 patients with DM2, left ventricular systolic dysfunction was found in 16 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an autopsy study of four patients with DM2 and sudden death, all had dilated cardiomyopathy, and two had conduction system fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Respiratory function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory complications are common in DM1, and stem from pharyngoesophageal weakness, weakness and myotonia of respiratory muscles, and a cerebral abnormality of control of respiration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/27\">",
"     27",
"    </a>",
"    ], suggesting an alteration of central respiratory drive. Weakness of respiratory muscles leads to a diminution in vital capacity and causes alveolar hypoventilation. Respiratory failure may occur, sometimes precipitated by general anesthesia because of heightened sensitivity to sedatives, anesthetics, and neuromuscular blocking agents [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Respiratory muscle weakness is not a major problem in patients with DM2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Impaired sleep and daytime sleepiness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DM1 may exhibit hypersomnia and excessive daytime somnolence (EDS) in the context of difficulty falling asleep and poorly restorative sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/55\">",
"     55",
"    </a>",
"    ]. The burden of impaired sleep and EDS among patients with DM1 is substantial, with prevalence rates of 33 to 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The wide range of prevalence rates is likely due to methodologic and population differences among studies.",
"   </p>",
"   <p>",
"    While EDS is described in patients with DM2, it is less severe and far less prevalent than in DM1. In one case-control study, the prevalence of EDS among 29 patients with DM1, 29 with DM2, and 65 population controls was 45, 7, and 6 percent respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is controversy and conflicting evidence about the cause of EDS in patients with DM1, and multiple potential and overlapping mechanisms have been proposed, including respiratory muscle weakness with retention of carbon dioxide [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/59\">",
"     59",
"    </a>",
"    ], increased susceptibility to obstructive sleep apnea due to weakness of pharyngeal muscles, nonobstructive sleep apnea and sleep-related alveolar hypoventilation, declining muscular function, weakness of inspiration during REM sleep, increased upper airway resistance during non-REM sleep, and some central disorder of arousal that represents a primary manifestation of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/55,56,59-62\">",
"     55,56,59-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A distinction should be drawn between EDS associated with myotonic dystrophy and the narcolepsy phenotype in which EDS, short sleep latency, and sleep onset REM are accompanied by sleep paralysis, cataplexy, and hypnagogic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypnopompic hallucinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Endocrine abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hypogonadism (low-serum testosterone, elevated serum FSH concentration, oligospermia, and infertility), testicular atrophy, and associated oligospermia or azoospermia with infertility are common problems in DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/63\">",
"     63",
"    </a>",
"    ] and less common in DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insulin hypersecretion is another common finding in patients with DM. It is thought to be a compensatory beta cell response to tissue insulin resistance, and related to the formation of an insulin-resistant receptor because of aberrant regulation of mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/32\">",
"     32",
"    </a>",
"    ]. In DM1, insulin resistance is present, but frank diabetes is uncommon. The prevalence of diabetes is greater in DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperhidrosis of the hands and trunk is prominent in most individuals with DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/26\">",
"     26",
"    </a>",
"    ]. Premature, male-pattern frontal balding is seen in both DM1 and DM2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Autoimmune diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data from small observational studies suggest a possible association of DM2 with autoimmune disease. In one report, the frequency of autoreactive T-cell associated autoimmune disorders was significantly higher in DM2 than DM1 (6 of 28 [21 percent] versus 1 of 51 [2 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/64\">",
"     64",
"    </a>",
"    ]. The autoimmune diseases identified in the DM2 population included rheumatoid arthritis, Sj&ouml;gren&rsquo;s syndrome, Churg-Strauss syndrome, anterior uveitis, autoimmune hepatitis, vitamin B12 deficiency, and hyper- and hypothyroidism.",
"   </p>",
"   <p>",
"    The mechanism for the proposed association between DM2 and autoimmunity is unknown. The authors proposed that the DM2 mutation might directly influence immune function, or that there might be a genetic linkage, a mutation in genes flanking the DM2 expansion, conferring susceptibility for autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of pregnancy are seen in both DM1 and DM2.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study and literature review of DM1, preterm labor before 34 weeks occurred in 19 percent of gestations and was often but not exclusively attributed to congenitally affected fetuses [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/65\">",
"       65",
"      </a>",
"      ]. There were an increased number of operative deliveries because of prolonged labor, with a cesarean delivery rate of 36 percent. Ectopic pregnancy occurred in 4 percent, and placenta previa in 9 percent of gestations. Postpartum hemorrhage due to uterine atonia was a rare event.",
"     </li>",
"     <li>",
"      In a study of 96 pregnancies involving 42 women with DM2, early and late miscarriages occurred in 13 and 4 percent respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/66\">",
"       66",
"      </a>",
"      ]. Preterm labor occurred in 50 percent of pregnancies, resulting in 27 percent preterm deliveries in women with overt DM2 in pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Peripheral and cranial neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports suggest that patients with myotonic dystrophy can develop an axonal sensorimotor polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], and that this manifestation is independent of underlying glucose intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/69\">",
"     69",
"    </a>",
"    ]. Although data are limited, neuropathy may be found in as many as 46 percent of patients with myotonic dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/68,70\">",
"     68,70",
"    </a>",
"    ]. One morphological study characterized the neuropathy as chronic axonopathy of moderate severity, possibly due to axonal atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/71\">",
"     71",
"    </a>",
"    ]. However, an earlier histological study failed to identify any morphological abnormality of peripheral nerve in myotonic dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensorineural hearing loss is encountered occasionally in DM1, resembling precocious presbycusis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/73\">",
"     73",
"    </a>",
"    ]. In affected patients, brainstem-evoked potentials show a significant increase in the I to V interpeak interval [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/73\">",
"     73",
"    </a>",
"    ]. Abnormalities in the vestibuloocular reflex are also found in some patients with DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Congenital myotonic dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The congenital form of myotonic dystrophy, which is only seen as part of DM1, is characterized by profound hypotonia, facial diplegia, poor feeding, arthrogryposis (especially of the legs), and respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/10\">",
"     10",
"    </a>",
"    ]. Affected infants have a characteristic \"V\" shape of the upper lip that results from facial diplegia.",
"   </p>",
"   <p>",
"    In some cases, DM1 may present before birth as polyhydramnios talipes and reduced fetal movement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/75\">",
"     75",
"    </a>",
"    ]. In the most severely affected infants, polyhydramnios is common during pregnancy and is related to disturbance in swallowing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/76-81\">",
"     76-81",
"    </a>",
"    ]. Labor also tends to be either prolonged or abbreviated, presumably on the basis of maternal uterine muscle involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/78,82\">",
"     78,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myotonia is not usually present in the first year of life, and electrical myotonia is rare. Respiratory involvement is common and is the leading cause of death in the neonatal period. Mechanical ventilation is required for 80 percent or more of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/76\">",
"     76",
"    </a>",
"    ]. With intensive support, most infants survive the neonatal period, but the overall mortality rate is approximately 15 to 20 percent, and approaches 40 percent in severely affected infants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In early childhood, there is often a gradual improvement of motor function. Despite this improvement, some degree of hypotonia and facial weakness persist; at age three to five, foot deformities, learning, and behavioral abnormalities present as the main clinical problems [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/83\">",
"     83",
"    </a>",
"    ]. Subsequently, pronounced delays are experienced in motor and mental development, with mental retardation in 50 to 60 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/81,83,84\">",
"     81,83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be no correlation between the severity of congenital myotonic dystrophy at birth and the extent of complications during teenage years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/83\">",
"     83",
"    </a>",
"    ]. As patients with congenital DM1 age, they develop many of the symptoms and signs of classic, adult-onset DM1, such as the distal predominance of muscle weakness, myotonia, and ECG abnormalities. Those patients who survive early childhood typically experience significant cardiorespiratory morbidity and mortality.",
"   </p>",
"   <p>",
"    It is not uncommon for an adult (typically the mother) to be diagnosed with myotonic dystrophy only after giving birth to an affected neonate, underscoring the potential for subclinical presentation of this disorder.",
"   </p>",
"   <p>",
"    Only a small number of paternally inherited cases of congenital myotonic dystrophy have been reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/85-89\">",
"     85-89",
"    </a>",
"    ]. Whereas mothers of infants with maternally transmitted congenital myotonic dystrophy have larger mean trinucleotide (CTG) repeat sizes than mothers of patients with juvenile or adult onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/90\">",
"     90",
"    </a>",
"    ], fathers of infants with paternally transmitted congenital DM1 have small repeat sizes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are asymptomatic at the time of the affected child's birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious cardiac rhythm disturbances may occur as early as the second decade of life in children with the congenital or infantile form of DM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/92\">",
"     92",
"    </a>",
"    ]. In severely affected infants, cardiomyopathy may be apparent early on and contribute to neonatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/76,93\">",
"     76,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Juvenile myotonic dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of this childhood form of DM1, with onset of symptoms before the age of 12, typically reflect the involvement of systems and organs other than skeletal muscle; these include cognitive deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/10\">",
"     10",
"    </a>",
"    ], difficulty with speech (dysarthria) and hearing, poor coordination, and rarely, postoperative apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious cardiac rhythm disturbances may occur in asymptomatic adolescents with no or only subtle signs of myotonic dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/92\">",
"     92",
"    </a>",
"    ]. Sports and physical exercise precipitate arrhythmias in over one-half of these patients. Fewer than 10 percent of patients have clinical evidence of a cardiomyopathy and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates with DM1 myotonic dystrophy develop cognitive dysfunction in a pattern consistent with mental retardation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Congenital myotonic dystrophy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Mental retardation is a predominant feature of the congenital and childhood forms of DM1 and is often associated with generalized atrophy on MRI studies. Mental retardation is rare in DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/26\">",
"     26",
"    </a>",
"    ]. In general, for patients with DM1, the IQ decreases with younger age of onset. In addition, lower IQ has been correlated with longer CTG expansions, mainly related to maternal inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also evidence for subtle cognitive impairment in patients with DM1 and DM2, particularly involving executive and visual-spatial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/84,96-98\">",
"     84,96-98",
"    </a>",
"    ]. Even patients with IQ scores in the normal range may show impairment in executive function and abnormalities in visual perception, constructional ability, and visual memory [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/95\">",
"     95",
"    </a>",
"    ]. Furthermore, patients with DM1 have been described with personality and behavioral disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/95\">",
"     95",
"    </a>",
"    ]. However, the involvement in DM2 appears to be considerably less than in DM1.",
"   </p>",
"   <p>",
"    In both DM1 and DM2, frontal lobe cognitive impairment (attention deficits) worsens over time, but does not extend to other areas of cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/99\">",
"     99",
"    </a>",
"    ]. Thus, cognitive problems do not show the same degree of deterioration over time that is typical of muscle dysfunction in DM1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191953850\">",
"    <span class=\"h2\">",
"     Cancer susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mounting evidence suggests that myotonic dystrophy is associated with an increased risk of cancer. The largest study evaluated data from the Swedish and Danish registries that included 1658 patients with MMD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/100\">",
"     100",
"    </a>",
"    ]. In 14,170 patient-years of follow-up, the number of myotonic dystrophy cases who developed cancer was two-fold higher than expected (104 versus 52 expected, standardized incidence ratio 2.0 [95% CI 1.6-2.4]). In particular, significantly elevated risk was found for cancers of the endometrium, brain, ovary, and colon.",
"   </p>",
"   <p>",
"    A number of earlier case reports also suggested that myotonic dystrophy is associated with an increased risk of malignancy, mainly for pilomatricoma and multiple basal cell carcinomas of the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain MRI studies in patients with DM1 demonstrate abnormalities in the frontal and anterior portion of the temporal lobes, including cortical atrophy and subcortical white matter hyperintense lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54809 \" href=\"UTD.htm?5/8/5250\">",
"     image 1",
"    </a>",
"    ). In patients with DM1, and to a limited degree in DM2, PET studies demonstrate hypoperfusion of frontal and temporal lobes, a finding that might underlie the executive dysfunction seen primarily in DM1 and to a lesser extent in DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/102\">",
"     102",
"    </a>",
"    ]. Limited MRI data suggest that patients with DM2 develop loss of gray matter involving the brainstem, hypothalamic and thalamic regions, and white matter mainly involving the corpus callosum [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic process begins with the clinical impression that myotonic dystrophy might account for the presenting symptoms and signs. The clinical diagnosis of one of the myotonic dystrophies can be readily established when there is muscle weakness and clinical myotonia in the setting of a positive family history. A family history of affected neonates (congenital myotonic dystrophy) points to the diagnosis of DM1, as does a distribution of weakness that includes the neck, face, and distal muscles with relative sparing of the proximal muscles. Prominent early involvement of neck flexors, finger flexors, and later, hip girdle muscles, sparing facial and hand intrinsic muscles, should suggest the diagnosis of DM2.",
"   </p>",
"   <p>",
"    In the vast majority of patients with DM1 or typical DM2, the diagnosis can be made clinically and confirmed with genetic testing. The diagnostic role of electromyography is thus limited. However, it is still important in atypical cases where the detection of myotonia provides support for the diagnosis of myotonic dystrophy. Electromyography is also used when molecular testing for DM1 or DM2 is normal. In such cases, the demonstration of electrical myotonia supports the alternative diagnosis of a channelopathy, such as myotonia congenita, paramyotonia, and hyperkalemic periodic paralysis.",
"   </p>",
"   <p>",
"    In some instances the diagnosis may be challenging for both DM1 and DM2. As an example, patients may present with muscle pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mild to moderate elevations in serum creatine kinase, or with an extramuscular manifestation of DM in the absence of significant muscle weakness or a family history [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/31,104\">",
"     31,104",
"    </a>",
"    ]. In such circumstances, a high index of suspicion for a myotonic dystrophy is required so that appropriate testing can be carried out and the diagnosis established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific genetic testing to demonstrate the presence of an expanded CTG repeat in the DMPK gene is the gold standard for the diagnosis of DM1. It is appropriate to begin the confirmatory laboratory testing with genetic analysis and omit electrodiagnostic studies when there is a strong clinical suspicion for the diagnosis of DM1.",
"   </p>",
"   <p>",
"    Normal DMPK gene alleles contain 5 to 34 CTG repeats. Mutable normal alleles (premutation alleles) contain 35 to 49 repeats. Children of individuals with the premutation are at increased risk of inheriting a larger repeat size and having symptoms. Full penetrance alleles of &ge;50 CTG repeats are associated with disease manifestations. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Specific genetic testing for the CCTG repeat in the ZNF9 (CNBP) gene is appropriate if DM1 testing is negative and the clinical suspicion of myotonic dystrophy is high. DM2 is caused by a single mutational mechanism, a CCTG tetranucleotide expansion of &ge;75 repeats (up to 11,000 repeats). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography (EMG) is an important test in the evaluation of patients suspected of having a myopathic disorder and specifically, one of the myotonic dystrophies. It is useful for demonstrating the presence of myotonia if this has not been found clinically or if uncertainty persists regarding its presence or absence on examination. Electrical myotonia typically consists of repetitive discharges of muscle fiber action potentials at 20 to 80 Hz that wax and wane in amplitude and frequency, producing a sound often reminiscent of a dive bomber or a motorcycle engine when audio-amplified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of electromyography\", section on 'Myotonic discharges'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not every muscle will show evidence for myotonia, so a thorough EMG examination should include evaluation of multiple distal arm and facial muscles. Myotonia is generally easier to elicit in DM1 than DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/105\">",
"     105",
"    </a>",
"    ]. In DM1, it tends to be waxing-waning (ie, classic discharges that increase and decrease in both amplitude and frequency), whereas in DM2 it tends to be waning (ie, discharges that gradually decrease in frequency or amplitude). The most distal muscles (the tibialis anterior and first dorsal interosseous) are most likely to have myotonic discharge in both disorders. The severity of myotonia correlates with muscle weakness in DM1, but not in DM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/105\">",
"     105",
"    </a>",
"    ]. In occasional instances of DM2, neither clinical nor electrical myotonia can be demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/31,104,106\">",
"     31,104,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrical myotonia may also be encountered in non-dystrophic myopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/107\">",
"     107",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myotonia congenita",
"     </li>",
"     <li>",
"      Hyperkalemic periodic paralysis",
"     </li>",
"     <li>",
"      Paramyotonia",
"     </li>",
"     <li>",
"      Adult onset acid maltase deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myotonia is present uncommonly in a number of other conditions, including chronic denervating disorders, polymyositis, inclusion body myositis, and toxic myopathies (eg, associated with statins, clofibrate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle biopsy in DM1 and DM2 is notable for pathologic alterations, including a marked increase of internalized nuclei (arrayed in chains in longitudinal section), severely atrophic muscle fibers with pyknotic nuclear clumps, muscle fiber necrosis and regeneration of isolated muscle fibers, architectural changes such as sarcoplasmic masses and ring fibers, and a preferential atrophy of type I fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/12,108\">",
"     12,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic role for muscle biopsy is limited, given the availability of genetic testing for DM1 or DM2. However, muscle biopsy may be useful to help distinguish DM2 from an inflammatory or metabolic myopathy when they cannot be differentiated by clinical presentation alone. Muscle biopsy may suggest the diagnosis of myotonic dystrophy in atypical cases with minimal weakness, unexplained elevations in CK and nonspecific EMG findings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/31,104\">",
"     31,104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other investigations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrocardiography (ECG) is critically important, not only to provide support for the diagnosis of myotonic dystrophies, but for the recognition and characterization of asymptomatic cardiac conduction defects that are often encountered in DM1 and DM2 and require vigilant monitoring. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardiac abnormalities'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18057?source=see_link&amp;anchor=H11#H11\">",
"       \"Myotonic dystrophy: Prognosis and management\", section on 'Cardiac conduction disturbances'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Creatine kinase concentration may be mildly to moderately elevated in both DM1 and DM2, and g-glutamyltransferase level is often increased in DM2, but these tests do not have a definitive role in the diagnostic process other than raising the index of suspicion that a myopathic disorder may be present.",
"     </li>",
"     <li>",
"      Slit lamp examination may reveal the characteristic posterior subcapsular cataracts, which are detectable as red and green iridescent opacities.",
"     </li>",
"     <li>",
"      Serum immunoglobulin studies will typically disclose IgG and IgM hypogammaglobulinemia in both DM1 and DM2 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/26/19882/abstract/32\">",
"       32",
"      </a>",
"      ]. As evidence of male hypogonadism, follicle-stimulating hormone (FSH) is elevated while testosterone levels may be low-normal or decreased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=see_link\">",
"       \"Patient information: Muscular dystrophy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/33/32276?source=see_link\">",
"       \"Patient information: Overview of muscular dystrophies (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) are multisystem disorders characterized by skeletal muscle weakness and myotonia, cardiac conduction abnormalities, cataracts, testicular failure, hypogammaglobulinemia, impaired sleep and excessive daytime sleepiness, and insulin resistance. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DM2 have symptoms due to proximal muscle weakness, particularly of the hip girdle muscles. In general, DM2 is a less severe disease than DM1. There are congenital, juvenile, and adult onset forms of DM1, whereas only an adult onset form of DM2 is recognized. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The congenital form of myotonic dystrophy, which is only seen as part of DM1, is characterized by hypotonia, poor feeding, and respiratory failure. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Congenital myotonic dystrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of the juvenile form of myotonic dystrophy (DM1) typically reflect the involvement of systems and organs other than skeletal muscle. The nonskeletal muscle manifestations of DM1 include cognitive deficiency, difficulty with speech (dysarthria) and hearing, poor coordination, or rarely, postoperative apnea. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Juvenile myotonic dystrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DM1 results from an expansion of a CTG trinucleotide repeat in the 3'-untranslated region of the DMPK gene. DM2 is caused by an expanded CCTG tetranucleotide repeat expansion located in intron 1 of the ZNF9 gene. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathophysiology of myotonic dystrophy is incompletely understood, but the leading theory is that the CUG and CCUG RNA repeat expansions mediate a dominant effect on other genes not localized to either the DM1 or DM2 loci by altering RNA binding protein activity. This in turn results in altered splicing and abnormal function of several genes, including the bridging integrator 1 gene (BIN1), the skeletal muscle chloride channel, the insulin receptor, and cardiac troponin T. Muscle weakness may result from alternative splicing of BIN1, which results in disorganized T tubules and impairment of excitation-contraction coupling. Skeletal muscle chloride channel dysfunction is responsible for the myotonia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of myotonic dystrophy can usually be made clinically in a patient with the characteristic presentation and a positive family history. Genetic testing for an expanded CTG repeat in the DMPK gene is the gold standard for confirming the diagnosis of DM1. Testing for the CCTG repeat in the ZNF9 gene is appropriate if DM1 testing is negative. Electromyography will usually demonstrate the presence of myotonia if this has not been found clinically or if uncertainty persists regarding its presence or absence on examination. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no disease-modifying therapy available for the treatment of myotonic dystrophy. Treatment is symptomatic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18057?source=see_link\">",
"       \"Myotonic dystrophy: Prognosis and management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/1\">",
"      Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992; 69:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/2\">",
"      Buxton J, Shelbourne P, Davies J, et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nature 1992; 355:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/3\">",
"      Fu YH, Pizzuti A, Fenwick RG Jr, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992; 255:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/4\">",
"      Harley HG, Brook JD, Rundle SA, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature 1992; 355:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/5\">",
"      Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992; 255:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/6\">",
"      Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293:864.",
"     </a>",
"    </li>",
"    <li>",
"     Bird, TD. Myotonic dystrophy type 1. GeneReviews. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=myotonic-d#myotonic-d (Accessed on November 02, 2010).",
"    </li>",
"    <li>",
"     Dalton, JC, Ranum, LPW, Day, JW. Myotonic dystrophy type 2. GeneReviews. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=myotonic-d2 (Accessed on November 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/9\">",
"      Hamshere MG, Harley H, Harper P, et al. Myotonic dystrophy: the correlation of (CTG) repeat length in leucocytes with age at onset is significant only for patients with small expansions. J Med Genet 1999; 36:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/10\">",
"      Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012; 11:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/11\">",
"      Puymirat J, Gigu&egrave;re Y, Mathieu J, Bouchard JP. Intergenerational contraction of the CTG repeats in 2 families with myotonic dystrophy type 1. Neurology 2009; 73:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/12\">",
"      Day JW, Ricker K, Jacobsen JF, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003; 60:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/13\">",
"      Arsenault ME, Pr&eacute;vost C, Lescault A, et al. Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions. Neurology 2006; 66:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/14\">",
"      Cho DH, Tapscott SJ. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta 2007; 1772:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/15\">",
"      Lee JE, Cooper TA. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans 2009; 37:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/16\">",
"      Kino Y, Washizu C, Oma Y, et al. MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1. Nucleic Acids Res 2009; 37:6477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/17\">",
"      Cooper TA. A reversal of misfortune for myotonic dystrophy? N Engl J Med 2006; 355:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/18\">",
"      Fugier C, Klein AF, Hammer C, et al. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med 2011; 17:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/19\">",
"      Charlet-B N, Savkur RS, Singh G, et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002; 10:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/20\">",
"      Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001; 29:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/21\">",
"      Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998; 280:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/22\">",
"      Berg J, Jiang H, Thornton CA, Cannon SC. Truncated ClC-1 mRNA in myotonic dystrophy exerts a dominant-negative effect on the Cl current. Neurology 2004; 63:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/23\">",
"      Wheeler TM, Lueck JD, Swanson MS, et al. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007; 117:3952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/24\">",
"      Yadava RS, Frenzel-McCardell CD, Yu Q, et al. RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat Genet 2008; 40:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/25\">",
"      Nakamori M, Kimura T, Kubota T, et al. Aberrantly spliced alpha-dystrobrevin alters alpha-syntrophin binding in myotonic dystrophy type 1. Neurology 2008; 70:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/26\">",
"      Meola G, Moxley RT 3rd. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol 2004; 251:1173.",
"     </a>",
"    </li>",
"    <li>",
"     Harper, PS. Myotonic Dystrophy, 3rd Ed, WB Saunders, London 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/28\">",
"      Avaria M, Patterson V. Myotonic dystrophy: relative sensitivity of symptoms signs and abnormal investigations. Ulster Med J 1994; 63:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/29\">",
"      Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994; 44:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/30\">",
"      Udd B, Krahe R, Wallgren-Pettersson C, et al. Proximal myotonic dystrophy--a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromuscul Disord 1997; 7:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/31\">",
"      Milone M, Batish SD, Daube JR. Myotonic dystrophy type 2 with focal asymmetric muscle weakness and no electrical myotonia. Muscle Nerve 2009; 39:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/32\">",
"      Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 2005; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/33\">",
"      Suokas KI, Haanp&auml;&auml; M, Kautiainen H, et al. Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve 2012; 45:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/34\">",
"      George A, Schneider-Gold C, Zier S, et al. Musculoskeletal pain in patients with myotonic dystrophy type 2. Arch Neurol 2004; 61:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/35\">",
"      Auvinen S, Suominen T, Hannonen P, et al. Myotonic dystrophy type 2 found in two of sixty-three persons diagnosed as having fibromyalgia. Arthritis Rheum 2008; 58:3627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/36\">",
"      R&ouml;nnblom A, Forsberg H, Danielsson A. Gastrointestinal symptoms in myotonic dystrophy. Scand J Gastroenterol 1996; 31:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/37\">",
"      Bellini M, Biagi S, Stasi C, et al. Gastrointestinal manifestations in myotonic muscular dystrophy. World J Gastroenterol 2006; 12:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/38\">",
"      Tieleman AA, van Vliet J, Jansen JB, et al. Gastrointestinal involvement is frequent in Myotonic Dystrophy type 2. Neuromuscul Disord 2008; 18:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/39\">",
"      Tieleman AA, Knuijt S, van Vliet J, et al. Dysphagia is present but mild in myotonic dystrophy type 2. Neuromuscul Disord 2009; 19:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/40\">",
"      Fragola PV, Luzi M, Cal&ograve; L, et al. Cardiac involvement in myotonic dystrophy. Am J Cardiol 1994; 74:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/41\">",
"      Florek RC, Triffon DW, Mann DE, et al. Electrocardiographic abnormalities in patients with myotonic dystrophy. West J Med 1990; 153:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/42\">",
"      Hawley RJ, Milner MR, Gottdiener JS, Cohen A. Myotonic heart disease: a clinical follow-up. Neurology 1991; 41:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/43\">",
"      Melacini P, Buja G, Fasoli G, et al. The natural history of cardiac involvement in myotonic dystrophy: an eight-year follow-up in 17 patients. Clin Cardiol 1988; 11:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/44\">",
"      Schoser BG, Ricker K, Schneider-Gold C, et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology 2004; 63:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/45\">",
"      Phillips MF, Harper PS. Cardiac disease in myotonic dystrophy. Cardiovasc Res 1997; 33:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/46\">",
"      Olofsson BO, Forsberg H, Andersson S, et al. Electrocardiographic findings in myotonic dystrophy. Br Heart J 1988; 59:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/47\">",
"      Griggs RC, Davis RJ, Anderson DC, Dove JT. Cardiac conduction in myotonic dystrophy. Am J Med 1975; 59:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/48\">",
"      Hiromasa S, Ikeda T, Kubota K, et al. Myotonic dystrophy: ambulatory electrocardiogram, electrophysiologic study, and echocardiographic evaluation. Am Heart J 1987; 113:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/49\">",
"      Motta J, Guilleminault C, Billingham M, et al. Cardiac abnormalities in myotonic dystrophy. Electrophysiologic and histopathologic studies. Am J Med 1979; 67:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/50\">",
"      Nguyen HH, Wolfe JT 3rd, Holmes DR Jr, Edwards WD. Pathology of the cardiac conduction system in myotonic dystrophy: a study of 12 cases. J Am Coll Cardiol 1988; 11:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/51\">",
"      Church SC. The heart in myotonia atrophica. Arch Intern Med 1967; 119:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/52\">",
"      Wahbi K, Meune C, B&eacute;cane HM, et al. Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: a case control study. Neuromuscul Disord 2009; 19:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/53\">",
"      Bhakta D, Lowe MR, Groh WJ. Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I. Am Heart J 2004; 147:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/54\">",
"      Klompe L, Lanc&eacute; M, van der Woerd D, et al. Anaesthesiological and ventilatory precautions during cardiac surgery in Steinert's disease. J Card Surg 2007; 22:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/55\">",
"      Culebras A. Sleep and neuromuscular disorders. Neurol Clin 2005; 23:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/56\">",
"      Laberge L, B&eacute;gin P, Montplaisir J, Mathieu J. Sleep complaints in patients with myotonic dystrophy. J Sleep Res 2004; 13:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/57\">",
"      Heatwole C, Bode R, Johnson N, et al. Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 2012; 79:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/58\">",
"      Tieleman AA, Knoop H, van de Logt AE, et al. Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. J Neurol Neurosurg Psychiatry 2010; 81:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/59\">",
"      Gilmartin JJ, Cooper BG, Griffiths CJ, et al. Breathing during sleep in patients with myotonic dystrophy and non-myotonic respiratory muscle weakness. Q J Med 1991; 78:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/60\">",
"      van der Mech&eacute; FG, Bogaard JM, van der Sluys JC, et al. Daytime sleep in myotonic dystrophy is not caused by sleep apnoea. J Neurol Neurosurg Psychiatry 1994; 57:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/61\">",
"      Gibbs JW 3rd, Ciafaloni E, Radtke RA. Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy. Sleep 2002; 25:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/62\">",
"      Park JD, Radtke RA. Hypersomnolence in myotonic dystrophy: demonstration of sleep onset REM sleep. J Neurol Neurosurg Psychiatry 1995; 58:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/63\">",
"      Vazquez JA, Pinies JA, Martul P, et al. Hypothalamic-pituitary-testicular function in 70 patients with myotonic dystrophy. J Endocrinol Invest 1990; 13:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/64\">",
"      Tieleman AA, den Broeder AA, van de Logt AE, van Engelen BG. Strong association between myotonic dystrophy type 2 and autoimmune diseases. J Neurol Neurosurg Psychiatry 2009; 80:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/65\">",
"      Rudnik-Sch&ouml;neborn S, Zerres K. Outcome in pregnancies complicated by myotonic dystrophy: a study of 31 patients and review of the literature. Eur J Obstet Gynecol Reprod Biol 2004; 114:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/66\">",
"      Rudnik-Sch&ouml;neborn S, Schneider-Gold C, Raabe U, et al. Outcome and effect of pregnancy in myotonic dystrophy type 2. Neurology 2006; 66:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/67\">",
"      Panayiotopoulos CP, Scarpalezos S. Dystrophia myotonica. Peripheral nerve involvement and pathogenetic implications. J Neurol Sci 1976; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/68\">",
"      Logullo F, Censori B, Danni M, et al. Peripheral neuropathy in myotonic dystrophy: electrophysiological and clinical features. Electromyogr Clin Neurophysiol 1992; 32:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/69\">",
"      Olson ND, Jou MF, Quast JE, Nuttall FQ. Peripheral neuropathy in myotonic dystrophy. Relation to glucose intolerance. Arch Neurol 1978; 35:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/70\">",
"      Mondelli M, Rossi A, Malandrini A, et al. Axonal motor and sensory neuropathy in myotonic dystrophy. Acta Neurol Scand 1993; 88:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/71\">",
"      Cros D, Harnden P, Pouget J, et al. Peripheral neuropathy in myotonic dystrophy: a nerve biopsy study. Ann Neurol 1988; 23:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/72\">",
"      Pollock M, Dyck PJ. Peripheral nerve morphometry in myotonic dystrophy. Arch Neurol 1976; 33:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/73\">",
"      Huygen PL, Verhagen WI, Noten JF. Auditory abnormalities, including 'precocious presbyacusis', in myotonic dystrophy. Audiology 1994; 33:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/74\">",
"      Verhagen WI, ter Bruggen JP, Huygen PL. Oculomotor, auditory, and vestibular responses in myotonic dystrophy. Arch Neurol 1992; 49:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/75\">",
"      Zaki M, Boyd PA, Impey L, et al. Congenital myotonic dystrophy: prenatal ultrasound findings and pregnancy outcome. Ultrasound Obstet Gynecol 2007; 29:284.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe, JJ. Neuromuscular disorders: Muscle involvement and restricted disorders. In: Neurology of the Newborn. 5th ed. Saunders Elsevier, Philadephia 2008. p.801.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/77\">",
"      Pearse RG, H&ouml;weler CJ. Neonatal form of dystrophia myotonica. Five cases in preterm babies and a review of earlier reports. Arch Dis Child 1979; 54:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/78\">",
"      Shore RN, MacLachlan TB. Pregnancy with myotonic dystrophy: course, complications and management. Obstet Gynecol 1971; 38:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/79\">",
"      Dunn LJ, Dierker LI. Recurrent hydramnios in association with myotonia dystrophica. Obstet Gynecol 1973; 42:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/80\">",
"      Moosa A. The feeding difficulty in infantile myotonic dystrophy. Dev Med Child Neurol 1974; 16:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/81\">",
"      Hageman AT, Gabre&euml;ls FJ, Liem KD, et al. Congenital myotonic dystrophy; a report on thirteen cases and a review of the literature. J Neurol Sci 1993; 115:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/82\">",
"      Sarnat HB, O'Connor T, Byrne PA. Clinical effects of myotonic dystrophy on pregnancy and the neonate. Arch Neurol 1976; 33:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/83\">",
"      Roig M, Balliu PR, Navarro C, et al. Presentation, clinical course, and outcome of the congenital form of myotonic dystrophy. Pediatr Neurol 1994; 11:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/84\">",
"      Modoni A, Silvestri G, Pomponi MG, et al. Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 2004; 61:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/85\">",
"      Nakagawa M, Yamada H, Higuchi I, et al. A case of paternally inherited congenital myotonic dystrophy. J Med Genet 1994; 31:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/86\">",
"      Ohya K, Tachi N, Chiba S, et al. Congenital myotonic dystrophy transmitted from an asymptomatic father with a DM-specific gene. Neurology 1994; 44:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/87\">",
"      Tachi N, Ohya K, Yamagata H, et al. Haplotype analysis of congenital myotonic dystrophy patients from asymptomatic DM father. Pediatr Neurol 1997; 16:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/88\">",
"      de Die-Smulders CE, Smeets HJ, Loots W, et al. Paternal transmission of congenital myotonic dystrophy. J Med Genet 1997; 34:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/89\">",
"      Tanaka Y, Suzuki Y, Shimozawa N, et al. Congenital myotonic dystrophy: report of paternal transmission. Brain Dev 2000; 22:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/90\">",
"      Harley HG, Rundle SA, MacMillan JC, et al. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet 1993; 52:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/91\">",
"      Zeesman S, Carson N, Whelan DT. Paternal transmission of the congenital form of myotonic dystrophy type 1: a new case and review of the literature. Am J Med Genet 2002; 107:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/92\">",
"      Bassez G, Lazarus A, Desguerre I, et al. Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurology 2004; 63:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/93\">",
"      Igarashi H, Momoi MY, Yamagata T, et al. Hypertrophic cardiomyopathy in congenital myotonic dystrophy. Pediatr Neurol 1998; 18:366.",
"     </a>",
"    </li>",
"    <li>",
"     Moxley, RT III, Meola, G. Myotonic dystrophy. In: Neuromuscular Diseases: From Basic Mechanisms to Clinical Management, Deymeer, F (Ed), S Karger AG, Basel 2000. p.61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/95\">",
"      D'Angelo MG, Bresolin N. Cognitive impairment in neuromuscular disorders. Muscle Nerve 2006; 34:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/96\">",
"      Meola G, Sansone V, Perani D, et al. Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy. Neurology 1999; 53:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/97\">",
"      Meola G, Sansone V, Perani D, et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord 2003; 13:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/98\">",
"      Gaul C, Schmidt T, Windisch G, et al. Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2). Neurology 2006; 67:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/99\">",
"      Sansone V, Gandossini S, Cotelli M, et al. Cognitive impairment in adult myotonic dystrophies: a longitudinal study. Neurol Sci 2007; 28:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/100\">",
"      Gadalla SM, Lund M, Pfeiffer RM, et al. Cancer risk among patients with myotonic muscular dystrophy. JAMA 2011; 306:2480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/101\">",
"      Mueller CM, Hilbert JE, Martens W, et al. Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control 2009; 20:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/102\">",
"      Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve 2007; 36:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/103\">",
"      Minnerop M, Luders E, Specht K, et al. Grey and white matter loss along cerebral midline structures in myotonic dystrophy type 2. J Neurol 2008; 255:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/104\">",
"      Merlini L, Sabatelli P, Columbaro M, et al. Hyper-CK-emia as the sole manifestation of myotonic dystrophy type 2. Muscle Nerve 2005; 31:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/105\">",
"      Logigian EL, Ciafaloni E, Quinn LC, et al. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve 2007; 35:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/106\">",
"      Young NP, Daube JR, Sorenson EJ, Milone M. Absent, unrecognized, and minimal myotonic discharges in myotonic dystrophy type 2. Muscle Nerve 2010; 41:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/107\">",
"      Miller TM. Differential diagnosis of myotonic disorders. Muscle Nerve 2008; 37:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/26/19882/abstract/108\">",
"      Lieberman AP, Fischbeck KH. Triplet repeat expansion in neuromuscular disease. Muscle Nerve 2000; 23:843.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5147 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-02B1BD5894-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19882=[""].join("\n");
var outline_f19_26_19882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Skeletal muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Muscle pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Myotonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gastrointestinal tract involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiac abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Conduction disturbances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Structural abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Respiratory function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Impaired sleep and daytime sleepiness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Endocrine abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Peripheral and cranial neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Congenital myotonic dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Juvenile myotonic dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H191953850\">",
"      Cancer susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other investigations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5147\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5147|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/8/5250\" title=\"diagnostic image 1\">",
"      MRI myotonic dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5147|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/42/7843\" title=\"figure 1\">",
"      T-tubule alterations and muscle weakness in myotonic dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5147|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/41/33435\" title=\"table 1\">",
"      Genetics myotonic dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/50/24363\" title=\"table 2\">",
"      Muscle characteristics myotonic dystrophy I and II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/3/5180\" title=\"table 3\">",
"      Nonmuscle features myotonic dystrophy I and II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/6/5228\" title=\"table 4\">",
"      Weakness myotonic dystrophy I and II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21415?source=related_link\">",
"      Emery-Dreifuss muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=related_link\">",
"      Limb-girdle muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18057?source=related_link\">",
"      Myotonic dystrophy: Prognosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=related_link\">",
"      Oculopharyngeal, distal, and congenital muscular dystrophies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=related_link\">",
"      Patient information: Muscular dystrophy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/33/32276?source=related_link\">",
"      Patient information: Overview of muscular dystrophies (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_26_19883="Questions that are helpful in detecting possible narcolepsy";
var content_f19_26_19883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Questions that are helpful in detecting possible narcolepsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Question",
"       </td>",
"       <td class=\"subtitle1\">",
"        Implication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Are you sleepy most of the day?",
"       </td>",
"       <td>",
"        Sleepiness present, but could be caused by a variety of conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do you feel rested upon waking in the morning? Are your naps refreshing?",
"       </td>",
"       <td>",
"        Sleepiness probably not caused by poor quality sleep (eg, sleep apnea, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do you have vivid dreams during daytime naps?",
"       </td>",
"       <td>",
"        Possible REM sleep during naps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do you ever have muscle weakness when you tell a joke or laugh?",
"       </td>",
"       <td>",
"        Cataplexy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do you ever see, hear, or feel things that you know aren't there as you are falling asleep?",
"       </td>",
"       <td>",
"        Hypnagogic hallucinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Are you ever unable to move when you first awake or just before falling asleep?",
"       </td>",
"       <td>",
"        Sleep paralysis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19883=[""].join("\n");
var outline_f19_26_19883=null;
var title_f19_26_19884="Prevention of dental caries in high-risk individuals";
var content_f19_26_19884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevention of dental caries in high-risk individuals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rationale",
"       </td>",
"       <td class=\"subtitle1\">",
"        Directions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral hygiene and non-cariogenic diet",
"       </td>",
"       <td>",
"        Decreases the substrate available for cariogenic bacteria",
"       </td>",
"       <td>",
"        <p>",
"         Brush teeth at least twice daily using soft-bristled toothbrush",
"        </p>",
"        <p>",
"         Daily use of dental floss",
"        </p>",
"        <p>",
"         Restrict the amount of refined carbohydrates in daily meals",
"        </p>",
"        Avoid sugary and acidic beverages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoride products",
"       </td>",
"       <td>",
"        Increases tooth surface resistance to acids and acts as a reservoir for remineralization of early caries",
"       </td>",
"       <td>",
"        <p>",
"         Fluoride toothpaste should be used twice/day",
"        </p>",
"        <p>",
"         Fluoride gel in tray should be applied daily",
"        </p>",
"        Fluoride varnish can be professionally applied up to four time per year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium-phosphate based remineralizing agents",
"       </td>",
"       <td>",
"        <p>",
"         Casein phosphopeptide - amorphous calcium phosphate (CPP-ACP) product provide a source of calcium and phosphate",
"        </p>",
"        Facilitates remineralization of early carious lesions",
"       </td>",
"       <td>",
"        Use daily with fluoride",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Xylitol products",
"       </td>",
"       <td>",
"        Unlike sucrose or fructose, xylitol is not utilized by",
"        <em>",
"         S.mutans",
"        </em>",
"        as a source of energy",
"       </td>",
"       <td>",
"        <p>",
"         Use xylitol-containing products (gum, candy) three to five times per day",
"        </p>",
"        Fluoride toothpaste with at least 10 percent xylitol should be used twice/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine dental visits",
"       </td>",
"       <td>",
"        <p>",
"         Caries screening through clinical examination and bitewing radiographs",
"        </p>",
"        <p>",
"         Restoration of carious lesions",
"        </p>",
"        <p>",
"         Professional dental cleaning",
"        </p>",
"        Fluoride varnish application",
"       </td>",
"       <td>",
"        <p>",
"         Recall visits every six months",
"        </p>",
"        <p>",
"         Bitewings radiographs annually, or more frequent if high caries risk",
"        </p>",
"        Dental caries should be treated as soon as identified",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nathaniel Treister, DMD, DMSc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19884=[""].join("\n");
var outline_f19_26_19884=null;
var title_f19_26_19885="Thoracic ultrasound - Lung sliding";
var content_f19_26_19885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PULM/55433/Thorac_US_sliding_lung_conv.mp4?title=Thoracic+ultrasound+-+Lung+sliding\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thoracic ultrasound: Lung sliding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19885=[""].join("\n");
var outline_f19_26_19885=null;
var title_f19_26_19886="Modified Hyper CVAD";
var content_f19_26_19886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD) regimen for acute lymphoblastic leukemia (ALL) in adults",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Dose intensive phase:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        The dose intensive phase consists of 8 courses of therapy administered at 21-day intervals. The drugs used in each course alternate such that Hyper-CVAD is used for courses 1, 3, 5, and 7 while high-dose methotrexate plus cytarabine is given for courses 2, 4, 6, and 8.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Hyper-CVAD (courses 1, 3, 5, and 7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        300 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        over 2 to 3 hours every 12 hours for 6 doses",
"       </td>",
"       <td>",
"        Days 1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mesna",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /day administered as a continuous infusion starting with cyclophosphamide and ending 6 hours after last dose of cyclophosphamide",
"       </td>",
"       <td>",
"        Days 1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vincristine",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        2 mg per day",
"       </td>",
"       <td>",
"        Days 4 and 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxorubicin",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        <p>",
"         if LVEF &ge;50 percent: 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         over 24 hours",
"        </p>",
"        <p>",
"         if LVEF &lt;50 percent: 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         over 48 hours",
"         <sup>",
"          [1,2]",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        Day 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexamethasone",
"       </td>",
"       <td>",
"        PO or IV",
"       </td>",
"       <td>",
"        40 mg per day",
"       </td>",
"       <td>",
"        Days 1 to 4 and days 11 to 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        High dose methotrexate plus cytarabine (courses 2, 4, 6, and 8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        administered over first 2 hours then 800 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        administered over 24 hours (total dose per cycle of 1 gram/m",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leucovorin",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        50 mg IV 12 hours after end of methotrexate; then 15 mg IV every 6 hours for 8 doses or until methotrexate level &le;0.1 micromol/L. Dose modifications made based upon methotrexate levels.",
"       </td>",
"       <td>",
"        Day 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytarabine",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        <p>",
"         for patients &lt;60 years old: 3 g/m",
"         <sup>",
"          2",
"         </sup>",
"         administered over 2 hours every 12 hours for 4 doses",
"        </p>",
"        <p>",
"         for patients &ge;60 years old: 1 g/m",
"         <sup>",
"          2",
"         </sup>",
"         administered over 2 hours every 12 hours for 4 doses",
"        </p>",
"       </td>",
"       <td>",
"        Days 2 and 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylprednisolone",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        50 mg twice daily",
"       </td>",
"       <td>",
"        Days 1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Rituximab for CD20+ ALL (courses 1, 2, 3, 4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rituximab",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Give only if &ge;20 percent of lymphoblasts are CD20 positive: 375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Days 1 and 11 of Hyper-CVAD and Days 1 and 8 of high dose methotrexate plus cytarabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        CNS prophylaxis: total number of intrathecal treatments varies based upon risk factors*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        IT",
"       </td>",
"       <td>",
"        12 mg (6 mg if through Ommaya)",
"        <sup>",
"         [3,4]",
"        </sup>",
"       </td>",
"       <td>",
"        Day 2 of each cycle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytarabine",
"       </td>",
"       <td>",
"        IT",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        Day 8 of each cycle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Maintenance phase:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Therapy after the intensive phase varies depending upon ALL subtype:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        &bull; Patients with Burkitt leukemia (mature B-cell ALL) are not given maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        &bull; Patients with Philadelphia chromosome positive ALL undergo allogeneic hematopoietic cell transplantation if they are candidates for this procedure and have a donor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"4\">",
"        &bull; All other patients receive maintenance chemotherapy with POMP intensification plus intensification cycles of Hyper-CVAD and methotrexate plus L-asparaginase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Maintenance POMP: administered months 1 through 5, 8 through 17, 20 through 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mercaptopurine",
"       </td>",
"       <td>",
"        PO",
"       </td>",
"       <td>",
"        50 mg three times a day on an empty stomach",
"       </td>",
"       <td>",
"        Days 1 to 28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        PO",
"       </td>",
"       <td>",
"        20 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Days 1, 8, 15, and 22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vincristine",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        2 mg",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisone",
"       </td>",
"       <td>",
"        PO",
"       </td>",
"       <td>",
"        200 mg per day",
"       </td>",
"       <td>",
"        Days 1 to 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Intensification Hyper-CVAD: administered months 6 and 18, plus rituximab on days 1 and 11 if CD20+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Intensification methotrexate and L-asparaginase: administered months 7 and 19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Day 1 weekly x 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L-asparaginase",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        20,000 units",
"       </td>",
"       <td>",
"        Day 2 weekly x 4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Details on dose modification, prophylactic antibiotics, growth factor support, and mediastinal irradiation can be found in the original articles. In addition, it is now standard practice to include a tyrosine kinase inhibitor for patients with Philadelphia chromosome positive ALL.",
"    <div class=\"footnotes\">",
"     LVEF: left ventricular ejection fraction.",
"     <br/>",
"     * Patients were given central nervous system (CNS) prophylaxis based upon risk factors as follows: Patients with a lactate dehydrogenase level &gt;600 u/liter or with a proliferative index of 14 percent or above were considered \"High risk\" and received 8 intrathecal (IT) treatments. Patients with neither of these features were considered \"Low risk\" and received 6 IT treatments. Patients with unknown risk received 8 IT treatments",
"     <sup>",
"      [1]",
"     </sup>",
"     . Patients with cranial neuropathies or CNS involvement are given whole brain radiation therapy (24 to 30 Gy) at the time of diagnosis and receive even more frequent IT therapy.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010; 28:3880.",
"      </li>",
"      <li>",
"       Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004; 104:1624.",
"      </li>",
"      <li>",
"       Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547.",
"      </li>",
"      <li>",
"       Kantarjian HM, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101:2788.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19886=[""].join("\n");
var outline_f19_26_19886=null;
var title_f19_26_19887="Kayser Fleischer ring";
var content_f19_26_19887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kayser-Fleischer ring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kayser-Fleischer ring (arrow) in a patient with advanced neuropsychiatric Wilson disease. The dense brown copper deposits encircle the iris. It is rare to see Kayser-Fleischer rings without the aid of a slit lamp examination because Wilson disease is usually recognized at an earlier stage when the rings are not as prominent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_26_19887=[""].join("\n");
var outline_f19_26_19887=null;
